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The influenza virus, a member of the Orthomyxoviridae family, causes regular, 
large-scale morbidity and mortality in birds and humans and significant human 
suffering and economic loss. The primary aim of this study was to develop a novel 
influenza vaccine. Vaccines are an essential tool for the control of influenza because 
they increase resistance to infection, prevent illness and death and help to limit virus 
transmission to other birds and mammals, including humans. By reducing the 
environmental contamination of influenza virus in global poultry stocks, the risk of a 
new pandemic virus being generated by the human-avian link is diminished. 
 
Marek’s Disease is a common lymphoproliferative disease of poultry that is readily 
controlled worldwide using the live attenuated vaccine, CVI988. The Marek’s 
Disease Virus (MDV) CVI988 viral genome, available as a Bacterial Artificial 
Chromosome (BAC), forms viable infectious viral particles when transfected into 
Chicken Embryo Fibroblast (CEF) cells. Using BAC mutagenesis, two non-essential 
genes in the MDV CVI988 BAC (UL41 and US10), were identified and replaced by 
the low pathogenic influenza haemagglutinin 10 (H10) gene. These live recombinant 
MDV-H10 vectors will allow simultaneous vaccination against both pathogens. In 
addition, the non-essential genes were also replaced with GFP creating MDV-GFP 
constructs. Both genes were expressed initially using a CMV promoter, although this 
disrupted the MDV CVI988 BAC; a second promoter, PGK-1, proved more 
successful. A third MDV gene (UL50) was deleted, but severe attenuation prevented 
the incorporation of H10 into this open reading frame.  
 
Future work to test the MDV-HA constructs in vivo will be carried out in 
collaboration with the Istituto Zooprofilattico Sperimentale delle Venezie in Italy. In 
addition, development of MDV constructs containing multiple HA genes (H10 and 
H5) linked by the 2A polyprotein can be developed with the goal of establishing 
heterosubtypic immunity.  
iv 
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1.1. Influenza virus 
 
1.1.1. Influenza classification 
Influenza viruses A, B and C belong to the Orthomyxoviridae family, a group of 
enveloped viruses that possess segmented, negative-sense, single-stranded RNA 
genomes (Palese and Shaw, 2007). The name Orthomyxoviridae derives from the 
Greek orthos, meaning ‘standard, correct’ and myxa, meaning ‘mucus’ (Cheung and 
Poon, 2007). Influenza A has the broadest host range and infects a variety of animals 
that includes humans, pigs, birds, horses and sea mammals. Aquatic birds are the 
source of all influenza A viruses in other species (Webster et al, 1992; Noda and 
Kawaoka, 2010; Taubenberger and Morens, 2010). Influenza B viruses naturally 
infect humans and occasionally seals (Baigent and McCauley, 2003; Osterhaus et al, 
2000; Noda and Kawaoka, 2010), while influenza C viruses benignly infect humans, 
pigs and dogs (Guo et al, 1983; Webster et al, 1992; Noda and Kawaoka, 2010). 
Only influenza A viruses have been responsible for all influenza pandemics (Cheung 
and Poon, 2007). In addition to the influenza viruses, this family also contains the 
genera Thogotovirus, which contains two different species, Dhori and Thogoto virus, 
both isolated from ticks; and Isavirus, which includes the species Infectious salmon 
anaemia virus (Cheung and Poon, 2007; Palese and Shaw, 2007; Wright et al, 2007). 
The influenza viruses are classified according to antigenic differences exhibited by 
two of the internal structural proteins, the nucleocapsid and the matrix proteins 
(Webster et al, 1992; Cheung and Poon, 2007; Noda and Kawaoka, 2010). In 
addition, antigenic variations in the surface glycoproteins, Haemagglutinin (HA) and 
Neuraminidase (NA), are used to subtype the influenza A viruses (Fouchier et al, 
2005; Palese and Shaw, 2007; Wright et al, 2007; Cheung and Poon, 2007; Bouvier 
and Palese, 2008; Noda and Kawaoka, 2010). Antigenic subtypes have not been 
identified for influenza B and C (Palese and Shaw, 2007). With regards to influenza 
A, there are now 16 different haemagglutinin subtypes (H1-H16) (Fouchier et al, 
2005) and 9 different neuraminidase subtypes known (N1-N9) (Laver et al, 1984; 
Cheung and Poon, 2007; Palese and Shaw, 2007; Bouvier and Palese, 2008; 
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Taubenberger and Morens, 2010). Only three HA (H1, H2 and H3) and two NA (N1 
and N2) subtypes have caused human epidemics, defined by sustained and 
widespread person-to-person transmission (Palese and Shaw, 2007; Bouvier and 
Palese, 2008). However, the avian influenza strains H5N1, H7N7 and H9N2, have 
also been transmitted to humans (Baigent and McCauley, 2003; Cheung and Poon, 
2007; Wright et al, 2007; Taubenberger and Morens, 2010). 
Different influenza strains are named according to their genus, the species from 
which the virus was isolated (omitted in the case of humans), the location of the 
isolate, the number of the isolate, the year of isolation, and in the case of influenza A 
viruses, the haemagglutinin and the neuraminidase subtypes. For example, an 
influenza strain isolated by Shope (Shope, 1931) was given the designation 
A/Swine/Iowa/15/30 (H1N1) virus, meaning that it was the 15
th
 isolate of an H1N1 
subtype virus isolated from pigs in Iowa in 1930 (Palese and Shaw, 2007; Wright et 
al, 2007; Bouvier and Palese, 2008; Taubenberger and Morens, 2010). 
 
1.1.2. Structure of influenza A virus 
The influenza virus is an enveloped virus, surrounded by a lipid bilayer that is 
derived from the host’s cell membrane during the viral budding process (Figure 1). 
The virions are pleomorphic, displaying shapes that range from spherical to 
filamentous (Cheung and Poon, 2007; Lee and Saif, 2009; Noda and Kawaoka, 2010; 
Rossman and Lamb, 2011). Laboratory isolated strains of influenza are roughly 
spherical with a diameter of 80-120 nm (Stanley, 1944; Palese and Shaw, 2007; 
Bouvier and Palese, 2008; Noda and Kawaoka, 2010). The filamentous form was 
first observed in 1949 (Chu and Dawson, 1949) and it has been determined that this 
shape occurs in newly isolated strains. Recently, electron microscopic analysis of 
autopsied lung tissue, acquired from a patient who died as a result of the Swine-
Origin H1N1 2009 pandemic influenza strain, revealed filamentous viral particles 
(Nakajima et al, 2010; Rossman and Lamb, 2011).  
  




          
           
           
           
        
                                     
           
          
 










Figure 1. A diagram of the structure of the influenza A virus. Presented with 
permission (Lee and Saif, 2009). 
 
Figure 2.  Negative staining electron microscopy showing purified influenza 
virions (Bar; 100 nm). Presented with permission (Noda and Kawaoka, 
2010). 
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The influenza virion is coated with the surface glycoproteins HA and NA, which are 
anchored in the lipid bilayer, in a ratio of approximately four to one. Laver and 
Valentine (1969) were the first to demonstrate that the surface projections, visible on 
electron micrographs, were the HA and NA proteins (Figure 2). The envelope, which 
also contains the matrix 2 (M2) protein, overlays the matrix 1 (M1) proteins that 
enclose the virion core. This core comprises of the nuclear export protein (NEP), also 
referred to as the non-structural protein 2 (NS2), as well as the ribonucleoprotein 
(RNP) complex (Cheung and Poon, 2007; Palese and Shaw, 2007; Bouvier and 
Palese, 2008; Noda and Kawaoka, 2010). The eight RNP complexes consist of a 
genomic viral RNA (vRNA) segment coated with nucleoprotein (NP) and the RNA 
polymerase, which is composed of two polymerase basic (PB1 and PB2) and one 
polymerase acidic (PA) subunit.  The ends of each vRNA segment form a helical 
hairpin, which is bound by the heterotrimeric RNA polymerase complex. The M1 
protein provides structural support by interacting with both the cytoplasmic tails of 
HA and NA in the plasma membrane, as well as the NP of the RNP complex 
(Rossman and Lamb, 2011). The NP, which provides a net positive charge that binds 
the negatively charged, phosphate backbone of the vRNA, is the major determinant 
of the rod-like structure of the RNP complex (Cheung and Poon, 2007; Palese and 
Shaw, 2007; Bouvier and Palese, 2008; Noda and Kawaoka, 2010). 
The genome of the influenza A virus contains eight vRNA segments, which can be 
observed as an ordered 7 + 1 configuration in budding virions (Figure 3) (Noda and 
Kawaoka, 2010). In total, from eight vRNA segments, twelve proteins are produced 
(Cheung and Poon, 2007; Palese and Shaw, 2007; Bouvier and Palese, 2008, Wise et 
al, 2009). Segments 1 (PB2), 3 (PA), 4 (HA), 5 (NP) and 6 (NA) are monocistronic, 
encoding just one protein per segment. Viral mRNA from segment 2 contains an 
alternate +1 open reading frame; one frame encodes the protein PB1, while the 
alternative open reading frame encodes the PB1-F2 protein. In addition, a third major 
polypeptide, PB1-N40, is synthesised from PB1 mRNA via differential AUG codon 
usage, although its function is unknown (Wise et al, 2009). Viral mRNA derived 
from segments 7 and 8 can undergo alternative splicing for protein expression. 
Segment 7 encodes for the proteins M1 and M2, while segment 8 encodes for the 





          




                            
           
           
           
           
           
           
           
           
           
           
           
  
Figure 3.  Thin-section electron microscopy showing transversely sectioned 
budding influenza virions containing eight RNPs (Bar; 100 nm). Presented 
with permission (Noda and Kawaoka, 2010). 





Table 1: The genomic segments of influenza A and their encoded proteins 
RNA Segment Encoded 
Protein 
Protein Function 
1 PB2 Polymerase Subunit, mRNA cap recognition 
2 PB1 Polymerase Subunit; RNA elongation, 
endonuclease activity 
PB1-F2 Pro-apoptopic activity 
PB1-N40 Unknown 
3 PA Polymerase Subunit, Endonuclease activity 
4 HA Surface glycoprotein, major antigen, receptor 
binding and fusion activity 
5 NP RNA binding protein; Nuclear Import 
regulation 
6 NA Surface glycoprotein; sialidase activity; virus 
release 
7 M1 Matrix protein; vRNP interaction; RNA nuclear 
export regulation; viral budding 
M2 Ion channel; virus uncoating and assembly 
8 NS1 Interferon antagonist protein; regulation of host 
gene expression 
NEP/NS2 Nuclear Export of RNP 
 
(Palese and Shaw, 2007; Bouvier and Palese, 2008; Wise et al, 2009) 
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non-structural protein 1 (NS1) and the NEP/NS2 (Table 1). The NS1 protein 
possesses regulatory functions, controlling both mRNA splicing and translation, as 
well as acting as an interferon antagonist to help the influenza virus evade the host 
immune response (Palese and Shaw, 2007; Wright et al, 2007; Lee and Saif, 2009; 
Neumann et al, 2009; Rossman and Lamb, 2011). The PB1-F2 protein can trigger 
apoptosis in immune-related cells such as monocytes (Chen et al, 2001; Palese and 
Shaw, 2007; Lee and Saif, 2009; Neumann et al, 2009; Rossman and Lamb, 2011).  
 
1.1.3. Replication of Influenza A virus 
 
Virus Attachment 
The HA glycoprotein of influenza is a type I integral membrane protein that is 
responsible for receptor binding and membrane fusion. It is a rod-shaped homotrimer 
with two structurally distinct regions: a triple-stranded coiled-coil of alpha-helices 
that form a stem and a globular head of antiparallel beta-sheets on top that contains 
the sialic acid receptor binding domain (Figure 4) (Cheung and Poon, 2007; Palese 
and Shaw, 2007; Bouvier and Palese, 2008). The COOH-terminus is inserted into the 
viral membrane and the hydrophilic end projects away from the viral surface forming 
the spike (Palese and Shaw, 2007). 
The HA recognises and binds to the N-acetylneuraminic (sialic) acid on the surface 
of the host cell (Figure 5), binding preferentially to either α-2,3- or α-2,6-linkages 
that are formed by the association of carbon-2 with either the carbon-3 or carbon-6 of 
galactose (Baigent and McCauley, 2003; Cheung and Poon, 2007; Bouvier and 
Palese, 2008). In ducks and other avian species, α-2,3-linkages predominate in the 
gut epithelium, whereas in human epithelial cells sialic acids with α-2,6-linkages are 
more common. α-2,3-linkages are present in human epithelial cells especially in the 
lower respiratory tract and, although they are much less common than the α-2,6-
linkages, this does mean that avian influenza viruses can infect humans and cause 
severe infection (Matrosovich et al, 2004; Palese and Shaw, 2007; Wright et al, 
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2007; Bouvier and Palese, 2008; Lee and Saif, 2009; Neumann et al, 2009). In 
addition, Ito et al (1998) demonstrated that the trachea of pigs contained both α-2,3 
and α-2,6-linked sialic acids, indicating that pigs could readily be infected by both 
human and avian influenza virus strains, potentially resulting in reassortant pandemic 
viruses (Ito et al, 1998; Wright et al, 2007; Neumann et al, 2009). 
 
Virus Entry 
Following attachment of the HA protein to the sialic acid, the influenza virus is taken 
into the cell by receptor-mediated endocytosis (Rust et al, 2003; Cheung and Poon, 
2007; Palese and Shaw, 2007; Bouvier and Palese, 2008; Rossman and Lamb, 2011). 
The low pH environment of the acidic endosome triggers two key events. In the first, 
a conformational change in the HA occurs, exposing the fusion peptide and aligning 
it antiparallel to the membrane anchor of the HA2. This subsequently mediates the 
merging of the viral envelope with the endosomal membrane, opening a pore and 
releasing the viral RNPs into the cytoplasm. In the second, hydrogen ions from the 
endosome are pumped into the virion causing disruption of the internal protein-
protein interactions, allowing the viral RNPs to be released (Bui et al, 1996; Cheung 
and Poon, 2007; Palese and Shaw, 2007; Bouvier and Palese, 2008). This is mediated 
by the M2 protein, a highly conserved, tetrameric, type III integral membrane protein 
which functions as an ion channel for the acidification of the interior of the viral 
particle during viral infection (Pinto et al, 1992; Cros and Palese, 2003; Boulo et al, 
2007; Cheung and Poon, 2007; Palese and Shaw, 2007; Bouvier and Palese, 2008; 
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Figure 4. A. Structure of a haemagglutinin monomer: HA1 (blue) and 
HA2 (red). Adapted with permission (Wang & Palese, 2009) B. 
Structure of the haemagglutinin trimer. Adapted with permission 
(Stevens et al, 2004). 
Figure 5.  Life cycle of the influenza virus. Adapted with permission 
(Subbarao et al, 2006). 
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Synthesis of Viral RNA 
Unlike some other negative-sense, single-stranded RNA viruses, influenza virus 
RNA synthesis takes place in the nucleus of infected cells (Amorim and Digard, 
2006; Cheung and Poon, 2007; Palese and Shaw, 2007; Noda and Kawaoka, 2010). 
This is possibly due to the fact that the influenza virus requires components of the 
host’s cellular mRNA splicing machinery present in the nucleus (Amorim and 
Digard, 2006; Boulo et al, 2007). Once released, the RNPs are transported to the 
nucleus as a result of nuclear localisation signals (NLSs) present on all proteins of 
the RNP complex (Cros and Palese, 2003; O’Neill et al, 1995; Boulo et al, 2007; 
Palese and Shaw, 2007). Signals on the NP, however, are sufficient and necessary for 
the transport of viral RNA (O’Neill et al, 1995; Palese and Shaw, 2007).  
Three polymerase subunits, PB1, PB2 and PA, along with NP, are required for both 
viral transcription and replication (Huang et al, 1990; Cheung and Poon, 2007). NP 
mediates binding and packaging of the influenza viral genome. PB1 plays a key role 
in the assembly of the RNP complex and the catalytic function of RNA 
polymerisation, with the sequential addition of nucleotides during RNA chain 
elongation. The initiation of transcription begins with the binding of the 5’ end of the 
negative RNA strand (vRNA) to the PB1 subunit which, in turn, allows the PB2 
protein to recognise and bind the 5’ cap structure on host pre-mRNAs. The influenza 
RNP complex binds cellular mRNAs and, in a process known as ‘cap snatching’, the 
PA endonuclease cleaves approximately 10-15 bases from host pre-mRNA 
transcripts to initiate viral mRNA synthesis (Amorim and Digard, 2006; Cheung and 
Poon, 2007; Palese and Shaw, 2007; Bouvier and Palese, 2008; Dias et al, 2009). PA 
is also essential for viral transcription and replication (Cheung and Poon, 2007; 
Palese and Shaw, 2007) and for the efficient accumulation of the PB1 subunit in the 
nucleus (Fodor and Smith, 2004; Boulo et al, 2007; Cheung and Poon, 2007).  
The viral RNA-dependent RNA polymerase uses the negative-sense vRNA as a 
template to synthesise two positive-sense RNA species: capped and polyadenylated 
mRNA templates for viral protein synthesis in the cytoplasm, and complementary 
RNA (cRNA) intermediates that are used for the transcription of more copies of 
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vRNA in the nucleus to form the genomes of progeny virus (Cheung and Poon, 2007; 
Palese and Shaw, 2007; Bouvier and Palese, 2008; Lee and Saif, 2009). Following 
virus replication, the nuclear export of RNP complexes to the cell surface is mediated 
by the viral proteins M1 and NEP/NS2 (Palese and Shaw, 2007; Bouvier and Palese, 
2008). The M1 protein binds to vRNP, promoting nuclear export and inhibiting 
nuclear import (Martin and Helenius, 1991; Cheung and Poon, 2007); while the 
NEP/NS2 is responsible for directing the export of the RNP complex (Cros and 
Palese, 2003; Boulo et al, 2007; Palese and Shaw, 2007; Lee and Saif, 2009; Noda 
and Kawaoka, 2010). 
 
Synthesis of viral membrane proteins 
The integral membrane proteins, HA, NA and M2, are synthesised from viral mRNA 
on membrane-bound ribosomes within the endoplasmic reticulum. Once folded the 
proteins are transported to the golgi apparatus for post-translational modification and 
the HA and NA become glycosylated. The HA glycoprotein is synthesised as the 
precursor polypeptide, HA0, which is post-translationally cleaved by serine proteases 
into the disulphide-linked subunits, HA1 and HA2 (Cheung and Poon, 2007; Palese 
and Shaw, 2007; Bouvier and Palese, 2008). The cleavage of HA0 is necessary for 
the infectivity of the influenza virus as it liberates the fusion peptide which is 
important for membrane fusion (Baigent and McCauley, 2003; Cheung and Poon, 
2007). The HA cleavage site of low pathogenic avian influenza (LPAI) viruses 
contains a single arginine so only extracellular trypsin-like proteases, normally found 
in the respiratory and intestinal tract of the host, can cause cleavage. Highly 
pathogenic avian influenza (HPAI) viruses possess a HA with a multi-basic cleavage 
site, containing arginine and lysine, meaning the HA0 protein is cleavable by 
endogenous proteases, such as furin, throughout the body (Horimoto and Kawaoka, 
1994; Cheung and Poon, 2007; Palese and Shaw, 2007; Lee and Saif, 2009). HA1 
contains the receptor binding and antigenic sites; HA2 mediates the fusion of the 
virus envelope with cell membranes. Apical sorting signals subsequently direct the 
HA, NA and M2 proteins to the cell membrane for virion assembly, where M1 is 
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thought to play a key role in combining the RNP-NEP complex with the envelope 
bound HA, NA and M2 (Cheung and Poon, 2007; Palese and Shaw, 2007; Bouvier 
and Palese, 2008). The HA and NA selectively accumulate at and are incorporated 
into lipid rafts; non-ionic, detergent-resistant lipid microdomains within the plasma 
membrane that are rich in cholesterol and sphingolipids. Raft association of HA is 
essential for efficient virus replication and is mediated by the transmembrane domain 
(Takeda et al, 2003; Palese and Shaw, 2007; Rossman and Lamb, 2011).  
 
Packaging, assembly and virus budding 
Budding of the influenza virus occurs at the cell membrane and is likely to be 
initiated by the accumulation of HA and M1 protein which stimulates the outward 
curvature of the plasma membrane (Palese and Shaw, 2007; Rossman and Lamb, 
2011). Packaging of the eight vRNA segments occurs selectively as a result of 
discreet packaging signals on all vRNA segments (Fujii et al, 2003; Hutchinson et al, 
2010), resulting in the 7 + 1 configuration (Noda and Kawaoka, 2010). This ensures 
a full genome is incorporated into the majority of virus particles, essential for a fully 
infectious virion. The release of the virion, though membrane scission, is mediated 
by the M2 protein in a cholesterol-dependent manner (Rossman et al, 2010). Once 
budded, HA continues to bind the virion to sialic acids until released by the sialidase 
activity of the NA protein. The NA spike is a mushroom-shaped, type II integral 
membrane homotetramer which acts to release the virus progeny by destroying the 
receptors through hydrolysing sialic acid groups from glycoproteins (Cheung and 
Poon, 2007; Palese and Shaw, 2007; Bouvier and Palese, 2008). Host antibodies to 
NA, as well as therapeutic inhibitors of NA, prevent virus release from infected cells, 
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1.1.4. Influenza – Antigenic Drift and Shift 
 
Antigenic Drift 
Influenza viruses seem to be in evolutionary stasis in their natural host reservoir, the 
aquatic birds, however in other hosts they evolve rapidly in response to immune 
selection (Webster et al, 1992; Wright et al, 2007; Lee and Saif, 2009). As strains 
evolve to evade detection by host antibodies directed against the surface 
glycoproteins, frequent amino acid changes occur at the antigenic sites within HA1, 
NA or both (Treanor, 2004; Carrat and Flahault, 2007; Wright et al, 2007; Bouvier 
and Palese, 2008). The accumulation of these changes is known as antigenic drift. 
Antigenic drift occurs because the influenza’s RNA polymerase complexes have no 
proof reading ability; therefore, high mutation rates can lead to point mutations in the 
antigenic sites (Taubenberger and Morens, 2010). Mutations that include deletions, 
substitutions, and insertions can affect the antigenic binding sites and are among the 
most important mechanisms for producing antigenic variation in influenza viruses 
(Webster et al, 1992 Carrat and Flahault, 2007). Eventually, antigenic sites mutate to 
the point that they are no longer recognised and neutralised by the host immune 
system (Treanor, 2004; Carrat and Flahault, 2007; Wright et al, 2007; Bouvier and 
Palese, 2008). Genetic drift of the haemagglutinin protein in poultry occurs at a 
similar rate to those observed in mammals (Suarez, 2000; Lee and Saif, 2009). In 
humans, antigenic drift means that current seasonal influenza vaccines containing 
H3N2 and H1N1 subtypes, and an influenza B subtype, must be updated every 1-3 
years to account for the changes to HA and NA proteins in circulating viruses 
(Neumann et al, 2009). 
 
Antigenic Shift 
The segmented nature of the genome means that a reassortment event known as 
antigenic shift can occur, where the influenza A strain acquires the HA segment, and 
sometimes the NA segment, from another influenza A subtype. Reassortment can 
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produce genetic diversity rapidly, thus providing an evolutionary advantage, and can 
occur in cells simultaneously infected with different strains of human and animal 
viruses. Mixtures of parental gene segments may be assembled into virions and the 
resulting virus may encode antigenic proteins for which the human population has no 
pre-existing immunity. The result can be a pandemic or worldwide epidemic 
(Treanor, 2004; Webster et al, 1992; Carrat and Flahault, 2007; Wright et al, 2007; 
Bouvier and Palese, 2008; Hutchinson et al, 2010). Antigenic shift triggered the 1957 
and 1968 pandemic outbreaks as well as the most recent swine-origin H1N1 
pandemic virus (Hutchinson et al, 2010).  And, in addition, it likely produced the 
extremely virulent influenza A (H1N1) virus that caused the 1918-1919 ‘Spanish 
flu’, where the HA, NA and PB1 genes all contributed to the high pathogenicity in an 




Pandemics are defined as outbreaks that affect large populations, typically on more 
than one continent, in a short space of time. Typically, they occur at intervals of 
between ten and forty years, although reliable records only date back to the 1918 
pandemic (Wright et al, 2007). To date, there have now been five pandemics, 
including the 1918 Spanish influenza. 
 
The Pandemic of 1918 – Spanish Influenza (H1N1) 
Worldwide, this strain killed as many as 50 million people, and the outbreak remains 
unprecedented in its severity (Johnson and Mueller, 2002; Neumann et al, 2009; 
Taubenberger and Morens, 2010). Kansas, in the spring of 1918, saw the first case 
which was attributed to a soldier who had been cleaning pig pens. The first wave was 
highly contagious, moving along rail lines and via troopships to Europe, but caused 
few deaths. In August, however, a virulent form emerged that caused a significant 
increase in the death toll, mostly due to secondary bacterial pneumonia (no 
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antibiotics were available) and respiratory failure, although some showed massive 
acute pulmonary haemorrhage or edema indicating just how virulent the virus was. In 
addition, many of the dead were young adults, with a mortality rate for that age 
group twenty times higher than in previous years (Wright et al, 2007; Taubenberger 
and Morens, 2010). Recovered viral RNA from an Inuit female, exhumed from a 
mass grave in Alaska’s permafrost, confirmed the causative agent to be an H1N1 
virus (Reid et al, 1999; Wright et al, 2007). All eight gene segments were avian in 
origin (Taubenberger and Morens, 2010) and, as previously stated, Pappas et al 
(2008) determined that the 1918 HA, NA and PB1 genes all contributed to the high 
pathogenicity of the virus. Recombinant influenza viruses that express the 1918 HA 
protein induce a strong, macrophage-derived cytokine inflammatory response, 
causing haemorrhaging that was typical of the pandemic strain (Kobasa et al, 2004; 
Wright et al, 2007). However, despite its high pathogenicity, the HA of the H1N1 
virus lacked a multibasic cleavage site, indicative of current highly pathogenic 
strains (Wright et al, 2007; Neumann et al, 2009). 
 
The Pandemic of 1957 – Asian Influenza (H2N2) 
Originating in the Southern Chinese province of Guizhou in February 1957, this 
strain caused more than one million deaths worldwide, with infection rates highest in 
the 5-19 year old group. Isolated in May 1957, it was found to have originated by 
reassortment between human and avian viruses and contained HA, NA and PB1 
genes of avian virus origin (Wright et al, 2007; Neumann et al, 2009; Taubenberger 
and Morens, 2010). Although the virus itself was not particularly pathogenic, a lack 
of existing immunity led to increased mortality (Wright et al, 2007). 
 
The Pandemic of 1968 – Hong Kong Influenza (H3N2) 
This strain was isolated in Hong Kong in July 1968, and like the previous pandemic, 
probably originated in Southern China. The H3N2 virus contained an avian H3 and 
PB1 gene, produced through reassortment (Wright et al, 2007; Neumann et al, 2009; 
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Taubenberger and Morens, 2010). The virus spread around the world, predominantly 
affecting the 10-14 year old age group, but although it caused a significant number of 
deaths, it was not as severe as the Asian influenza outbreak. This was probably due 
to pre-existing antibodies against the N2 protein in the population previously affected 
by the H2N2 pandemic (Wright et al, 2007; Taubenberger and Morens, 2010). 
 
The re-emergence of H1N1 viruses in 1977 – Russian Influenza (H1N1) 
First noticed in China in May 1977, this outbreak spread through China and Russia, 
reaching other countries the following winter. Confirmed as H1N1, the mortality was 
almost exclusively limited to persons younger than 25 years (Wright et al, 2007). 
This evidence of pre-existing immunity in the older members of the population, 
coupled with the lack of mutations normally acquired during replication in an animal 
host, has lead to the opinion that this pandemic was caused by a previous H1N1 
strain, accidentally reintroduced by humans from a frozen source (Wright et al, 2007; 
Neumann et al, 2009). In addition, a characteristic of influenza virus infection in 
humans is that when a new pandemic strain emerges, it tends to displace the 
previously circulating subtype which disappears. The exception was the H1N1 
Russian pandemic because since 1977, both H3N2 and H1N1 viruses have co-
circulated in humans (Webster et al, 1992; Wright et al, 2007; Neumann et al, 2009). 
 
The H5N1 Outbreak 
Although it has not caused a pandemic, the H5N1 influenza virus was, and continues 
to be, a source of concern. In May 1997, the first documented infection of humans by 
an influenza A virus (H5N1) that was entirely of avian origin, occurred in Hong 
Kong. Prior to this it was believed that the difference in host receptor binding 
specificities would provide a host range barrier making the transmission highly 
unlikely (Wright et al, 2007). The outbreak started with the infection of a three year 
old boy, who later died. In total, eighteen people were infected, with six deaths. The 
source of the infection was domestic poultry but the virus did not appear to be 
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transmissible from human to human. Officials in Hong Kong ordered the culling of 
all poultry in the live bird markets, despite considerable economic loss, which 
prevented any further human cases (Wright et al, 2007; Neumann et al, 2009). 
Unfortunately the virus re-emerged in May 2001 and April 2002, again resulting in 
the depopulation of poultry stocks. An outbreak in July 2003, affecting poultry in 
Vietnam, Indonesia and Thailand, spread to Cambodia, Laos, South Korea, Malaysia, 
Japan, China and Mongolia. Since then the virus has spread to Russia, Ukraine, 
central and south east Europe, the Middle East, and Africa. This spread may have 
resulted from infected migratory birds or possibly the movement of infected poultry 
(Wright et al, 2007). 
The dominant highly pathogenic H5N1 influenza virus strain, genotype Z, contains 
all eight RNA gene segments from avian viruses, indicating that genetic reassortment 
had arisen from multiple reassortment events among avian influenza viruses and not 
between human and avian strains (Li et al, 2004; Wright et al, 2007). Highly 
pathogenic H5N1 viruses are characterised as possessing the multibasic cleavage site 
in the HA protein (Wright et al, 2007) and are lethal to chickens and mice (Wright et 
al, 2007; Neumann et al, 2009). Most importantly, they continue to be transmitted to 
humans resulting in high levels of morbidity and mortality. As of April 21, 2011, 553 
cases of human H5N1 influenza infection have been confirmed, resulting in 323 
deaths (http://www.who.int/csr/disease/avian_influenza/country/cases_table_2011_  
04_21/en/index.html). H5N1 viruses are characterised by their high mortality rate but 
inefficient spread among humans (Neumann et al, 2009). The obvious fear is that, 
through reassortment, this virus may acquire that ability causing a pandemic on the 
scale of the 1918 Spanish influenza. 
 
Swine-Origin influenza virus (S-OIV) H1N1 - 2009 Pandemic 
The first cases of infection with this virus were observed in the Mexican town of La 
Gloria, Veracruz, in February 2009. In April 2009, public health authorities alerted 
the Pan American Health organisation (PAHO), the regional office of the World 
Health Organisation (WHO), to a possible outbreak. The Centre for Disease Control 
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(CDC) subsequently identified two cases of S-OIV in Southern California, caused by 
a similar virus. By the end of April, the international spread of the virus, with human 
to human transmission reported in at least two countries, prompted the WHO to 
elevate the pandemic to phase 5 of 6 (Smith et al, 2009; Neumann et al, 2009). On 
11th June 2009, the pandemic alert was raised to level 6 (Girard et al, 2010). As of 
1st August 2010, more than 214 countries worldwide had reported laboratory 
confirmed cases of pandemic influenza H1N1 2009, including over 18449 deaths, 
although the majority of cases were mild (http://www.who.intt/csr/don/2010_08_06/ 
en/index.html). The virus presented the highest risk to pregnant woman, younger 
children and young adults, while older adults displayed evidence of pre-existing 
immunity from previously circulating H1N1 viruses. Many of the deaths caused by 
the pandemic H1N1 virus occurred in patients with an underlying health condition 
(Peiris et al, 2009; Leung and Nicoll, 2010; Girard et al, 2010). 
The H1N1 S-OIV was determined to have resulted from the reassortment of North 
American H3N2 and H1N2 swine viruses with Eurasian avian-like swine viruses. 
Prior to this, the American H3N2 and H1N2 swine viruses were avian/human/swine 
triple reassortments themselves, meaning the H1N1 S-OIV is a quadruple reassortant 
(Neumann et al, 2009; Girard et al, 2010; Taubenberger and Morens, 2010). The 
H1N1 S-OIV possesses a PB1 gene from human H3N2 virus origin, PB2 and PA 
genes of North American avian virus origin, NA (N1) and M genes of Eurasian 
avian-like swine virus origin and HA (H1), NP and NS genes of classical swine virus 
origin (Smith et al, 2009; Neumann et al, 2009; Girard et al, 2010). The influenza 
virus of classical swine origin, including the H1, is a direct descendent of the 1918 
H1N1 influenza virus, that has circulated in pigs ever since. These viruses have 
remained antigenically stable in pigs, due to the short life span of the pig and this 
may provide an explanation as to why older humans possessed immunity to the 
pandemic H1N1 strain (Peiris et al, 2009). 
Fortunately, the H1N1 S-OIV does not possess markers associated with high 
virulence, such as an HA with a multibasic cleavage site or a PB2 with a lysine at 
position 627 (Wright et al, 2007; Neumann et al, 2009; Peiris et al, 2009; Girard et 
al, 2010). The virus generally caused a mild, self-limiting upper respiratory tract 
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illness, however, the clinical spectrum ranged from asymptomatic to primary viral 
pneumonia with acute respiratory distress, multi-organ failure and death (Peiris et al, 
2009; Girard et al, 2010). The severity of the pulmonary symptoms in some patients 
can be accounted for by the fact that S-OIV can bind to both α2,6-linked sialic acid 
in the upper respiratory tract, as well as α2,3-linked sialic acid receptors deep in the 
lungs (Childs et al, 2009; Girard et al, 2010). The S-OIV H1N1 continues to co-
circulate with seasonal influenza strains and has now been incorporated into the 
trivalent seasonal vaccine for both hemispheres (Leung and Nicoll, 2010). 
 
The next pandemic.... 
The Swine-Origin H1N1 2009 pandemic came as a complete surprise (Girard et al, 
2010), for no-one had predicted the emergence of this subtype. The significance of 
this statement is profound as it underscores our inability to accurately predict when 
or where the next pandemic may occur, let alone what subtype it might be (Girard et 
al, 2010). Previous dogma had dictated that, as previous pandemics arose from a 
subtype that differed from the prevailing influenza in circulation, the most recent 
pandemic should have been anything other than an H1 or an H3 subtype (Peiris et al, 
2009). It remains unclear as to whether H5N1, and other avian-adapted influenza 
viruses, have the ability to acquire the means necessary for efficient human to human 
transmission. It is unknown whether the S-OIV H1N1 will co-circulate with the 
current H3N2 and H1N1 strains or replace them, and whether current vaccination 
strategies will increase or decrease the likelihood of the next pandemic. However, it 
seems likely that reassortment will play a major role in the next pandemic; the last 
three pandemics have resulted from reassortment of pre-existing swine or human 
adapted viruses with imported genes from avian influenza viruses. Finally, it seems 
true of influenza that the more we learn, the less we know and are certain of, when it 
comes to the determinants of pandemics. What is clear is that to prevent and manage 
future pandemics, regardless of subtype, we need to develop pre-emptive and 
effective intervention strategies, which includes novel vaccines, combined with 
effective surveillance and communication (Taubenberger and Morens, 2010).  
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1.1.6. Avian Influenza 
Influenza A viruses infecting poultry can be divided into two distinct groups, Highly 
Pathogenic Avian Influenza (HPAI) or Low Pathogenicity Avian Influenza (LPAI), 
on the basis of the severity of disease they cause. Influenza viruses that cause LPAI 
produce a localized infection resulting in mild disease consisting of respiratory 
disease, depression and decreased egg production in laying birds (Capua and 
Marangon, 2007; Wright et al, 2007). HPAI viruses, such as the H5N1 (Genotype Z), 
are very virulent and cause a systemic infection where flock mortality in susceptible 
species can be as high as 100% (Capua and Marangon, 2007; Wright et al, 2007). 
Other signs of HPAI infection include excessive lacrimation, cyanosis of unfeathered 
skin, and oedema of the head, diarrhoea and nervous disorders (Webster et al, 1992). 
As HPAI viruses possess a HA with a multibasic cleavage site, they are capable of 
replicating throughout the bird, resulting in a systemic infection that causes damage 
to vital organs and increased morbidity and mortality (Rott, 1992; Senne et al, 1996; 
Suarez and Schultz-Cherry, 2000; Alexander, 2003; Baigent and McCauley, 2003; 
Alexander, 2007; Capua and Marangon, 2007; Wright et al, 2007; Lee and Saif, 
2009; Neumann et al, 2009). It is thought that that the conversion from a basic to a 
multi-basic cleavage site occurs through spontaneous duplication of purine triplets 
(Alexander, 2003; Perdue et al, 2003; Alexander, 2007), which appear only after the 
viruses have moved from their natural wild bird host to poultry (Capua and 
Marangon, 2007; Alexander, 2007). The current European Union legislation defines 
HPAI avian influenza as ‘an infection of poultry caused by either any influenza A 
virus that has an intravenous pathogenicity index in 6-week-old chickens greater than 
1.2 or any influenza A virus of H5 or H7 subtype’ (CEC, 1992; Alexander, 2003; 
Capua and Marangon, 2003; Lee and Saif, 2009).  
There have been several serious major outbreaks of HPAI avian influenza that have 
devastated the poultry industry and caused significant human health issues, including 
the risk of generating a new pandemic virus via the human-avian link. These 
outbreaks include the Italian outbreak of HPAI H7N1 in 1999-2000 which saw the 
culling of approximately 14 million birds; the Dutch outbreak in 2003 of HPAI 
H7N7 that resulted in the deaths of over 25 million birds; and the Canadian outbreak 
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of HPAI H7N3 in 2004, where approximately 16 million birds were killed 
(Alexander, 2007; Capua and Marangon, 2007). For years, vaccination against HPAI 
viruses was discouraged, as it was considered that it would interfere with the 
diagnosis of HPAI. However, the increase in outbreaks of HPAI combined with the 
spread of H9N2 and H5N1 has lead to the widespread introduction of avian influenza 
(AI) vaccines in combination with increased biosecurity (Alexander, 2007). AI 
vaccines, when administered properly, can help to prevent, manage or eradicate 
avian influenza and subsequently limit economic losses, improve the health and 
welfare of billions of poultry and positively impact on public health by reducing 
environmental contamination (Swayne and Kapczynski, 2008). 
 
1.2. The Chicken Immune System 
 
1.2.1. The immune system in chickens 
It is evident that, while the immune systems of avian species differ from those of 
model mammalian species, there are also similarities. For example, as with 
mammalian species, dendritic cells and other immune cells such as macrophages are 
present, as are interferons type I-III that include IFN-α, IFN-β, IFN-γ and IFN-λ. 
There are also, however, many differences in terms of the genes, molecules, cells and 
organs that chickens possess, as well as the functional mechanisms that have evolved 
(Kaiser, 2010). The major difference is in the lymphatic system. In mammals, the 
lymph nodes contain B cells, T cells, macrophages and dendritic cells and are the 
primary sites for the immunologic interaction that is important for immune activation 
(Swayne and Kapczynski, 2008). Chickens, however, lack lymph nodes but they do 
possess small concentrations of non-encapsulated lymphoid tissue throughout the 
body (Swayne and Kapczynski, 2008; Kaiser, 2010). The avian-specific primary 
lymphoid organ is the bursa of Fabricius, which is the site of development for B cell 
differentiation and production (Swayne and Kapczynski, 2008; Kaiser, 2010). Other 
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lymphoid tissues include the caecal tonsils, Meckel’s diverticulum, Peyer’s patches 
and the Harderian gland (Swayne and Kapczynski, 2008).  
In addition, chickens possess a different range of Toll-like receptors (TLRs) that 
show a pattern of gene duplication and gene loss (Table 2) when compared to 
mammals (Cormican et al, 2009; Kaiser, 2010). TLRs are type I integral membrane 
glycoproteins, expressed on various immune cells associated with the innate immune 
system, including macrophages, dendritic cells and B cells (Akira et al, 2006; Kaiser, 
2007). They represent a set of immune pattern-recognition receptors (PRRs) capable 
of recognising pathogen-associated molecular patterns (PAMPs), thereby alerting the 
immune system as soon as an infection occurs and causing the recruitment and 
activation of cells of both the innate and adaptive immune response (Akira et al, 
2006; Kaiser, 2010; Moser and Leo, 2010). Birds lack functional eosinophils and the 
avian functional equivalent of the neutrophil is the heterophil, a polymorphonuclear 
cell that actively phagocyte invading pathogens. Furthermore, in comparison to 
mammals, birds also have different cytokines, chemokines, defensins and integrins 
(Lynn et al, 2007; Kaiser, 2007; Kaiser, 2010). Finally, only three immunoglobulin 
classes have been shown to exist in chickens: IgA, IgM and IgY, where IgY is the 
functional equivalent to mammalian IgG (Warr et al, 1995; Karlsson et al, 2004). 
 
1.2.2. The avian immune response 
Despite the physiologic differences in structure and organisation between species, the 
functional aspects of the lymphoid cells and peripheral organs are similar. The avian 
immune system is a multilayered defence system, and as with mammals, it comprises 
the innate immune response and the adaptive immune response which is further 
divided into humoral and cell-mediated immune responses (Swayne and Kapczynski, 
2008; Moser and Leo, 2010).  
 
 






Table 2: - Comparison of the Toll-Like Receptor (TLR) repertoire between humans 
and chickens 
 
TLR Pattern Recognition 
Receptor 
Human Chicken 







TLR1LA and TLR1LB 















CpG recognised by 
TLR21 
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Innate immunity represents the first line of host defence against pathogenic 
organisms that have entered the body, providing almost immediate protection. 
However, it lacks memory and focuses on a limited set of microbial determinants, the 
PAMPs, which are shared by a large number of pathogens (Esser et al, 2003; Moser 
and Leo, 2010). Despite this, the innate immune response is of crucial importance, 
not only as an effective initial response, but also in determining the course of the 
adaptive immune response. Pathogens are targeted by the effector cells of the innate 
response, the dendritic cells (DC), heterophils and Natural Killer (NK) cells and, in 
the case of DCs, presents pathogen antigen to the adaptive immune response via the 
major histocompatability complex (MHC) class II pathway. In addition, the innate 
response also produces cytokines and chemokines that drive the inflammatory 
response and influence the adaptive response (Kaiser, 2010). 
Adaptive immunity provides a second line of defence that is comparatively slower 
and is characterised by a very large set of effector molecules and cells, able to 
efficiently recognise and eradicate pathogens. After elimination, the immune 
response establishes ‘memory’, allowing it to mount a rapid and effective response 
upon re-infection with the same infectious agent (Kaiser, 2010; Moser and Leo, 
2010). The adaptive immune response is further divided into humoral and cell-
mediated immune responses which utilise antibodies and T cell receptors as 
recognition systems respectively (Swayne and Kapczynski, 2008; Moser and Leo, 
2010). Intracellular pathogens are cleared by the cell-mediated immune response; 
extracellular pathogens are cleared via the antibodies of the humoral immune 
response. The end result of the adaptive immune response is clearance of the 




Subsets of T cells, within the cell-mediated immune response, include CD4
+
 T helper 
cells and CD8
+
 cytotoxic T cells that are matured in the thymus (Erf, 2004; Swayne 
and Kapczynski, 2008). There are two main subsets of CD4
+
 T helper cells (Th1 and 
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Th2) that orchestrate and direct the immune response by secreting cytokines, playing 
a regulatory role in the adaptive immune response. Th1 corresponds to the cellular 
immune responses, releasing cytokines that activate macrophages, NK cells and 
CD8
+
 cytotoxic T cells, whereas Th2 corresponds to the humoral response, 
producing cytokines that are associated with antibody production (Esser et al, 2003; 
Erf, 2004; Degen et al, 2005; Swayne and Kapczynski, 2008; Kaiser, 2010). In the 
course of an antibody response, antigen specific CD4
+
 T helper cells interact with 
antigen MHC class II complexes, formed from peptides of endosomal origin, on the 
surface of antigen presenting cells such as DCs, macrophages or B cells. This 
interaction is essential for the induction of high affinity antibodies and immune 
memory through the induction of cytokines (Erf, 2004; Moser and Leo, 2010). The 
CD8
+
 cytotoxic T cells, in comparison, perform targeted removal of host cells 
infected by intracellular pathogens though the delivery of proteases that induce cell 
death (Esser et al, 2003; Zepp, 2010; Moser and Leo, 2010). Cells that have been 
infected present peptides, processed intracellularly via the MHC class I pathway, 
which are displayed for surveillance by the immune system (York and Rock, 1996). 
Cells presenting viral peptides are targeted and destroyed by the effector T cells, the 
CD8
+
 cytotoxic lymphocytes (CTLs) (Erf, 2004; Cinatl Jr et al, 2007; Moser and 
Leo, 2010). Both CD4
+
 T helper cells and CD8
+
 cytotoxic T cells can differentiate 
into memory cells, essential for long-term immunity (Esser et al, 2003; Erf, 2004; 
Ahmed and Gray, 1996). 
 
Humoral Immunity 
Upon an encounter with a specific antigen, in combination with a CD4+ T cell, B 
lymphocytes that express a given antibody are stimulated to divide and differentiate 
into plasma cells, which produce antigen-specific antibodies and memory B cells. 
Antibodies are bifunctional proteins that can both recognize and eliminate an antigen 
or pathogen. They are roughly Y-shaped molecules, made up of two heavy and light 
chains linked together, with constant regions that determine functional properties, as 
well as variable regions that contribute to the antigen binding sites (Moser and Leo, 
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2010). The initial binding of an antibody to its target activates and enhances effector 
mechanisms that lead to removal or destruction of the antigen. These effector 
mechanisms include activation of the classical complement pathway directly on the 
antigen; opsonisation of the antigen for more effective phagocytosis; antigen 
agglutination; and antigen neutralisation as binding would prevent it from interacting 
with cellular receptors, thus inhibiting its infectivity (Erf, 2004). Exposure to the 
same antigen, in combination with signals from CD4+ T helper cells, induces a rapid 
secondary response composed of IgY antibodies that rapidly neutralises the antigen 
(Moser and Leo, 2010). In poultry, abrogation of the bird’s ability to produce a 
humoral response can be achieved by removing the bursa of Fabricius, in ovo, 
eliminating the ability of the chicken to produce B cells and subsequently protective 
antibodies (Swayne and Kapczynski, 2008). 
 
1.2.3. Protective immunity 
Protective immunity may be described as an achieved level of immune-related 
function with the production of antibodies or antigen-specific lymphocytes that 
allows a bird to resist disease following exposure to a pathogen. Protective immunity 
against the influenza virus in immunocompetent birds is predominantly due to 
neutralising IgY antibodies directed against the influenza HA proteins, blocking viral 
attachment, neutralising the infectivity of the virus and preventing infection (Swayne 
and Kapczynski, 2008). By evaluating the relative neutralisation titres of serum 
antibody, shedding of challenge virus and protection against lethal HPAI challenge 
virus, Nayak et al (2010) determined that the HA glycoprotein was the major 
contributor to the induction of neutralising IgY antibodies and protective immunity 
in chickens (Suarez and Schultz-Cherry, 2000; Swayne and Kapczynski, 2008; 
Nayak et al, 2010). NA was found to provide partial immunity but the M2 protein 
did not induce a detectable level of serum-neutralising antibodies or provide 
protection against lethal HPAI virus challenge (Nayak et al, 2010). Antibodies 
directed at the HA glycoprotein of the influenza virus are long-lived in the absence 
of antigenic drift (Cinatl Jr et al, 2007). The understanding of T cell immunity 
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against the influenza virus in chickens is limited, although it has been demonstrated 
that cross-reactive cellular immunity with CD8+ T cells, induced by the H9N2 
influenza virus, protects chickens from the lethal H5N1 virus (Seo and Webster, 
2001, Seo et al, 2002; Haghighi et al, 2009). Haghighi et al (2009) identified a T cell 
epitope of the HA antigen that induced T cell proliferation in chickens immunized 
with a fowlpox virus-based vaccine expressing the H5 protein. The peptide was 
presented by both MHC class I and II molecules, leading to activation of CD4+ and 
CD8+ T cell subsets. Finally, Singh et al (2010) determined that chicken CD8+ T 
lymphocytes respond to the influenza nucleocapsid (NP) and haemagglutinin (HA) 




1.3.1. Early Beginnings 
One of the most effective means to combat infectious diseases is though vaccination 
(Mäkelä, 2000). In 1798, Edward Jenner published his method for the prevention of 
smallpox, following his observation that inoculation with pus from a cowpox lesion, 
which caused a mild disease in humans, would provide immunity to smallpox 
(Jenner, 1798; Strassburg, 1982; Mäkelä, 2000; Borysiewicz, 2010). Regarded as the 
first vaccine, it should be noted that, by this time, human populations had been using 
a form of vaccination, known as variolation, to prevent smallpox for centuries 
(Mäkelä, 2000). With variolation, immunity was induced by inoculating the smallpox 
virus under the skin but the technique had variable outcome, could promote the 
spread of the disease and had a procedural mortality rate of 2-3% (Borysiewicz, 
2010). When vaccination was first proposed, it was widely ridiculed, exemplified in 
James Gillray’s satirical cartoon where the vaccinator is surrounded by his victims 
who have cows emerging from their bodies (Borysiewicz, 2010). However, mortality 
rates fell, as a direct result of vaccination, and the focus of smallpox control switched 
from national to global eradication. The last recorded case of naturally occurring 
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smallpox in the world was diagnosed on 31st October 1977 and on 8
th
 May 1980, the 
World Health Organization declared the world free of smallpox (Strassburg, 1982; 
Borysiewicz, 2010).  
 
1.3.2. Vaccines 
Vaccination has been one of the most effective interventions to decrease mortality 
and morbidity due to infectious diseases. The best immune response is induced 
following natural infection with the pathogenic organism, although this may result in 
high mortality. Vaccines work on the principle that they induce protective immunity 
against the disease causing pathogen, but without causing the disease (Swayne and 
Kapczynski, 2008; Zepp, 2010). The goal of a vaccine is to induce long term 
immunological memory that, once reactivated, can respond quickly and efficaciously 
(Esser et al, 2003; Moser and Leo, 2010). An ideal vaccine is a non-virulent, 
attenuated or inactivated form of a pathogen, able to elicit a strong and protective 
immune response in vivo (Moser and Leo, 2010). The primary mechanism of 
protection is through the generation of neutralising antibodies, rather than the 
induction of cell-mediated immunity (Wilson-Welder et al, 2009). However, 
advances in biotechnology and the development of a greater understanding of the 
immunology and pathogenesis of disease, has allowed an increased level of 
sophistication of vaccine design (Mäkelä, 2000). This is necessary as, although 
vaccination is undoubtedly the most effective means of controlling infectious 
disease, the problem becomes more complex when dealing with zoonotic infections, 
such as avian influenza. The successful control of this virus continues to present a 
major challenge, although combating the influenza virus at the animal source would 
help to reduce human exposure to emerging strains by decreasing the global levels of 




Chapter 1  Introduction 
30 
 
1.3.3. Vaccine Adjuvants 
To improve the immunogenicity of vaccines, adjuvants (from the Latin word 
adjuvare, meaning ‘to help’) can be introduced into the vaccine formulations 
(Nicholls et al, 2010; Zepp, 2010). An adjuvant is an agent that increases the 
response to a vaccine by providing a reservoir for the slow release of antigen 
(Wilson-Welder et al, 2009).  In addition, the presence of an adjuvant enhances the 
immune response by functioning as a delivery system, enhancing the uptake of the 
antigen by antigen presenting cells (APCs) (Wilson-Welder et al, 2009; Leroux-
Roels, 2010). Only inactivated/killed or component vaccines such as subunit or DNA 
vaccines require the addition of adjuvants; live and recombinant vaccines induce 
effective humoral and cell-mediated immune responses so do not require the 
presence of adjuvants in the formulation (Brun et al, 2008; Nicholls et al, 2010). This 
is due to the fact that inactivated or highly purified vaccines lose part of their 
intrinsic immunostimulatory ability when produced, and thus are simply not 
considered threatening enough by the immune system (Moser and Leo, 2010; 
Leroux-Roels, 2010).  
Aluminium compounds were originally identified as adjuvants more that eighty years 
ago, and since then aluminium salts have been widely used in vaccines to generate 
effective immune responses (Brewer, 2006; Leroux-Roels, 2010). Aluminium salts 
provide proinflammatory or immunostimulatory effects as well as prolonging the 
persistence of vaccine antigens by slowing down antigen degradation (Nicholls et al, 
2010; Zepp, 2010). Oil emulsion vaccines slowly release antigen over time, resulting 
in higher immune responses than would be produced from antigen alone (Swayne 
and Kapczynski, 2008). Water-in-oil (w/o) emulsions, such as Freund’s adjuvant and 
oil-in-water (o/w) emulsions, such as MF59, have both been utilised in avian 
influenza vaccine preparations (Leroux-Roels, 2010; Nicholls et al, 2010). In 
addition, modifying the oil phase can change the overall immune response to the 
vaccine. For example, non-metabolizable oils like mineral oil generally produce 
higher antibody responses when compared with biodegradable oils such as vegetable 
oil, although the non-metabolizable oils can cause increased damage to host tissue at 
the site of injection (Swayne and Kapczynski, 2008). Other adjuvants include 
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liposomes and virosomes, TLR ligands, the water soluble polymer polyphosphazene, 
saponins such as Quil A, and immune-stimulating complexes (ISCOM) that are 
composed of lipids, cholesterol, antigen and Quil A (Leroux-Roels, 2010; Nicholls et 
al, 2010). Finally, cytokines can enhance the immune response (Wilson-Welder et al, 
2008). Chicken myelomonocytic growth factor (cMGF), for example, has a positive 
effect on the efficacy of Marek’s Disease vaccines by activating macrophages, 
increasing survival time and lowering viraemia following challenge with a very 
virulent Marek’s Disease Virus (vvMDV) strain (Djeraba et al, 2002; Asif et al, 
2004; Gimeno, 2008). Other cytokines that have been shown to possess adjuvant 
activity include interleukin-18, IFN-α, IL-β and IFN-γ, all of which have the 
potential to be used in vaccine formulations to provide improved protection against 
disease (Asif et al, 2004; Hung et al, 2010; Nicholls et al, 2010). 
 
1.3.4. Avian Influenza Vaccines 
Avian influenza represents one of the greatest concerns to public health that has 
emerged from an animal reservoir. The emergence of H5N1 HPAI viruses in Asia, 
and the subsequent outbreaks of serious disease in humans and poultry, focused the 
attention of the world on the influenza virus. With the potential risk of human 
pandemic viruses being created via the avian-human link, infections caused by this 
virus have assumed a completely different profile in both the veterinary and medical 
scientific communities (Webster et al, 2006; Capua and Marangon, 2007). In June 
2009, fears of a potential influenza pandemic were confirmed when a new influenza 
A H1N1 virus emerged and spread through the human population causing the first 
pandemic of the 21
st
 century (Peiris et al, 2009; Smith et al, 2009; Neumann et al, 
2009; Girard et al, 2010). 
Vaccines are essential tools for the control of avian influenza because they increase 
resistance to infection, prevent illness and death, reduce virus replication and reduce 
virus transmission to other birds and mammals, including humans (Swayne and 
Kapczynski, 2008). The successful control of influenza would also help avoid severe 
economic losses that would result from mass depopulation policies in the event of an 
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outbreak (Capua and Marangon, 2003). Avian influenza vaccines, properly selected 
and correctly administered, will protect against clinical signs and mortality, reduce 
the levels and duration of virus excretion and increase the resistance of the host to 
infection. However, it is important that vaccination is never the sole method of 
disease control. It should be combined with other control measures such as good 
biosecurity and strict monitoring systems (Capua and Marangon, 2003; Marangon et 
al, 2008; Capua and Alexander, 2008; Swayne and Kapczynski, 2008).  
In addition, the considerations for the development of veterinary vaccines differ from 
humans in some respects, one of the most important of which is cost, as a high cost 
would preclude the use of certain types of vaccines. Also, the ability to distinguish 
between infected and vaccinated animals (DIVA) is essential for the eventual 
eradication of HPAI or LPAI, without the mass culling of birds. The DIVA strategy 
is necessary due to the lack of clinical signs seen in birds infected with a field virus 
(Brun et al, 2008; Capua and Alexander, 2008). Most importantly, vaccines should 
produce a consistent immune response, be protective against circulating field strains, 
and be administered properly to a high percentage of the susceptible population to 
produce flock immunity (Swayne and Kapczynski, 2008). 
There are six general types of avian influenza vaccine which include inactivated, 
subunit, DNA vaccines, live attenuated virus, recombinant vectors expressing foreign 
genes and most recently, virus like particles (VLPs). All have specific advantages 
and disadvantages but only inactivated and recombinant type AI vaccines have 
received licensure for commercial use (Swayne and Kapczynski, 2008, Brun et al, 
2011). 
 
Inactivated vaccines  
Inactivated viral vaccines are essentially inert antigens that induce CD4
+
 T cell and 
humoral responses (Dudek and Knipe, 2006). The overwhelming majority of AI 
vaccines produced and sold for use in poultry are oil emulsion, inactivated whole AI 
virus vaccines that are administered either subcutaneously or intramuscularly.  
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Conventional inactivated vaccines aimed at H5, H7 and H9 subtypes are now 
commercially available and have been licensed for use in a number of countries 
(Capua and Alexander, 2008). These vaccines have the advantage of being very safe 
as, although most of the proteins that induce the protective immune response are 
present, the organism cannot replicate and therefore establish a persistent infection or 
revert to a virulent form (Wilson-Welder et al, 2009).  It is rare for such vaccines to 
contain residual infective virus that has resisted inactivation and there is no reversion 
to virulence by the vaccine (Graham and Crowe Jr, 2007). Inactivated vaccines are 
prepared by first propagating the virus in 9-11 day old embryonating chicken eggs, 
harvesting the infected allantoic fluid and chemically inactivating the viruses with 
formalin, β-propiolactone or binary ethylenimine (Capua and Alexander, 2008; 
Swayne and Kapczynski, 2008; Swayne, 2009). The inactivated vaccine can induce 
protection in multiple species of poultry but in order to ensure a high immunological 
protection, more than one administration may be required (Marangon et al, 2008). In 
general, inactivated vaccines primarily provide protection via humoral immunity and 
do not stimulate cell-mediated immunity. This is due to the fact that, for an effective 
CD8+ cytotoxic T lymphocyte response, antigens must be processed through the 
proteasome so that the peptides can be transported in the endoplasmic reticulum and 
associate with the MHC class I molecules (Graham and Crowe Jr, 2007; Cinatl Jr et 
al, 2007; Swayne and Kapczynski, 2008). To help increase the immunogenicity and 
produce a greater immune response, an adjuvant such as an oil emulsion can be 
added (Swayne and Kapczynski, 2008). Recent research has focused on developing 
safe and effacious oil-adjuvented H5N1 avian influenza vaccines (Kydyrbayev et al, 
2010; Imamura et al, 2010).  
  
Protein Subunit vaccines 
Improvements in industrial fermentation, purification and production processes have 
allowed subcomponents of pathogens to be isolated and produced in large quantities 
(Zepp, 2010). Avian influenza protein subunit vaccines are based on in vitro 
expression of the HA gene in animal or plant cells, bacteria or yeast. Once expressed, 
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the HA protein is purified away from cell extracts, quantified, oil emulsified and 
injected parenterally. No live virus is involved so protein subunit vaccines are safe; 
however, production costs can be very high (Swayne and Kapczynski, 2008; 
Swayne, 2009). In addition, the immune response tends to be weaker so multiple 
doses, as well as adjuvantation, is required to induce sufficient protection (Cinatl Jr 
et al, 2007; Zepp, 2010). Baculovirus vectors have been used to express both H5 and 
H7 HA in cell culture supernatants, for the immunization of poultry, and induced 




DNA vaccination involves the introduction of DNA expression vectors encoding 
immunogenic proteins into cells, thereby inducing a CD8
+
 cytotoxic T cell response 
(Ulmer et al, 1993). Using this method, plasmid DNA-based vaccines that express 
the AI HA gene can provide protective immunity towards influenza. Following 
vaccine application and uptake by host cells, the HA gene is transcribed into RNA 
and transported to the cytoplasm for protein translation. The endogenously expressed 
protein antigen is processed intracellularly via MHC class I proteins, stimulating 
cytotoxic T cells, or by MHC class II molecules for the stimulation of humoral 
immunity (Swayne and Kapczynski, 2008; Swayne 2009). DNA vaccines are safe as 
the production of plasmids does not require handling of infective agents and, because 
immunity is only directed towards the plasmid encoded antigen, it is easy to 
differentiate infected from vaccinated animals. However, although DNA vaccines do 
induce a humoral and cellular response, they have a relatively low efficacy and a 
large amount of DNA is required to produce a strong response (Brun et al, 2011). 
The development of DNA vaccines to deliver the haemagglutinin gene was first 
carried out in 1993 (Robinson et al, 1993; Fynan et al, 1993). Currently, however, no 
DNA vaccines have been licensed for use in poultry due to the high manufacturing 
costs and the requirement of multiple vaccinations to achieve immunity (Swayne and 
Kapczynski, 2008).  
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Live attenuated vaccines 
A live attenuated vaccine is a live virus that has lost its virulence while maintaining 
its ability to replicate (Brun et al, 2008; Wilson-Welder et al, 2008). Live attenuated 
vaccines induce humoral and cellular immunity and provide superior and longer 
lasting protection compared with inactivated vaccines (Brun et al, 2008; Swayne and 
Kapczynski, 2008; Zepp, 2010). In addition, these vaccines have a relatively low 
manufacturing cost as they do not require adjuvants in the formulation (Brun et al, 
2008; Wilson-Welder et al, 2009). However, in regards to avian influenza, there is a 
danger that live LPAI vaccines could reassort and mutate from LPAI to HPAI viruses 
(Graham and Crowe Jr, 2007; Swayne and Kapczynski, 2008; Zepp, 2010), although 
this could be avoided using in ovo vaccination as other influenza strains would not be 
present in the egg (Cai et al, 2011). Additionally, live LPAI vaccines may cause 
unacceptable respiratory disease or drops in egg production and can spread to 
neighbouring farms (Swayne and Kapczynski, 2008). One solution to address this 
was to use reverse genetics (Hoffmann et al, 2000; Hoffmann et al, 2002) to engineer 
an AI virus with reduced pathogenicity, either by mutating the haemagglutinin 
cleavage site (Cai et al, 2011), or by deleting the NSI gene which is associated with 
virulence and evasion of the host immune system (Palese and Shaw, 2007). The 
resulting vaccine displayed decreased replication and attenuation of infectivity, but 
retained immunogenicity, safely eliciting both humoral and cell-mediated immune 
responses (Palese and Shaw, 2007; Swayne and Kapczynski, 2008; Cauthen et al, 
2007; Brahmakshatriya et al, 2010). 
 
Recombinant vectors expressing avian influenza genes 
Recombinant vaccines for avian influenza viruses have been produced by inserting 
the gene coding for the influenza virus HA protein into a live virus vector and using 
this recombinant virus to vaccinate against influenza. These live vaccines are ideal as 
they replicate, presenting the foreign antigen to the immune system in the context of 
an intracellular infection, with the expectation of stimulating humoral and cellular 
immunity. This intracellular expression and processing of the antigen allows for 
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presentation to the immune system in the context of the MHC class I system, giving 
the option to stimulate specific cytotoxic T cells (Capua and Alexander, 2008; Zepp, 
2010). In addition, viral vectors can be mass applied to vaccinate with minimal 
labour, such as the robotic vaccination of fertile eggs or with rapid vaccinations used 
at one day of age (Swayne and Kapczynski, 2008). They allow easy distinction 
between vaccinated and infected birds as antibodies to the common influenza 
proteins, matrix and nucleoprotein, are not produced (Capua and Alexander, 2008). 
Disadvantages include a limited host range and vaccine failure if the birds to be 
vaccinated already possess immunity to the vector (Capua and Alexander, 2008).  
There are several examples of viral vectors used for the in vivo expression of 
influenza haemagglutinin genes in poultry. A live attenuated fowlpox virus was 
originally developed which expressed the HA molecule from a highly virulent H5 
strain of avian influenza (Taylor et al, 1988; Swayne, 2009). A recombinant fowlpox 
(recFP) vector expressing the H5 HA gene, designated TROVACTM-AIV H5 
(TROVAC H5), was commercialized and used extensively in Mexico, El Salvador 
and Guatemala, with 1.6 billion doses used in the field (Bublot et al, 2006; Swayne 
and Kapczynski, 2008). Other examples of live attenuated viruses used to deliver an 
influenza HA gene include vaccinia virus (Chambers et al, 1988), adenovirus (Gao et 
al, 2006; Tang et al, 2009), Rous sarcoma virus (Hunt et al, 1988), infectious 
laryngotracheitis virus (Luschow et al, 2001; Pavlova et al, 2009), Venzuelan equine 
encephalitis virus (Schultz-Cherry et al, 2000) and Newcastle disease virus (Ge et al, 
2007; Nayak et al, 2009). 
 
Virus-Like particles 
Virus-like particles (VLPs) are composed of recombinantly expressed viral proteins 
that spontaneously assemble into structures resembling infectious viruses. VLPs are 
highly immunogenic, however, because they lack viral nucleic acid, they are non-
pathogenic and very safe (Brun et al, 2011). Gómez-Peurtas et al (2000) 
demonstrated that the matrix (M1) protein is the only viral component which is 
essential for VLP formation and that the viral RNPs are not required for virus 
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particle formation. By developing a recombinant baculovirus that expressed the HA, 
NA, M1 and M2 proteins of the influenza virus in Sf9 insect cells, Latham and 
Galarza (2001) demonstrated the successful formation of influenza VLPs. These 
closely resembled the influenza virus in size, morphology and fine structure of 
surface spikes, but lacked the influenza ribonucleoprotein complex (Latham and 
Galarza, 2001). A further study demonstrated that the influenza virus HA and NA, 
but not the M2 protein, are required for the formation of plasmid derived VLPs 
(Chen et al, 2007). In comparison with available influenza vaccines, the 
immunization of mice with influenza VLPs elicited better immune responses that 
inactivated whole virus vaccine or recombinant HA (Bright et al, 2007). Most 
recently, influenza VLPs have been created for the successful vaccination of ferrets 
against the 2009 pandemic H1N1 influenza strain (Pushko et al, 2010), and the 
vaccination of poultry against an H9N2 influenza virus (Lee et al, 2011). 
 
1.3.5. A universal influenza vaccine 
By evolving variants through genetic mutation, in response to the host immune 
response, influenza viruses can evade neutralisation. As a result of this antigenic 
drift, influenza vaccines must be prepared each year so that they closely match 
circulating strains. However, as the 2009 H1N1 pandemic demonstrated, completely 
new strains can unexpectedly emerge, against which the currently used strain-
specific vaccine cannot protect (Nabel and Fauci, 2010). An ideal influenza vaccine, 
therefore, would be effective at producing a protective immune response against a 
range of virus subtypes, including emergent pandemic strains (Cinatl Jr et al, 2007; 
Du et al, 2010). To this end, research has focused on areas of the influenza virus that 
would induce heterosubtypic immunity, where protective immunity against a range 
of influenza subtypes can be induced by a single vaccine (Nabel and Fauci, 2010).  
For example, a human vaccine study has focused on the M2e peptide, the highly 
conserved ectodomain of the influenza M2 protein, rather than haemagglutinin, to 
provide protective immunity (Fiers et al, 2009). However, as previously stated, 
immunization of chickens with the M2 protein did not provide protection against 
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lethal HPAI virus challenge (Nayak et al, 2010). An alternative approach has 
concentrated on the creation of influenza vaccine constructs that contain the stem 
region of the haemagglutinin spike, HA2, but not the globular head, HA1. The 
rational is that HA2 is more conserved, and during normal infection or vaccination, it 
is masked from neutralising antibodies by the bulky, and immunogenic, globular 
head (Steel et al, 2010; Nabel and Fauci, 2010). What is not yet clear is whether 
these antibodies will be effective against wildtype strains, which still possess the 
globular head. However, with the continued identification of conserved regions in the 
HA glycoprotein, vaccines that can induce stronger immunity and improved cross-
protective efficacy against divergent influenza virus strains may be created (Du et al, 
2010). 
 
1.4. Marek’s Disease (MD) 
 
1.4.1. Marek’s Disease Virus (MDV) 
Marek’s Disease (MD), a lymphoproliferative disease of chickens, is caused by the 
Marek’s Disease Virus (MDV), which was first identified in 1967 using electron 
microscopy and negative staining (Churchill and Biggs, 1967). Witter et al (1969) 
subsequently confirmed that MDV was the etiologic agent of Marek’s Disease 
(Witter et al, 1969). The virus is highly cell-associated; cell-free virus is only found 
in the feather follicle epithelium (FFE) of infected birds, an important and efficient 
route of transmission for the disease (Calnek et al, 1970; Gimeno, 2008).  
MDV, which belongs to the Alphaherpesvirinae family, includes three serotypes that 
were determined initially using indirect immunofluorescence tests (Bülow and Biggs, 
1975). MDV serotype 1 (MDV-1) includes all the oncogenic strains and their 
attenuated forms; MDV serotype 2 (MDV-2) includes all the non-oncogenic strains 
isolated in chickens; serotype 3 includes all the non-oncogenic strains isolated in 
turkeys, Herpesvirus of Turkey (HVT) (Bülow and Biggs, 1975; Nair, 2005; 
Gimeno, 2008). All three serotypes are grouped in the taxonomic genus of 
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Mardivirus (Nair, 2005; Gimeno, 2008). MDV-1 is now classified as Gallid 
herpesvirus 2 (GaHV-2), MDV-2 as Gallid herpesvirus 3 (GaHV-3) and HVT as a 
meleagrid herpesvirus (Schumacher et al, 2000). 
Initially, MDV was thought to belong to the same family as the Epstein-Barr virus, 
Gammaherpesvirinae, due to their similar biological properties. Both viruses grow 
slowly in cell culture and induce T cell lymphomas (Osterrieder et al, 2006). 
However, when the molecular structure and genomic organisation of MDV was 
analysed, it was found to have more similarities with Herpes Simplex Virus (HSV), 
an alphaherpesvirus (Fukuchi et al, 1984; Tulman et al, 2000). This was confirmed 
using gene sequence and mapping data from MDV and HVT, which indicated that 
the sequences bore a greater similarity to the alphaherpesvirus, Varicella Zoster 
Virus (VZV), than to EBV (Buckmaster et al, 1988).  
 
1.4.2. Marek’s Disease (MD) 
Marek’s Disease was first described by Joszef Marek in 1907 as a polyneuritis with 
low morbidity and negligible mortality (Marek, 1907; Gimeno, 2008). Also known 
as fowl paralysis, the disease was found to cause lymphoid tumours in visceral 
organs and pathological changes to the nervous system (Pappenheimer et al, 1929a; 
Pappenheimer et al, 1929b). Marek’s disease is a great concern for the poultry 
industry as it is capable of causing devastating losses to commercial poultry stocks 
(Gimeno, 2008). 
All chickens are susceptible to infection with MDV. The infection occurs by the 
inhalation of dust in the poultry house environment that has been contaminated with 
viruses shed from the FFE of infected birds. Lymphoid cells are the main targets of 
MDV, and after initial replication in the lungs, the virus replicates in the lymphoid 
tissue (bursa of Fabricius, thymus and spleen). B lymphocytes and macrophages 
undergo a lytic infection that results in the activation of T cells, which are targeted 
by the virus. Infected T cells carry the virus to the FFE. After the early cytolytic 
phase, infection switches to a latent phase in the infected T cells after 7-8 days. 
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These T cells become targets for neoplastic transformation resulting in the 
development of lymphomatous tumours in various visceral organs as well as nerves, 
the brain and the skin (Nair, 2005; Baigent et al, 2006; Gimeno, 2008). 
Only MDV-1 viruses are pathogenic and capable of causing tumours. Highly virulent 
strains are capable of inducing a high frequency of lymphoproliferative lesions in the 
brain and a higher rate of mortality due to brain edema (Gimeno, 2008).  
 
1.4.3. MDV vaccination 
Over time, Marek’s Disease has changed in severity and clinical manifestations, 
turning from an endemic, mild paralytic syndrome (mMDV), into a highly 
contagious, aggressive, neoplastic disease with a worldwide distribution. The ability 
of MDV strains to continuously evolve towards greater virulence is becoming a 
major concern for the poultry industry and veterinarians (Witter, 1997; Nair, 2005). 
At the start of the twentieth century, poultry production was characterised by low 
population densities, low egg production and varied combinations of different ages 
and breeds. World War II accelerated the growth of the poultry industry and, as 
greater intensive poultry farming practices were introduced, the disease became more 
severe. With the new form of the disease, chickens developed MD at a younger age 
with a high incidence of visceral lymphoid tumours, nerve lesions and a mortality 
rate in excess of 30%. This much more severe form of the disease became known as 
acute or virulent MD (vMDV) and, by the 1960s, had become the predominant form 
in most countries that had a well-developed poultry industry (Witter, 1997; Gimeno, 
2008). 
Marek’s Disease has been successfully controlled since 1969, when it was found that 
attenuated MDV protected chickens against challenge with a vMDV strain (Churchill 
et al, 1969). This first vaccine, an attenuated strain (HPRS-16) of MDV-1 (Churchill 
et al, 1969), was the first vaccine against a neoplastic disease, as well as being one of 
the most effective for a herpesvirus. The control of MD by vaccination was a major 
step in the development of the modern poultry industry (Gimeno, 2008). 
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Soon after, a second vaccine was developed (Okazaki et al, 1970), based on the HVT 
strain that had been isolated from the kidney cell culture of normal turkeys 
(Kawamura et al, 1969). This HVT vaccine brought about a widespread reduction in 
MDV-induced poultry losses (Nair, 2005), although this was not sustained as the use 
of MD vaccines was accompanied with an increase in virulence of MDV (Witter, 
1997). A unique feature of HVT is that it can be obtained as a cell-free virus by the 
sonication of infected cell cultures, allowing the production of cell-free lyophilized 
HVT vaccines. MDV, unlike HVT, is highly cell-associated and must be produced in 
chicken embryo cells, stored in liquid nitrogen, and administered as a viable cell 
suspension (Baigent et al, 2006; Gimeno, 2008). Cell-associated vaccines are very 
labile, so although the efficacy of HVT vaccines is not as high, they are a good 
solution for some countries where the logistics of maintaining a cold chain is a factor 
(Gimeno, 2008). 
The introduction of vaccines, combined with the major changes to the poultry 
industry, seemed to play a major role in this increased virulence (Nair, 2005). Prior 
to this, both the virus and the host co-existed in a balanced state. With the advent of 
highly intensive farming practices, the poultry house provided the virus with a large 
number of genetically susceptible hosts and an ideal environment to persist outside 
the host for long periods (Nair, 2005). This, coupled with the widespread use of 
vaccines, forced the virus to evolve rapidly and a new, more virulent MDV strain 
emerged. This strain was termed vvMDV, to differentiate it from the previous milder 
strains, mMDV and vMDV (Witter, 1983; Witter, 1997; Gimeno, 2008).  
To respond to these new, more virulent strains, a bivalent vaccine was created, 
consisting of HVT and the apathogenic, MDV-2 strain, SB-1 (Schat et al, 1982; 
Gimeno, 2008). Combinations of strains provide better protection than either vaccine 
alone, an effect known as protective synergism (Baigent et al, 2006; Gimeno, 2008). 
Although this was initially successful, fresh outbreaks of the disease occurred due to 
even more virulent strains, designated vv+MDV (Witter, 1997; Nair, 2005). 
Subsequently, a third vaccine was introduced. Known as the CVI988 Rispens strain, 
it had been developed from a natural isolate of MDV-1 and had been used widely in 
Europe since 1972 (Rispens et al, 1972a; Rispens et al, 1972b; Nair, 2005; Gimeno, 
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2008). The CVI988 strain, which was found to be serologically identical to the 
(HPRS-16) strain (Bülow, 1977), had a low oncogenic potential upon isolation but 
was further attenuated by passaging the virus in duck embryo fibroblast (DEF) cell 
culture 26-35 times (Gimeno, 2008). As before, the introduction of this vaccine saw 
a reduction in MD-induced mortality caused by the vv+MDV strain (Nair, 2005).  
The step-wise evolution of MDV is shown in Figure 6, demonstrating the increasing 
virulence of emerging MDV strains in response to the introduction of different 
generations of vaccines (Nair, 2005). Currently the CVI988 vaccine provides the best 
protection when compared to other vaccines (Witter et al, 1995; Gimeno, 2008). It 
has, however, been suggested that there may be a limit to the ability of the chicken to 
develop protective immunity in response to vaccination and this threshold has 
already been achieved with CVI988 (Witter and Kreager, 2004; Gimeno, 2008). 
Outbreaks of MDV-induced morbidity and mortality in vaccinated birds, by these 
increasingly virulent strains, may be in part due to inherent weakness in the 
vaccination strategies. For example, the traditional vaccination of 1 day old chicks 
does not allow sufficient time for the formation of an adequate immune response (7-
14 days of age). Early immunity is essential as the chicks generally face challenge 
from MDV within a few days of being introduced into the brooding pens. Instead, it 
was found that in ovo vaccination with CVI988 at 18 days of embryonation induced 
early post-hatch protection against vvMDV (Zhang and Sharma, 2001; Baigent et al, 
2006; Gimeno, 2008). Currently, over 80% of US broilers are immunised in ovo with 
MD vaccine. Compared with field vaccination, in ovo vaccination provides uniform 
and fast delivery, reduced labour costs and decreased stress to the birds and the 
production of an early immune response (Cai et al, 2011). In addition, vaccination 
with suboptimal vaccine doses, or the immunosuppression caused by other 
pathogens, means that MDV strains can replicate in partially immune birds. Under 
such conditions, the virus will not be prevented from adapting and evolving into 
more virulent strains (Nair, 2005).  
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1.4.4. The future of MDV vaccines 
Current MDV vaccines greatly reduce the level of latency of the wild-type virus and 
the development of tumours. This is due to the vaccine-stimulated host defences 
acting on the replication of MDV, reducing the viral load. Subsequently, the 
probability of neoplastic transformation of lymphoid cells is decreased and the 
immunosuppressive effects of MDV are diminished, allowing the host to mount a 
more effective immune response (Payne et al, 1978; Gimeno, 2008). Vaccinated 
birds can, however, be superinfected by virulent strains, and although the quantity of 
virulent MDV shed from the FFE is reduced, a minimum level of replication in the 
FFE is enough to spread the disease very efficiently to other chickens. This failure of 
vaccines to induce sterile immunity in the host and prevent the infection, replication 
and shedding of virulent virus strains means that the evolution of the virus is not 
halted. Fortunately, through the continued development of MDV vaccines, MD has 
been successfully controlled (Nair, 2005; Gimeno, 2008). 
There is concern, however, that the CVI988 strain is one of the last in the line of 
effective vaccines against MDV and that, as the evolution of MDV produces greater 
virulence that the CVI988 vaccine cannot protect against, the effect on the poultry 
industry will be catastrophic (Nair, 2005; Spatz et al, 2007). Consequently, 
vaccination techniques are monitored, improved and revaccination is repeated if 
necessary. A real-time polymerase chain reaction (PCR) assay for the quantification 
of CVI988 vaccine virus in the feather tips has been developed commercially to 
confirm the successful vaccination of chicks (Baigent et al, 2005; Baigent et al, 
2006). Any disease outbreaks of MD that occur are managed using polyvalent 
vaccines (combined serotypes 1, 2 and 3). In addition, research has focused on 
gaining a better understanding of the biology of MDV and its genome, potentially 
paving the way for a new generation of molecularly defined vaccines (Nair, 2005). 
To this end, the MDV genome was cloned into a Bacterial Artificial Chromosome, so 
that the functions of various genes could rapidly and efficiently be ascertained.   
 
 







































Figure 6. Step-wise evolution of virulence of MDV. Adapted with 
permission (Nair, 2005). 
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1.5. Bacterial Artificial Chromosomes (BACs) 
Bacterial Artificial Chromosomes (BACs) are DNA constructs derived from the 
naturally occurring F’ (Fertility) plasmid found in the bacterium Escherichia coli (E. 
coli) (Kim et al, 1992; Shizuya et al, 1992). F’ plasmids, carrying inserted bacterial 
DNA, are capable of maintaining fragments as large as 1 Mb, which led to 
speculation that they would suitable for cloning viral genomes (Shizuya et al, 1992). 
The first herpesvirus BAC mutant was created for murine cytomegalovirus in 1997 
and since then the technology has proved to be an invaluable tool for studying 
herpesvirus pathogenesis (Messerle et al, 1997; Warden et al, 2011). Knowing the 
function of individual, or families of, genes is important in understanding their role 
in pathogenesis, in determining their potential as a therapeutic target or for the 
purpose of vaccine design (Adler et al, 2003). The BAC approach was conceived 
because the herpesvirus genomes, ranging in size from 125-240 kb, are too large to 
be incorporated into an individual plasmid or cosmid construct which can incorporate 
up to 10 kb or 30 kb of DNA, respectively (Warden et al, 2011). A technique for the 
construction of recombinant herpesviruses from cloned overlapping cosmid clones 
was developed, allowing the study of herpesvirus pathogenesis through the 
introduction of mutations (Zijl et al, 1988; Brune et al, 2000; Reddy et al, 2002). 
This technique, however, relies on several recombination events to create the mutant 
virus and this was difficult to control (Messerle et al, 1997). In addition, cosmid 
technology does not easily allow the construction of revertants that can prove the 
altered property is a function of the deliberately introduced mutation (Brune et al, 
2000). Yeast artificial chromosomes (YACs) can also incorporate large DNA 
sequences, but BACs are more suitable for virus studies as they are more stable and 
less prone to undesired genomic rearrangements (Monaco and Larin, 1994; Brune et 
al, 2000; Warden et al, 2011). It was found that the F’ plasmid could propagate 
mammalian genomic DNA inserts with significantly greater stability (Kim et al, 
1992). Using the BAC system, large DNA fragments from varied genomic sources 
can be cloned into E. coli, where the DNA is stable, easy to manipulate and 
represents a single foreign DNA source (Shizuya et al, 1992). In addition, purified 
BAC DNA containing the CMV genome was infectious and this allowed the 
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generation of replication-competent viruses following transfection into an 
appropriate cell line (Messerle et al, 1997). 
 
1.5.1. BAC Vectors 
To create the viral BACs, the F’ plasmid or BAC vector cassette sequence was 
inserted into the viral genome using site-directed mutagenesis (Warden et al, 2011). 
A typical BAC vector is about 10 kb in length and contains an origin of replication 
(oriS) and BAC replication (repE) gene which are both responsible for the 
unidirectional replication of the F’ plasmid. The genes parA and parB both control 
the rate of replication so that the number of copies in a bacterial cell is limited to one 
or two (Shizuya et al, 1992; Warden et al, 2011). In addition, an antibiotic resistance 
gene such as chloroamphenicol and a selectable marker (SacB) must be present so 
that bacterial colonies containing the BAC can be selected. The SacB gene encodes a 
protein called levansucrase, which catalyzes the polymerization of fructosyl groups 
in sucrose to form levan, a substance toxic to E. coli (Lepesant et al, 1972; Bramucci 
and Nagarajan, 1996; Wagner et al, 2002). The BAC vector must be flanked by 500-
1000 base pairs that are homologous to the target sequence of the viral genome 
where the BAC vector will be inserted via homologous recombination (Warden et al, 
2011). For this to be successful, a long non-essential region of the virus must be 
identified to avoid severe growth defects in the virus (Brune et al, 2000; Warden et 
al, 2011). Finally, the BAC vector containing viral DNA is transformed into an E. 
coli strain (DH10B or DH5-α) via electroporation, made easier due to the tendency 
of the herpesvirus genome to circularise during replication (Warden et al, 2011). It is 
necessary to use a bacterial strain in which the recABCD recombination system is 
disrupted, as the repetitive sequences in herpesviruses genomes are targets for 
recombination. As the DH10B and DH5-α strains are recA-negative, this helps to 
increase the stability of cloned sequences. The recA enzyme, however, is essential 
for allelic exchange by homologous recombination to occur so is transiently 
expressed by the shuttle plasmid used in BAC mutagenesis (see below) (Brune et al, 
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2000; Wagner et al, 2002; Adler et al, 2003). Once created, viral BACs in E. coli can 
be stored at -80
o
C (Warden et al, 2011). 
 
1.5.2. BAC Mutagenesis 
The large size of herpesvirus BAC genomes prohibits the use of conventional 
enzymatic cleavage and ligation techniques to introduce or delete DNA (Wagner et 
al, 2002). BAC mutagenesis by homologous recombination is achieved by 
constructing a shuttle plasmid that contains the mutation to be introduced, flanked by 
sequences homologous to the integration site. The alignment of similar sequences 
allows a crossover between the aligned DNA strands resulting in an exchange of 
material, subsequently introducing the mutation into the herpesvirus BAC. Once 
constructed, the shuttle plasmid (encoding the recA gene, as well as the SacB gene 
and a temperature sensitive origin of replication, RepTS), is subsequently 
transformed into the same E. coli host (DH5-α) as the BAC and allelic exchange 
takes place through a two-step process of co-integrate formation and resolution 
(Wagner et al, 2002; Brune et al, 2000).  
 
1.5.3. Marek’s Disease Virus BACs 
Viral BACs have been created for many human and animal herpesviruses, listed in 
Table 3 (Warden et al, 2011). With regards to MDV, several BAC clones have now 
been developed for different strains. The development of a MDV BAC was critical to 
the understanding of this pathogen. A MDV BAC clone of the attenuated MDV-1 
strain, 584Ap80C, was created by inserting the F’ plasmid into the US2 region of the 
virus by homologous recombination. The growth of the BAC mutant, assessed by 
plaque formation and growth curves, was found to be indistinguishable from that of 
the parental strain, 584Ap80C (Schumacher et al, 2000).  
This MDV BAC clone was used to successfully investigate the essential role of 
various genes in virus growth, including the UL46-UL49 genes which encode the  











BAC-based human herpesvirus BAC-based animal herpesvirus 
Herpes Simplex Virus-1 (HSV-1) Bovine Herpesvirus Type I (BHV-1) 
Herpes Simplex Virus-2 (HSV-2) Equine Herpesvirus Type I (BHV-1) 
Varicella Zoster Virus (VZV) Feline Herpesvirus Type I (BHV-1) 
Kaposi’s Sarcoma-Associated 
Herpesvirus (KSHV) 
Guinea Pig Cytomegalovirus    
(GPCMV) 
Cytomegalovirus (CMV) Herpesvirus Saimiri (HVS) 
Human Herpesvirus 6 (HHV-6) Koi Herpesvirus (KHV) 
Epstein-Barr Virus (EBV) Marek’s Disease Virus (MDV) 
 Murine Cytomegalovirus (mCMV) 
Murine Gammaherpesvirus 68     
(MHV-68) 
Pseudorabies Virus (PrV) 
Rhesus Cytomegalovirus (rhCMV) 
Rhesus Rhadinovirus (RRV) 
Turkey Herpesvirus (HVT) 
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MDV-1 homologues of HSV-1 major tegument proteins (Dorange et al, 2002), and 
the UL10 and UL49.5 genes which encode the viral membrane glycoprotein M (gM) 
and envelope/tegument protein, respectively (Tisher et al, 2002). Recently, research 
to delete both copies of the Meq gene from a MDV BAC has produced a highly 
efficacious vaccine that was non-oncogenic in vivo and which provided protection 
greater than that of the CVI988 Rispens strain (Silva et al, 2010). The Meq protein is 
a 339-aa-long protein encoded within the MDV EcoRI Q fragment (MEQ) of MDV-
1 strains that is consistently expressed in MDV-induced tumour cells and has been 
proposed as a major virulence determinant (Jones et al, 1992; Lupiani et al, 2004; 
Spatz et al, 2007; Lee et al, 2008).          
In an attempt to understand why the CVI988 Rispens vaccine strain provided the best 
protection when compared to other vaccines, and to meet the challenges raised by the 
continuing increase in MDV virulence, the MDV CVI988 genome was cloned into a 
BAC (Petherbridge et al, 2003). As with the BAC clone of the MDV-1 strain, 
584Ap80C, the F’ plasmid was inserted into the US2 region of the CVI988 Rispens 
virus by homologous recombination. The viruses rescued from the BAC clones 
displayed plaque morphology and growth kinetics indistinguishable from those of the 
parental virus, despite the presence of the BAC vector sequence (Petherbridge et al, 
2003; Baigent et al, 2006). The BAC clones were stable during in vitro and in vivo 
passages in chicken embryo fibroblast (CEF) cells and they provided complete 
protection against the virulent RB1B MDV strain, demonstrating that MDV BAC 
clones could be developed as commercial vaccines (Petherbridge et al, 2003). 
To date, real time PCR to distinguish the CVI988 Rispens from virulent challenge 
viruses has not been possible because sequences differences between them are very 
limited (Spatz et al, 2007; Baigent et al, 2010). This puts limitations on investigating 
the effect of the CVI988 vaccine on challenge virus replication. The development of 
the MDV CVI988 BAC, where the BAC vector sequence replaced the US2 gene has, 
however, allowed it to be used as a marker virus to develop and validate real time 
quantitative PCR assays to quantify and distinguish between CVI988 and virulent 
MDV. The ultimate goal is to develop a Q-PCR system that can distinguish 
commercial CVI988 from virulent strains (Baigent et al, 2010). 
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1.5.4. BACs: Vaccine Vectors 
In addition to the study of herpesvirus genes and their role in virus growth and 
pathogenesis, BACs may also be used to develop novel vaccines. The large size of 
the herpesvirus genome, which can be manipulated easily using BAC technology, 
combined with the presence of virulence genes that are not essential for productive 
viral replication in vitro or in vivo, make herpesvirus BACs ideal candidates as 
potential vaccine vectors (Brun et al, 2008).  
There are several examples of animal herpesvirus vector vaccines, which have 
utilised the BAC technology for the generation of viruses expressing heterologous 
antigens. A novel live attenuated vaccine, protecting against varicella-zoster virus 
(VZV) and mumps virus (MuV), was created by replacing the ORF 13 gene of the 
VZV Oka vaccine strain with the MuV haemagglutinin-neuraminidase (HN) gene 
using the BAC system. The inserted MuV HN gene was expressed using a CMV 
immediate early (IE) promoter. The recombinant virus displayed growth 
characteristics similar to the parental strain and vaccination of guinea pigs induced 
both VZV and HN-specific antibodies, producing a strong neutralising activity 
against VZV and MuV (Somboonthum et al, 2007). A BAC clone of the murine 
cytomegalovirus (mCMV) strain was used as a vaccine vector to express the self 
fertility antigen, murine zona pellucid 3, and rendered female mice infertile with a 
single inoculation (Redwood et al, 2005). The most commonly used BAC vaccine 
vector is the equine herpesvirus type I (EHV-1) BAC which, due to its ability to 
enter cells of various host origins (Trapp et al, 2005), has been developed as a 
delivery vector in various species, including non-equine hosts. It has been used to 
deliver the West Nile Virus (WNV) prM and E proteins, both viral envelope proteins 
and important determinants of virulence. The prM and E proteins were expressed 
under the transcriptional control of the CMV IE promoter. Horses immunized with 
the recombinant virus produced WNV E-protein specific antibodies (Rosas et al, 
2007b). The equine herpesvirus BAC has also been used as a vector to deliver bovine 
viral diarrhoea virus (BVDV) structural proteins, inducing BVDV-specific 
neutralising antibodies and causing the reduction of levels of viraemia and nasal viral 
shedding in cattle after BVDV challenge infection (Rosas et al, 2007a). Finally, and 
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importantly for this study, recombinant EHV-1 BACs expressing influenza genes 
have been created. An EHV-1 BAC expressing the haemagglutinin, H3, under the 
control of the CMV IE promoter induced a robust immune response and caused a 
reduction of clinical signs and viral shedding in dogs (Rosas et al, 2008) and horses 
(Van de Walle et al, 2010). 
As stated previously, the identification of a non-essential region, where the foreign 
gene may be inserted, is crucial to avoid severe growth defects in the virus (Brune et 
al, 2000; Warden et al, 2011). When introducing the MuV haemagglutinin-
neuraminidase (HN) gene into the VZV BAC, the ORF 13 gene which codes for the 
thymidylate synthetase protein was replaced, as this was reported to be non-essential 
for virus replication in vitro (Cohen and Seidel, 1993; Somboonthum et al, 2007). 
The EHV-1 modified-live virus vaccine strain RacH, commonly used to vaccinate 
horses against EHV-1, was incorporated into a BAC by inserting the F’ plasmid, 
combined with the gene encoding the green fluorescent protein (GFP), into the Orf 
71 open reading frame. Despite the deletion of Orf 71, which encodes a major 
immunogenic glycoprotein (gp2), the recombinant virus was able to replicate to high 
titres and exhibited growth kinetics comparable to the attenuated strain RacH (Rosas 
et al, 2007a; Rosas et al, 2007b). The H3, WNV proteins and BVDV genes were all 
inserted into the Orf 71 open reading frame, replacing the GFP gene (Rosas et al, 
2007a; Rosas et al, 2007b; Rosas et al, 2008). Finally, a second strain of EHV-1 
(NY03) was produced where an H3 influenza gene was introduced into the Orf 1 
open reading frame, as deletion of the Orf 1 gene attenuated EHV-1, causing shorter 
primary pyrexia and significantly reduced nasal shedding (Van de Walle et al, 2010; 
Hussey et al, 2011). 
The use of MDV strains as vectors expressing foreign antigenic determinants could 
provide an efficient, safe, polyvalent vaccine against poultry diseases (Sakaguchi et 
al, 1993). MDV has several advantages as a recombinant vector because it has a 
natural host range limited to avian species and induces lifetime protection against 
MD (Sakaguchi et al, 1994). The first step in this process was to identify a non-
essential gene in the MDV viral genome so that the influenza haemagglutinin gene 
could be inserted, creating the recombinant MDV-HA construct. 
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1.6. MDV CVI988 BAC: Non-essential genes 
 
1.6.1. Non-essential genes 
The MDV genome encodes more than 100 genes (Figure 7), the functions of which 
have been deduced on the basis of homology to genes from other well studied 
alphaherpesviruses such as HSV-1 (Chattoo et al, 2006).  However, it is recognised 
that although some HSV-1 genes may be regarded as non-essential for virus 
propagation, the term non-essential only applies to one cell culture system. 
Homologous genes and their products, although non-essential in one cell type, may 
have critical functions in another (Parcells et al, 1994). 
To gain an accurate understanding of the functions of MDV genes and their role in 
virus replication, deletion studies have been performed. As discussed previously, the 
deletion of both copies of the Meq gene from the MDV genome did not affect in 
vitro or in vivo viral replication but did cause attenuation of the virus (Lupiani et al, 
2004). Similar studies have determined that the UL10 gene, which encodes the gM 
protein, and the UL49.5 gene that encodes an envelope/tegument protein, are both 
essential for MDV growth (Tischer et al, 2002). In a study to determine which genes 
were essential for the horizontal spread of the MDV virus from chicken to chicken, it 
was determined that the UL44 gene (Glycoprotein C) and UL13 (Protein Kinase) 
were both essential, however the US2 gene was dispensable (Jarosinski and 
Osterrieder, 2010). This corroborated previous work by Cantello et al (1993) who 
stably inserted the lacZ gene into the MDV US2 open reading frame, demonstrating 
that it was not essential for MDV growth in cell culture. And, as stated earlier, the 
CVI988 Rispens virus BAC clone was created by inserting the BAC vector sequence 
into the US2 region by homologous recombination, emphasising the fact that the 




Chapter 1  Introduction 
53 
 




Figure 7.  Organisation of the MDV genome. Adapted with permission 
(Osterrieder et al, 2006). 
 
TRL – Terminal Repeat (long) 
TRS – Terminal Repeat (short)    
IRL – Internal Repeat (long) 
IRS – Internal Repeat (short) 
UL – Unique long region        
US – Unique short region 
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The primary aim of this study was to incorporate an influenza haemagglutinin gene 
into the MDV CVI988 genome. The following genes were determined, using 
previously published research, to be non-essential for MDV replication and growth 
in vitro and in vivo.  
 
1.6.2. UL41 Open Reading Frame 
The UL41 open reading frame encodes the virion host shutoff (VHS) protein 
(Kwong and Frenkel, 1987; Kwong et al, 1988, Kwong and Frenkel, 1989; Gimeno 
and Silva, 2008). Common to alphaherpesviruses, the VHS protein is an 
endoribonuclease protein that degrades pre-existing and newly transcribed mRNAs 
in newly infected cells, reducing host protein synthesis (Read and Frenkel, 1983; 
Taddeo and Roizman, 2006; Gimeno and Silva, 2008). This process of reducing the 
host macromolecular metabolism precludes the host response to infection and diverts 
cell resources to the synthesis of viral proteins (Esclatine et al, 2004). 
Read and Frenkel (1983) determined that the expression of the VHS protein in HSV-
1 was not essential for virus replication in HEp-2 or Vero cells. In Marek’s Disease 
Virus, using random transposon mutagenesis, the MDV Orf 54 (UL41) was not 
found to be essential for MDV replication in vitro. Following the mutation of this 
gene, the mutant showed evidence of virus replication in CEF cells, indicating that 
the VHS protein was dispensable (Chattoo et al, 2006). Gimeno and Silva (2008) 
confirmed that the MDV UL41 gene was non-essential by creating a UL41 deletion 
mutant that replicated as well as the parental strain in vitro. The pattern and degree of 
neurovirulence and tumour lesions produced by the deletion mutant in vivo was the 
same as the pattern of lesions induced by the parental virus. Deletion of the MDV 
UL41 gene did not decrease the replication of the virus in the lymphoid organs or in 
the FFE. The only observable difference between the parental MDV and the UL41 
deletion mutant was that the early in vivo cytolytic infection was of a longer duration 
(Gimeno and Silva, 2008). 
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1.6.3. US10 Open Reading Frame 
The US10 gene, located in the short unique region (Us) of the MDV genome, is a 
minor virion protein (Sakaguchi et al, 1993) that binds the stem cell lymphocyte 
antigen 6 complex (Spatz et al, 2007). The MDV US10 gene is homologous to the 
US10 open reading frame of HSV-1 (Sakaguchi et al, 1992) which encodes a 
polypeptide of 313 amino acids predicted to have a molecular mass of 33 kDa 
(McGeoch et al, 1985; Parcells et al, 1994; Yamada et al, 1997).  
Jones et al (1991) determined that the gene product of a US10 homologue in human 
cytomegalovirus was not essential for virus replication and growth in tissue culture. 
Parcells et al (1994) replaced a 4.8 kb region of MDV that included US1, US10 and 
US2, as well three MDV-specific genes (Sorf1, Sorf2, Sorf3), with the lacZ gene, 
demonstrating that these genes were all non-essential for MDV growth in CEF cells. 
Sakaguchi et al (1994) determined that the US10 gene of MDV-1 was an effective 
site for the insertion of foreign genes from which to construct a polyvalent live 
vaccine for poultry. They incorporated the E. coli lacZ gene into the US10 open 
reading frame of the MDV-1 genome by homologous recombination. When tested in 
vitro, the recombinant virus replicated as well as the parental strain, indicating that 
the US10 gene was non-essential for viral growth in culture. In vivo, the deletion of 
this gene did not affect vaccine-induced immunity. Chickens immunized with the 
recombinant virus were protected when challenged with virulent MDV-1, producing 
a high level of antibodies against β-galactosidase as well as against MDV-1 antigens 
(Sakaguchi et al, 1994). 
 
1.6.4. UL50 Open Reading Frame 
The UL50 gene product is the ubiquitous enzyme dUTPase (deoxyuridine 
triphosphatase), which is required during deoxythymidine triphosphate (dTTP) 
synthesis and for the prevention of uracil-incorporation into DNA (Shlomai and 
Kornberg, 1978; Fuchs et al, 2000). This is significant as the presence of uracil in 
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DNA might result in premutagenic U:G mispairing unless removed and repaired 
(Shlomai and Kornberg, 1978; Krokan et al, 2002). 
UL50 homologues have been studied in several other alphaherpesviruses including 
HSV-1, BHV-1, VZV and ILTV. In HSV-1, it is dispensable for normal virus 
replication in vitro (Fisher and Preston, 1986; Pyles et al, 1992), whereas in vivo, 
HSV-1 dUTPase deficient mutants were attenuated for neurovirulence and 
neuroinvasiveness and displayed reduced reactivation frequency (Pyles et al, 1992). 
In BHV-1, a dUTPase negative mutant was fully viable and therefore the dUTPase 
was not required for virus growth in cell culture (Liang et al, 1993), a finding that 
was later corroborated using random-insertion mutagenesis with a Tn5 transposition 
system to identify non-essential genes (Robinson et al, 2008). In VZV, deletion of 
the Orf 8 gene, encoding the viral dUTPase, had no effect on growth and syncytia 
formation in vitro (Ross et al, 1997). Fuchs et al (2000) determined that an ILTV 
UL50 deletion mutant propagated like wild-type ILTV in cell culture, demonstrating 
that the gene was non-essential for virus replication. A GFP-expressing UL50-
deletion mutant of ILTV, however, showed reduced cell-to-cell spread in vitro, and 
was attenuated in vivo. To date, the impact of deleting the UL50 gene from the MDV 
has not been studied. 
 
1.6.5. Construction of a live recombinant MDV vaccine expressing HA 
Conventional MD vaccines stimulate both the B and T cell dependent immune 
systems, eliciting antibody and cell-mediated immune responses (Baaten et al, 2004). 
Kermani-Arab et al (1975) demonstrated that passive immunization with purified 
IgY, that possessed anti-MDV antibody activity, delayed the development of 
viraemia and lesions. Chickens vaccinated with a recombinant fowlpox vaccine 
expressing MDV gB elicited neutralising antibodies and were protected against 
virulent MDV (Nazerian et al, 1992). In addition, as MDV is strictly cell-associated 
in chickens, with the exception of the FFE, the cell-mediated immune response is 
important for protective immunity to MD (Markowski-Grimsrud and Schat, 2002). 
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CD8+ T cells, induced by MD vaccination, are essential for anti-virus activity 
(Morimura et al, 1998). 
A recombinant MDV CVI988 virus has been developed that expresses the infectious 
bursal disease virus (IBDV) host protective antigen, VP2, providing protection 
against both pathogens (Tsukamoto et al, 1999). However, to date, MDV has not 
been used for the expression of influenza haemagglutinin. A live recombinant MDV 
CVI988 vaccine, expressing the HA protein, would provide humoral and cellular 
immunity against MDV as well as the chosen strain of haemagglutinin.  
 
1.6.6. The 2A Polyprotein – expression of multiple HAs 
The 2A polyprotein has been derived from the picornavirus family, which includes 
poliovirus and Foot and Mouth Disease Virus (FMDV) (Ryan et al, 1991). FMDV 
encodes all of its proteins within a single open reading frame, producing a long 
polyprotein which is co- and post-translationally processed into smaller products. 
Rather than use proteases, FMDV employs the 18 aa long, 2A polypeptide that 
mediates a co-translational cleavage at its own COOH-terminus by manipulating the 
ribosome into ‘skipping’ the synthesis of a specific peptide bond, producing a 
discontinuity in the peptide backbone. When the ribosome reaches the 2A sequence, 
it skips the synthesis of the glycyl-prolyl peptide bond at the COOH-terminus of 2A. 
Following the release of the protein, and without disruption, translation of 
downstream genes is re-initiated by the ribosome (Felipe and Ryan, 2004; Felipe et 
al, 2006; Felipe et al, 2010).  
2A and 2A-like oligopeptide sequences are widely used in biotechnology to co-
express heterogeneous proteins within the same cell (Amrani et al, 2004; Felipe et al, 
2010). Multiple genes that encode proteins can be linked using the 2A sequence to 
form a single open reading frame (ORF). The translation of this single ORF results in 
the production of each protein, expressed as a discrete product, from a single 
transformation step (Felipe et al, 2006; Felipe et al, 2010). By linking HA genes with 
2A, and incorporating the entire open reading frame into MDV, this system may be 
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used to induce heterosubtypic immunity to influenza, through the simultaneous and 
stable co-expression of multiple HA proteins within the same cell.  
 
1.6.7. Project Aims 
The primary objective in this study was to incorporate a haemagglutinin gene into the 
MDV viral genome with the intention of creating a novel virus vector that would 
induce protective immunity against avian influenza (AI) and Marek’s Disease. By 
manipulating the MDV CVI988 BAC genome, HA genes and the GFP gene were 
inserted, replacing the identified non-essential genes. Subsequently, using in vitro 
analysis, CEF cells transfected with the MDV-HA and MDV-GFP constructs 
expressed detectable levels of HA and GFP proteins, determined by 
immunohistochemistry. In collaboration with the Istituto Zooprofilattico 
Sperimentale delle Venezie in Italy, the viral constructs will be tested in vivo to 
determine if they induce a protective level of antibody response in chickens to the 
H10 protein, while insuring adequate protection to MDV challenge.  
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2.1. Molecular Techniques 
 
    
2.1.1.           Polymerase Chain Reaction 
Polymerase Chain Reactions (PCR) were carried out using the reaction mixtures and 
thermocycler conditions listed in Appendix: PCR programs. High fidelity 
amplification of DNA was carried out using Phusion High Fidelity DNA Polymerase 
(Finnzyme, Finland). Reactions were set up using the supplied buffers and were 
made up to a final volume of 50 µl in a 0.2 ml thin-walled PCR tube (Applied 
Biosystems, UK). Taq DNA Polymerase (Invitrogen, UK) was used for colony PCR 
screening. When carrying out colony PCR, the 50 µl reaction mix was aliquoted into 
10 µl quantities, and inoculated with the specific bacterial colony to be tested. 
Reactions were carried out in a PCR Thermal cycler (Applied Biosystems, UK). 10 
mM dNTPs were supplied by Sigma, UK. Primers were supplied by MWG Biotech, 
Germany, and were made up to a concentration of 100 pmol/µl with stated volumes 
of dH2O. All primers are listed in Appendix: PCR programs. 
  
2.1.2.           Cloning of PCR products 
Once appropriately sized PCR products were successfully amplified and purified, 
they were cloned using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen, UK) 
according to the manufacturer’s instructions. A 1 µl sample of the PCR product was 
mixed with 0.5 µl TOPO vector, 0.5 µl salt solution and 1 µl H2O and incubated at 
room temperature (RT) for 30 minutes. Competent Escherichia coli (E. coli) were 
subsequently transformed with the ligation reaction (Section 2.2.2). 
 
2.1.3.           Purification of PCR products using Purification kit  
PCR products were purified using the QIAquick PCR purification kit (Qiagen, UK). 
Five volumes of supplied Buffer PB were added to one volume of PCR sample and 
mixed by pipetting. The total sample was added to the supplied spin column and 
centrifuged at 18,000 x g for 1 minute to bind the DNA to the column membrane. 
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Flow through was discarded. 750 µl of supplied buffer PE were added to the column 
to wash the sample, which was centrifuged twice to ensure complete removal of the 
wash buffer. The column was placed in a labelled, fresh, 1.5 ml microcentrifuge tube 
and 30 µl EB buffer (10 mM Tris, pH 8.5) were added. After 10 minutes incubation, 
the DNA was eluted by centrifugation at 18,000 x g. 
 
2.1.4.           Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to analysis DNA. Samples up to 50 µl in 
volume were mixed with 5-10 µl Orange G dye (Section 2.5.2) and loaded into 0.7-
1% (w/v) agarose gels containing 0.5 µg/ml ethidium bromide (EtBr) in Tris Acetic 
acid EDTA (TAE) (Section 2.5.2). Electrophoresis was carried out at 80 V/cm
2
 in 
horizontal gel tanks containing TAE. Samples were compared with DNA ladders to 
estimate the size of DNA products (1 kb DNA ladder, Invitrogen, UK; 1 kb Plus 
DNA Ladder, Invitrogen, UK). Gels were visualised on a UV transilluminator and 
photographed.  
 
Digested Bacterial Artificial Chromosome (BAC) DNA (2 µg) was analysed using 
agarose gel electrophoresis. Samples were loaded into a 0.8% (w/v) agarose gel and 
run slowly overnight at 40 V/cm
2
. Agarose gels were post-stained with 0.5 µg/ml 
EtBr in TAE buffer and incubated on an orbital shaker for 1 hour. Following two 30 
minute washes in TAE, the gel was visualised on a UV transilluminator and 
photographed. 
 
2.1.5.           Concentration of DNA by Ethanol Precipitation 
DNA was concentrated by adding 0.1 volume of 3 M Sodium Acetate (NaAc) pH 
5.2, and 3 volumes of ice-cold 100% ethanol. The sample was mixed by vortexing 
and incubated at -80
o
C overnight or on dry ice in ethanol for 30 minutes. The DNA 
precipitate was pelleted by centrifugation at 18,000 x g in a bench top 
microcentrifuge for 30 minutes. The pellet was rinsed gently with 70% ethanol and 
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pelleted again by centrifugation at 18,000 x g for 10 minutes. The pellet was air-
dried for 2-3 minutes and resuspended in an appropriate volume of EB buffer. 
 
2.1.6.           Restriction Enzyme Digestion of DNA 
Restriction enzyme digestion was carried out using a broad range of restriction 
endonucleases, for the purposes of cloning and plasmid identification. Unless 
otherwise stated all restriction enzymes were supplied by New England Biolabs 
(NEB, UK). DNA was digested according to the manufacturer’s instructions, using 
the recommended buffers and conditions. DNA digests were carried out with up to 5 
µg of DNA per reaction, in a total volume of 20-100 µl, with no more than 1 µl of 
enzyme per 10 µl total volume to reduce the chances of star activity. Digests were 
incubated at the appropriate temperature for between 1-4 hours depending on the 
enzyme activity.  
 
2.1.7.           DNA Blunting 
Digested plasmid DNA, with 5’ overhangs, was prepared for blunt cloning using a 
Quick Blunting Kit (NEB, UK). The enzyme mix was used to convert the 5’ 
overhangs to 5’ phosphorylated, blunt-ended DNA. Digested plasmid DNA was 
incubated at room temperature with the Blunt Enzyme mix and dNTPs (0.1 mM final 
concentration), in the recommended buffer, for 30 minutes. The enzyme was heat 
inactivated at 70
o
C for 10 minutes. 
 
2.1.8.           DNA De-phosphorylation 
To remove 5’ phosphate groups and prevent self ligation, plasmids digested with a 
single enzyme were incubated with Antarctic Phosphatase (AP) (New England 
Biolabs, UK), in the recommended buffer, for 1 hour. AP was inactivated by heating 
to 65
o
C for 15 minutes. 
 
Chapter 2  Materials and Methods 
63 
 
2.1.9.           DNA extraction from Agarose Gels 
Prior to ligation, all plasmids and PCR products digested with restriction enzymes 
were gel purified. Gel electrophoresis was used to isolate the DNA fragments. 
Following separation, the area containing the DNA of interest was excised from the 
gel using a clean scalpel blade. DNA was recovered from the agarose gel using a 
Qiagen Gel Extraction Kit (Qiagen, UK), according to the manufacturer’s protocol. 
The recovered gel slice was weighed and solubilised in the supplied Buffer QG, at a 
ratio of 3 µl per 1 mg. The sample was incubated at 50
o
C, vortexed until the gel slice 
had completely dissolved, and then added to the supplied spin column. The column 
was centrifuged at 18,000 x g for 1 minute to bind the DNA and the flow through 
was discarded. Residual agarose was removed by washing the column with 500 µl 
Buffer QG. Again, the flow though was discarded following centrifugation at 18,000 
x g. A second wash was carried out by adding 750 µl Buffer PE to the column and 
centrifuging as above. The flow through was discarded and the column was 
centrifuged again to remove residual wash buffer. The column was placed in a 
labelled, fresh, 1.5 ml microcentrifuge tube and 30 µl EB buffer were added. After 
30 minutes incubation, the DNA was eluted by centrifugation at 18,000 x g. 
 
2.1.10. DNA ligation 
 
The Ligafast Rapid DNA Ligation system (Promega, UK) was used for all ligations. 
A restriction enzyme digested vector and insert were combined at a molar ratio of 
2:1. T4 DNA ligase (1 μl) was added, along with 10x Ligase Buffer (1 μl). The 
sample was made up to a final volume of 10 μl with H2O and incubated overnight, on 
thawing ice. 50 μl of competent E. coli were subsequently transformed with the 
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2.1.11. Quantification of Nucleic acid  
 
The concentration of DNA and RNA was determined using the NanoDrop Nd-1000 
UV/Vis 1 µl Spectrophotometer (Thermo Fisher Scientific, UK) at an absorbance   
reading of OD260nm and OD280nm. 
 
 
2.1.12. Sequencing of Plasmid DNA 
To sequence selected DNA, 1 μl plasmid sample (300-500 ng/μl) was mixed with 1 
μl specific sequencing primers (3.2 pmol/μl), 1.5 μl 5x Big Dye Buffer and 1 μl Big 
Dye (Applied Biosystems, UK). Sequencing reactions were performed on a PCR 
thermal cycler using the recommended reaction conditions (96
o





C, 2 minutes for 30 cycles). Sequencing was carried out by Genepool at the 
School of Biological Sciences Sequencing Service (SBSSS) (Ashworth Laboratory, 
Kings Buildings, University of Edinburgh). 
 
 
2.1.13. Sequence Analysis and Primer Design 
DNA sequences were analysed using BioEdit software and NCBI nucleotide-
nucleotide BLAST (http://www.ncbi.nlm.nih.gov/BLAST). Vector NTI (Invitrogen, 
UK) was used for sequence analysis, plasmid construction, primer design and 
restriction digest mapping. 
 
2.1.14. Extraction of RNA 
 
RNA was extracted from cultured Chicken Embryo Fibroblast (CEF) cells that had 
been transfected with various Bacterial Artificial Chromosomes (BACs). 
Approximately 4 x 10
6
 cells were used as starting material. Cells were scraped off 
and resuspended in 1 ml TRI reagent (Applied Biosystems, UK) and incubated for 5 
minutes at room temperature. RNA was extracted by adding 200 µl chloroform per 1 
ml TRI reagent solution. Sample was vortexed, incubated for 10 minutes at room 
temperature and centrifuged at 18,000 x g for 15 minutes at 4
o
C to separate the 
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aqueous and organic phases. The RNA was isolated from the colourless, upper 
aqueous layer. 
RNA was isolated using the RNeasy Mini Kit (Qiagen, UK). The aqueous layer, 
containing the extracted RNA, was mixed with 350 µl 70% ethanol by pipetting and 
added directly to the RNeasy mini column. All tubes and samples were kept on ice at 
4
o
C. Columns were centrifuged at 18,000 x g for 2 minutes, in a bench top centrifuge 
at 4
o
C, to bind the RNA and the flow through was discarded. 350 µl of supplied 
buffer RW1 were added to the column, the column was centrifuged as above and the 
flow through was discarded. RNA samples were treated using the RNase-Free DNase 
set (Qiagen, UK). 10 µl DNase stock were added to 70 µl buffer RDD for every 
sample and mixed by gentle inversion. The total 80 µl mix was added to the column 
and incubated at room temperature for 15 minutes. Following DNase treatment, 350 
µl of buffer RW1 were added to the column, which was centrifuged at 18,000 x g for 
2 minutes. The column was transferred to a fresh 2 ml collection tube and washed 
twice using 500 µl RPE buffer, centrifuging and discarding the flow through as 
above. The column was transferred to a fresh 1.5 ml microcentrifuge tube. The RNA 
was eluted by adding 30 µl RNase-free H2O and centrifuging as above. 
 
2.1.15. Reverse transcription of RNA 
Reverse transcription was performed using Superscript III reverse transcriptase 
(Invitrogen, UK). Extracted, DNase-treated RNA was mixed with 3 µl random 
primers (50 ng/µl) or 2 µl gene-specific primers (1 pmol/µl), 1 µl dNTP (10 mM) 
mix and made up to 12 µl with sterile, distilled H2O. The sample was incubated at 
65
o
C for 5 minutes, rapidly chilled on ice for 1 minute and centrifuged briefly. 4 µl 
5x First strand buffer, 1 µl 0.1 M Dithiothreitol (DTT), 1 µl RNase OUT and 1 µl 
Superscript III reverse transcriptase were added, mixed by pipetting and incubated at 
25
o
C for 5 minutes, followed by 50
o
C for 60 minutes. If gene-specific primers were 
used, the reaction temperature was increased to 55
o
C. The enzyme was inactivated 
by heating the samples to 70
o
C for 15 minutes. cDNA samples were frozen at -20
o
C. 
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2.2. Bacterial Techniques 
 
 
2.2.1.            Bacterial Culture 
Laboratory strains of E. coli were grown in Luria (LB) medium (Section 2.5.4) or on 
LB plates with 1.5% (w/v) agar. The agar was melted and sterilised by autoclaving. 
Agar that contained additional sucrose was autoclaved using the sugar cycle. 
Following autoclaving, and once it had cooled to 50
o
C, LB agar was supplemented 
with the appropriate antibiotic and poured into 10 cm diameter petri dishes. The 
antibiotics ampicillin (100 µg/ml), kanamycin (50 µg/ml), chloramphenicol (20 
µg/ml) and gentamycin (15 µg/ml) were used (Sigma, UK). Bacteria were plated 
onto LB agar by streaking with a wire loop or spreading with a glass spreader and 




C. Single colonies were used to 
inoculate sterile, liquid LB medium, which was also supplemented with the 
appropriate antibiotic. Liquid cultures were incubated overnight in an orbital shaker, 






2.2.2.           Transformation of TOP10 / NEB chemically competent 
                     E. coli 
 
One-Shot TOP10 chemically competent E. coli (Invitrogen, UK) were used for 
routine cloning. Two strains of competent cells were purchased from NEB, UK. 10-




 competent E. coli strain was used for cloning plasmids that required digestion 
with methylation sensitive restriction enzymes. 
Cells were transformed using aseptic bacteriological technique. Single aliquots (50 
µl) were thawed on ice. 10 µl ligation reaction or 1 µl plasmid DNA (20-100 ng/µl) 
were added and the cells were incubated, on ice, for 30 minutes. The cells were then 
incubated at 42
o
C for exactly 30 seconds (heat pulsed), and placed on ice for 2 
minutes. 900 µl prewarmed SOC medium (Invitrogen, UK) were added and the 
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Subsequently, the cells were pelleted, resuspended in 100 µl and serially titrated out 
to 10
-2
 in 90 µl SOC medium. These titrations were plated onto labelled, prewarmed 






   
2.2.3.           Transformation of XL10-Gold Ultracompetent E. coli 
 
XL10-Gold Ultracompetent E. coli (Stratagene, UK) cells were used for cloning 
large plasmids. Single aliquots (100 µl) were thawed on ice and gently added to pre-
chilled 14 ml Falcon tubes. 4 µl of β-mercaptoethanol were added and the cells were 
incubated on ice for 10 minutes, swirling gently every two minutes. 10 µl ligation 
mixture were added and the cells were incubated on ice for 30 minutes. Following 
incubation, the cells were heat pulsed at 42
o
C for exactly 30 seconds and then placed 
on ice for 2 minutes. 900 µl of prewarmed SOC medium were added and the samples 
were shaken in an orbital shaker at 225 rpm for 1 hour at 37
o
C. Subsequently, the 
cells were pelleted, resuspended in 100 µl and serially titrated out to 10
-2
 in 90 µl 
SOC medium. These titrations were plated onto labelled, prewarmed LB plates 






       
2.2.4.            Preparation of Bacterial Stocks for Long Term Storage 
Bacteria containing plasmids of interest were stored in glycerol at -80
o
C. A single 
bacterial colony was used to inoculate 3 ml of LB medium containing the appropriate 
antibiotic. Cultures were incubated overnight at 225 rpm in an orbital shaker at 37
o
C 
until the culture had an absorbance reading of 0.6 OD (Optical Density)600. 850 µl of 
culture were mixed with 150 µl sterile glycerol in a 1.8 ml cryovial (Thermo Fisher 
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2.2.5.            Plasmid DNA isolation from Bacteria (Small scale) 
Plasmid DNA was extracted from transfected cultures using a Qiagen MiniPrep Kit 
(Qiagen, UK). A single bacterial colony, isolated from LB agar plates, was used to 
inoculate 7 ml of LB medium containing the appropriate antibiotic. Cultures were 





After 16 hours, 3 ml of the bacterial overnight culture were pelleted by centrifugation 
at 6000 x g for 3 minutes at room temperature (15–25 °C). The bacterial pellet was 
resuspended in 250 μl Buffer P1 and transferred to a 1.5 µl microcentrifuge tube. 250 
μl Buffer P2 was added to lyse the cells. This was mixed thoroughly by inverting the 
tube several times. The lysis reaction was stopped after 3 minutes by the addition of 
350 μl Buffer N3, followed by gentle inversion. The sample was then centrifuged for 
10 minutes at 18,000 x g in a bench top microcentrifuge to pellet the precipitate. 
The supernatant was applied to the QIAprep spin column by pipetting. The column 
was subsequently centrifuged at 18,000 x g for 1 minute to bind the plasmid DNA to 
the silica gel membrane. The flow through was discarded and the sample was washed 
by adding 500 µl Buffer PB, followed by 750 µl Buffer PE. After each wash the 
column was centrifuged at 18,000 x g for 1 minute and the flow through was 
discarded. Following the addition of Buffer PE, the column was centrifuged twice to 
completely remove residual wash buffer. The QIAprep column was transferred to a 
clean, 1.5 ml microcentrifuge tube. To elute DNA, 50 μl Buffer EB were applied to 
the column and allowed to stand for 1 minute. The plasmid DNA was eluted by 




2.2.6.            Plasmid DNA isolation from Bacteria (Large scale) 
Large-scale isolation of plasmid DNA was carried out using the Qiagen Endofree 
Plasmid Maxi Kit (Qiagen, UK) according to the manufacturer’s instructions. A 
single colony was isolated and inoculated into 3 ml LB medium supplemented with 
the appropriate selective antibiotic. This starter culture was incubated at 37
o
C for 8 
hours in an orbital shaker at 225 rpm. 200 µl of the starter culture were used to 
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inoculate 100 ml LB medium supplemented with the appropriate antibiotic. A large, 
sterile, 500 ml Erlenmeyer flask was used for suitable aeration. The large culture was 
incubated overnight at 225 rpm in an orbital shaker at 37
o
C. 
After 16 hours, using the Beckman J2-21 centrifuge prechilled to 4
o
C, bacteria were 
pelleted by centrifugation at 6000 x g for 15 minutes at 4
o
C. The bacterial pellet was 
resuspended in 10 ml Buffer P1, before being lysed by the addition of 10 ml Buffer 
P2 with vigorous inversion. The lysis reaction was stopped after 5 minutes by the 
addition of 10 ml Buffer P3, followed by vigorous inversion. The lysate was poured 
into the barrel of the QIAfilter Cartridge immediately and incubated at room 
temperature for 10
 
minutes, during which time the precipitate floated to the top of the 
solution. Using the supplied plunger, this lysate was gently filtered into a fresh 250 
ml polypropylene centrifuge tube (Beckman Coulter, UK). 2.5 ml Buffer ER was 
then added to the filtered lysate, mixed by inverting the tube approximately 10 times, 
and incubated on ice for 30 minutes. 
A QIAGEN-tip 500 was equilibrated by applying 10 ml of Buffer QBT, which was 
allowed to enter the silica resin by gravity flow. The filtered lysate was applied to the 
column and allowed to drain through the QIAGEN-tip by gravity flow. The flow 
through was discarded and the column was washed twice with 30 ml Buffer QC. 
Plasmid DNA was eluted using 15 ml of Buffer QF and collected in a sterile, 30 ml 
glass corex tube. DNA was precipitated by adding 10.5 ml room temperature 
isopropanol to the eluate, mixed by inversion and centrifuged immediately at 15,000 
x g for 30 minutes at 4 °C. Following centrifugation, the supernatant was carefully 
decanted and the pelleted DNA was washed with 5 ml of endotoxin-free room 
temperature 70% ethanol. The sample was centrifuged again at 15,000 x g for 10 
minutes, the supernatant was removed and the pellet was allowed to air dry. The 
pellet was redissolved in 500 µl Buffer TE (10 mM Tris·Cl, 1 mM EDTA, pH8.0) 
and stored at -20
o
C. 
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2.2.7.            BAC DNA isolation from Bacteria (Large scale) 
Large-scale isolation of Bacterial Artificial Chromosome (BAC) DNA was carried 
out using the Qiagen Large-Construct Kit (Qiagen, UK) according to the 
manufacturer’s instructions. A single colony was isolated and inoculated into 3 ml 
LB medium supplemented with the appropriate selective antibiotic. This starter 
culture was incubated at 37
o
C for 8 hours in an orbital shaker at 225 rpm. 1 ml of the 
starter culture was used to inoculate 500 ml LB medium supplemented with the 
appropriate antibiotic. A large, sterile, 2000 ml Erlenmeyer flask was used for 




After 16 hours, using the Beckman J2-21 centrifuge prechilled to 4
o
C, bacteria were 
pelleted in 250 ml polypropylene centrifuge tubes by centrifugation at 6000 x g for 
15 minutes at 4
o
C. The bacterial pellet was resuspended in 20 ml Buffer P1, before 
being lysed by the addition of 20 ml Buffer P2 with gentle inversion. The lysis 
reaction was stopped after 5 minutes by the addition of 20 ml Buffer P3, followed by 
gentle inversion. The lysate was incubated on ice for 10 minutes before being mixed 
again by gentle inversion and centrifuged at 20,000 x g for 30 minutes at 4 °C. The 
supernatant was filtered into a 250 ml polypropylene centrifuge tube through folded 
filter paper prewetted with distilled water. BAC DNA was precipitated by adding 36 
ml room temperature isopropanol to the cleared lysate. This was mixed gently and 
centrifuged immediately at 15,000 x g for 30 minutes at 4 °C. Subsequently, the 
supernatant was carefully decanted, the pellet was washed with 5 ml room-
temperature 70% ethanol and centrifuged again at 15,000 x g for 15 minutes at 4
o
C. 
The pellet was allowed to air dry for 2–3 minutes and dissolved in 9.5 ml Buffer EX 
by very gentle shaking. 200 μl ATP-Dependent Exonuclease and 300 μl ATP 
solution (100 mM, pH 7.5) were added to the dissolved DNA, mixed gently and 
incubated at 37
o
C for 60 minutes. 
 
A QIAGEN-tip 500 was equilibrated by applying 10 ml of Buffer QBT, which was 
allowed to enter the silica resin by gravity flow. 10 ml Buffer QS were added to the 
BAC DNA sample and the whole sample was applied to the QIAGEN-tip and 
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allowed to enter the resin by gravity flow. The flow through was discarded and the 
column was washed twice with 30 ml Buffer QC. BAC DNA was eluted using 15 ml 
of Buffer QF, prewarmed to 65 °C, and collected in a sterile, 30 ml glass corex tube. 
DNA was precipitated by adding 10.5 ml isopropanol to the eluate, mixing by 
inversion and centrifuged immediately at 15,000 x g for 30 minutes at 4 °C. 
Following centrifugation, the supernatant was carefully decanted and the pelleted 
DNA was washed with 5 ml of room-temperature 70% ethanol. The sample was 
centrifuged again at 15,000 x g for 10 minutes, the supernatant was removed and the 
pellet was allowed to air-dry. The pellet was redissolved in 250 µl TE Buffer at 55
o
C 





2.2.8.            Preparation of Electrocompetent DH5-α cells  
The genome of the Marek’s Disease Virus (MDV) vaccine strain (MDV CVI988 
Rispens) has been incorporated into a BAC by replacing the non-essential US2 gene 
with the 7.2 kb BAC vector. The MDV CVI988 BAC was transformed into DH5-α 
bacteria and stored as a glycerol stock which was acquired from Prof Nair (Institute 
for Animal Health, Compton, UK). 
The glycerol stock of DH5-α/CVI988 was streaked onto a selective LB agar plate 
containing the appropriate antibiotic and was incubated overnight at 37
o
C. A single 
bacterial colony, isolated from LB agar plates, was used to inoculate 5 ml of LB 
medium containing 20 µg/ml chloramphenicol and 0.1% L-arabinose (Sigma, UK). 
The culture was incubated overnight at 225 rpm in an orbital shaker at 37
o
C.  
The following day, 2.5 ml of the overnight culture were used to inoculate 20 ml LB 
medium containing 20 µg/ml chloramphenicol and 0.1% L-arabinose. The cultures 
were incubated for 3.5 hours at 225 rpm in an orbital shaker at 37
o
C. Bacterial cells 
were pelleted at 1300 x g at 4
o
C for 30 minutes. The supernatant was removed and 
the pellet, kept on ice throughout, was resuspended in 5 ml ice cold 10% glycerol in 
H2O (1:9 v/v). Bacterial cells were pelleted at 1300 x g at 4
o
C for 30 minutes. The 
supernatant was removed and the pellet, kept on ice throughout, was resuspended in 
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1 ml ice cold 10% glycerol in H2O (1:9 v/v) and transferred to a prechilled 1.5 ml 
microcentrifuge tube. Bacterial cells were pelleted at 9000 x g at 4
o
C for 2 minutes. 
The supernatant was removed and the pellet of competent DH5-α cells, kept on ice 
throughout, was resuspended in 400 µl ice cold 10% glycerol in H2O (1:9 v/v). 
 
2.2.9.           BAC Mutagenesis 
 
A recombination plasmid (shuttle plasmid) must be constructed first, where the 
mutation to be introduced is flanked by sequences (2-3 kb) homologous to the 
integration site. This alignment of similar sequences allows a crossover between the 
aligned DNA strands resulting in an exchange of material. The shuttle plasmids must 
be handled at 30
o
C, due to the presence of a temperature sensitive origin of 
replication (repTS). It is, therefore, constructed first in the high copy vector, Zero 
Blunt II TOPO (Invitrogen, UK). The insert (Flank – Gene – Flank) was transferred 
to the shuttle plasmid (pST76k) in the final cloning step. The shuttle plasmid, 
pST76k, is kanamycin resistant and contains the recA gene and the SacB gene, which 
allows for selection in the presence of 5% sucrose. 
 
Electrocompetent DH5-α cells (200 µl) were transferred to a 0.2 cm electroporation 
cuvette containing 1 µl of the shuttle plasmid DNA (5-20 ng/µl). Cells were 
transfected by electroporation with the Micro Pulsar (BioRad, UK) using the preset 
EC-1 program. Following electroporation, 1.5 ml SOC broth (37
o
C) were added and 
the culture was transferred to a universal. The culture was incubated at 30
o
C at 225 
rpm in an orbital shaker for 90 minutes. Subsequently, the bacterial cells were 
pelleted, diluted to 10
-2
 in SOC broth and plated onto selective LB agar containing 20 
µl/ml chloramphenicol and 50 µl/ml kanamycin. Plates were inverted and incubated 
for 48 hours at 30
o
C. To identify co-integrates, 5 colonies were picked and spread 
onto selective LB agar plates containing 20 µl/ml chloramphenicol and 50 µl/ml 
kanamycin. Plates were inverted and incubated overnight at 43
o
C to eliminate 
bacteria containing both uncombined plasmids but not the co-integrate. This 
selection is possible due to the presence of the repTS, which ensures that the shuttle 
plasmid cannot replicate at this temperature and therefore provide resistance to 
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kanamycin. To allow the temperature-resistant co-integrates to resolve, 5 colonies 
were picked and spread onto selective LB agar plates containing 20 µl/ml 
chloramphenicol. Plates were inverted and incubated for 48 hours at 30
o
C. To 
identify clones with resolved BAC plasmids, 5 colonies were picked and spread onto 
selective LB agar plates containing 20 µl/ml chloramphenicol and 5% sucrose. Plates 
were inverted and incubated for 48 hours at 30
o
C. To confirm resolution, 20 colonies 
were picked and inoculated onto a grid-labelled LB agar plate containing 50 µl/ml 
kanamycin and, in parallel, a grid-labelled LB agar plate containing 20 µl/ml 
chloramphenicol. Both plates were incubated at 37
o
C overnight. 80-100% of the 
clones were expected to be kanamycin sensitive. For those that were, colony PCR 
incorporating specific primers (Appendix: PCR Programs) was used to characterise 




2.3. Tissue Culture and Virus growth 
 
 
2.3.1.            Growth of Established Cell lines 
 
Vero cells (monkey kidney epithelial cells) were cultured in Dulbecco’s Modified 
Essential Medium (DMEM) (Gibco, UK), supplemented with 10% (v/v) Foetal Calf 
Serum (FCS) (Harlan, UK) and 1% (v/v) Penicillin and Streptomycin (Invitrogen, 
UK). Cells were maintained in 175 cm
2
 tissue culture flasks (Thermo Fisher 
Scientific, UK) and grown in a 37
o
C incubator with 5% CO2. Cell monolayers were 
split every three-four days. Confluent cells were rinsed with approximately 100 µl 
versene solution (0.2 g/L EDTA-4Na, Gibco, UK) per cm
2
 of the cells. The versene 
was removed and the cells were incubated with approximately 30 µl trypsin/EDTA 
(Gibco, UK) per cm
2
 of the cells until the cells had detached. The cells were 
resuspended in 10 ml DMEM medium and centrifuged for 5 minutes at 500 x g in a 
bench top centrifuge. The supernatant was discarded, the pellet was resuspended in 
10 ml DMEM and live cells were counted using a haemocytometer (50 μl cell 
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suspension and 50 μl Trypan Blue Solution, Sigma, UK). Viable cell numbers were 
calculated using the following equation:  






Cells were used to seed six-well plates at a cell density of 4.0 x 10
5 
cells per well and 
twelve-well plates containing sterile 10 mm glass coverslips (Scientific Laboratory 
Supplies, UK) at a cell density of 2.0 x 10
5
 cells per well. In addition, 175 cm
2
 flasks 
were seeded with approximately 5 x 10
6
 cells in 40 ml DMEM media.             
 
 
2.3.2.           Preparation of Primary Chicken Embryo Fibroblast cells 
 
Primary Chicken Embryo Fibroblast (CEF) cells were prepared from ten-day-old 
incubated eggs from the Roslin Institute. Embryos were euthanised by removing the 
head, and the wings and legs were excised. The remaining bodies were cut in half 
and placed in an Erlenmeyer flask containing 20 ml warm PBS (Section 2.5.1). The 
supernatant was removed and replaced with 20 ml trypsin/EDTA (Gibco, UK), 
which was incubated for 5 minutes at 37
o
C and subsequently discarded. 20 ml of 
fresh trypsin were added and incubated for 10 minutes at 37
o
C, shaken vigorously 
after 5 minutes. This was subsequently decanted into a universal tube containing 1 
ml Foetal Calf Serum (FCS) (Harlan, UK) to deactivate the trypsin. This was 
repeated three more times. The four universals were centrifuged (8 minutes, 200 x g), 
the supernatant was removed and the cells were resuspended in 5% CEF media (See 
below). Cells were pooled and counted using a haemocytometer and 175 cm
2
 flasks 
were seeded with approximately 1.6 x 10
7
 cells in 40 ml 5% CEF Media. CEF cells 
were grown overnight in a 38.5
o
C incubator with 5% CO2. After twenty-four hours, 
once the cells were confluent, the media was changed to 2% CEF Media (See below) 
and again the flasks were incubated at 38.5
o
C with 5% CO2 overnight.  
                
       cell count 
Cells/ml =    middle 25 squares         x dilution in trypan blue x 10
4 
                         (haemocytometer) 
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2.3.3.            Growth of Primary Chicken Embryo Fibroblast cells 
 
CEF cells were cultured in 2% or 5% CEF Media (M199, Gibco, UK) supplemented 
with 10% Tryptose Phosphate Broth (Invitrogen, UK), 7.5% NaHCO3 (Sigma, UK), 
2% or 5% Foetal Calf Serum (FCS) (Harlan, UK) and 1% Penicillin and 
Streptomycin (Invitrogen, UK). Cells were maintained in 75 cm
2
 or 175 cm
2
 tissue 
culture flasks, as well as grown in six-well dishes (Thermo Fisher Scientific, UK). 
CEFs were grown in a 38.5
o
C incubator with 5% CO2. Confluent cell monolayers 
were passed only once. As in Section 2.3.1, CEF cells were removed with 
trypsin/EDTA and counted using the haemocytometer. Cells were used to seed six-




 flasks were seeded 
with approximately 1 x 10
7 
cells in 40 ml 5% CEF media and 75 cm
2
 flasks were 
seeded with 5 x 10
6 
cells in 20 ml 5% CEF media. 
 
        
2.3.4.            Preparation of cells for long term storage 
 
Confluent cell monolayers were removed and counted as described previously 
(Section 2.3.1). The cells were pelleted by centrifugation at 200 x g for 5 minutes 
and resuspended in 1 ml of freezing solution (90% v/v FCS, 10% v/v dimethyl 
sulphoxide). Vero cells were resuspended at a concentration of 5 x 10
6
 cells per ml; 
CEF cells were resuspended at a concentration of 1 x 10
7
 cells per ml. Cells were 
aliquoted into cryovials and frozen overnight at -80
o
C, wrapped in cotton wool. 
Samples were transferred to liquid nitrogen the following day for long-term storage.  
 
   
2.3.5.           Growing cells from frozen stocks 
All media were prewarmed to 37
o
C. Cryovials were removed from liquid nitrogen 
and kept on dry ice until ready to thaw. Cells were thawed rapidly in a 37
o
C water 
bath and transferred to 10 ml of the appropriate medium immediately. Cells were 
pelleted by centrifugation at 200 x g for 5 minutes, resuspended in 10 ml of fresh 
medium and transferred to a 75 cm
2
 flask. Two cryovials of CEF cells were used to 
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seed one 175 cm
2
 flask. Vero cells were grown in a 37
o
C incubator with 5% CO2; 
CEF cells were grown in a 38.5
o
C incubator with 5% CO2.  
           
2.3.6.          Transfection of Vero cells with plasmid DNA using  
          Lipofectamine 
The day prior to transfection, Twelve-well and six-well plates were seeded with 2.0 x 
10
5
 and 4.0 x 10
5
 Vero cells per well, respectively. Seeded plates were incubated 
overnight at 37
o
C with 5% CO2. Previously, the concentration of each plasmid was 
determined using the NanoDrop Nd-1000 UV/Vis 1 µl Spectrophotometer (Section 
2.1.11).  For each well of a six-well plate, 1 μg of plasmid DNA was made up to 100 
μl in volume with serum-free Opti-mem media (Gibco, UK). For each well of a 
twelve-well plate, 0.5 μg of plasmid DNA was made up to 100 μl in volume with 
Opti-mem. Separately, 5 μl of lipofectamine were mixed with 95 μl of Opti-mem 
media. Both the DNA and lipofectamine samples were mixed and incubated for 45 
minutes at room temperature, allowing complexes to form. During this incubation, 
media was removed from the Vero cells, which were subsequently rinsed with 2 ml 
sterile PBS. 800 μl of Opti-mem were added to the wells of the six-well dishes; 400 
µl Opti-mem were added to the wells of the twelve-well dishes. The 
DNA/Lipofectamine solution was diluted in 600 μl of Opti-mem media and added 
carefully onto the cell sheet. For each well of the six-well dishes, 800 μl of plasmid 
DNA/lipofectamine mix were added; for each well of the twelve-well dishes, 400 μl 
of plasmid DNA/lipofectamine mix were added. Plates were incubated at 37
o
C with 
5% CO2. Media was changed from serum free Opti-mem media to DMEM 
containing 10% FCS after 6 hours.  
       
2.3.7.          Transfection of CEF cells with plasmid/BAC DNA using     
                    Lipofectamine 
 
The day prior to transfection, six-well plates were seeded with 5.0 x 10
5
 CEF cells 
per well. Seeded plates were incubated overnight at 38.5
o
C with 5% CO2. For each 
well, 1 μg of BAC DNA or 0.5 μg of plasmid DNA were made up to 100 μl in 
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volume with serum-free Opti-mem media. Separately, 5 μl of lipofectamine were 
mixed with 95 μl of Opti-mem media. Both the DNA and lipofectamine samples 
were mixed and incubated for 45 minutes at room temperature, allowing complexes 
to form. During this incubation, media was removed from the CEF cells, which were 
subsequently rinsed with 2 ml sterile PBS. 800 μl of Opti-mem were added to the 
wells of the six-well dishes. The DNA:Lipofectamine solution was diluted in 600 μl 
of Opti-mem and the total 800 μl of plasmid/BAC DNA:lipofectamine mix was 
added to each well. Plates were incubated at 38.5
o
C with 5% CO2. Media was 
changed from serum free Opti-mem media to prewarmed 5% CEF Media after 5 
hours.  
 
2.3.8.           ‘Reverse’ transfection of CEF cells with BAC DNA using     
               Lipofectamine 
 
The transfection of CEFs with MDV DNA is improved if DNA is introduced at the 
seeding stage, rather than once the CEF monolayer is formed (Morgan et al, 1990). 
This method was referred to as a ‘Reverse’ transfection.  
For each well of a six-well dish, 1 μg of BAC DNA was made up to 100 μl in 
volume with serum-free Opti-mem media. Separately, 5 μl of lipofectamine were 
mixed with 95 μl of Opti-mem media. The DNA and lipofectamine samples were 
mixed and incubated for 45 minutes at room temperature. During this incubation, 
CEF cells were removed from the T175 cm
2
 flask using trypsin/EDTA, resuspended 
in 10 ml of Opti-mem and counted, as previously described in Section 2.3.1. For 
each well, the DNA:Lipofectamine solution was diluted in 600 μl Opti-mem and the 
total 800 μl of plasmid/BAC DNA:lipofectamine was mixed with 5.0 x 10
5
 CEF 
cells. The DNA:lipofectamine:CEF cell culture was made up to 3 ml with Opti-mem 
and added to one well. Seeded plates were incubated at 38.5
o
C with 5% CO2. Media 
was changed from serum-free Opti-mem media to prewarmed 5% CEF media after 5 
hours. Media was changed to prewarmed 2% CEF media once cells were confluent. 
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2.3.9.            Growth and storage of MDV Cell-Associated Viral stocks 
Six-well dishes containing CEF cells transfected with MDV CVI988 BAC and 
mutant BACs, displayed cytopathic effect (CPE) in the form of plaques after 5-7 
days. The entire contents of three wells of a six-well dish were removed using 
trypsin/EDTA as described previously in Section 2.3.1. The infected cells were 
resuspended in 10 ml of 5% CEF medium and centrifuged for 5 minutes at 200 x g. 
The supernatant was discarded and the pellet was resuspended in 10 ml prewarmed 
5% CEF media. 
One cryovial of CEF cells was removed from liquid nitrogen and kept on dry ice 
until ready to thaw. The cells were thawed rapidly in a 37
o
C water bath, transferred 
to a universal containing 10 ml of prewarmed 5% CEF media and pelleted by 
centrifugation at 200 x g for 5 minutes.  Pelleted cells were resuspended in 10 ml of 
fresh 5% CEF media and transferred to a labelled T75 cm
2
 flask. 10 ml infected cells 
were transferred to the flask which was incubated at 38.5
o
C with 5% CO2. 
Flasks were checked daily until extensive cytopathic effect was seen, approximately 
after 2-3 days. The infected cell monolayers were removed using trypsin/EDTA as 
described previously. The cells were resuspended in 10 ml 5% CEF media and 
pelleted by centrifugation at 200 x g for 5 minutes. Four cryovials of CEF cells were 
removed from liquid nitrogen and kept on dry ice until ready to thaw. Two cryovials 
of CEF cells were thawed rapidly in a 37
o
C water bath and transferred to a universal 
containing 10 ml of prewarmed 5% CEF media. This was repeated and cells in both 
universals were pelleted by centrifugation at 200 x g for 5 minutes. Pelleted cells 
were resuspended in 10 ml of fresh 5% CEF media and transferred to a labelled T175 
cm
2
 flask. 5 ml of infected cells were transferred to each T175 cm
2 
flask as well as 25 
ml fresh, prewarmed 5% CEF media. Both T175 cm
2
 flasks were incubated in a 
38.5
o
C incubator with 5% CO2. Once extensive cytopathic effect was visible, the 
infected cell monolayers were removed using trypsin/EDTA as described previously 
and pelleted by centrifugation at 200 x g for 5 minutes.  
Pelleted cells were resuspended in 2 ml of freezing solution (90% v/v FCS, 10% v/v 
dimethyl sulphoxide) and aliquoted into cryovials (200 µl/cryovial). All cryovials 
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were frozen overnight at -80
o
C, wrapped in cotton wool. Samples were transferred to 
liquid nitrogen the following day for long term storage.  
 
2.3.10. Plaque Assay 
 
Plaque assays were used to determine the infectivity titre of the frozen stocks of cell 
associated MDV CVI988 and MDV mutant viruses. CEF cells were used to seed six-
well plates at a density of 5.0 x 10
5
 cells per well, and these were incubated at 38.5
o
C 
with 5% CO2 until confluent. For each construct, one 200 µl cryovial of infected 
CEF cells was removed from liquid nitrogen and kept on dry ice until ready to thaw. 
Infected CEF cells were thawed rapidly in a 37
o
C water bath and, in duplicate, 100 





, were pipetted onto a labelled well of the seeded 6 well dish. Plates 
were incubated at 38.5
o
C with 5% CO2 overnight. Media was changed to prewarmed 
2% CEF media after 24 hours. 
 
 
2.3.11. Immunohistochemistry of transfected Vero cells 
 
Vero cells, transfected with GFP or DsRed plasmid constructs, did not require 
antibody staining. Media was pipetted from the well and the coverslip was gently 
rinsed twice with PBS. Transfected cells were fixed onto coverslips for 20 minutes 
using 4% (w/v) paraformaldehyde (BDH laboratories, UK) in PBS. Following fixing, 
coverslips were washed twice for 5 minutes using PBS and mounted onto 
microscope slides using Mowiol Mounting medium (EMD Biosciences, Germany). 
These were subsequently stored, wrapped in foil, at 4
o
C until viewed using a 
confocal microscope.  
 
 
2.3.12. Immunohistochemistry of CEF Plaques with antibody 
specific for MDV glycoprotein B (gB) 
 
MDV-induced plaques can be visualised using the MDV-specific antibody, HB3 
(Millipore, UK), to detect the virally expressed glycoprotein B (gB). Media from 
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cells displaying CPE in the form of plaques were removed and the cells were gently 
rinsed twice with PBS. Transfected cells were fixed using ice-cold acetone:methanol 
(1:1 v/v) for 2 minutes at room temperature. Following fixing, cells were washed 
twice for 5 minutes using PBS.  
 
The cells were incubated for 1 hour in CAS Block (Invitrogen, UK). Blocking 
solution was pipetted off and the cells were incubated for 1 hour with HB3 (α-gB) 
antibody, diluted 1/100 in CAS block. Cells were washed three times for 5 minutes 
with PBS. The secondary antibody, horse radish peroxidase-conjugated rabbit anti-
mouse IgG (Dako P0260), was diluted 1/200 in CAS Block and applied to the cells 
for 1 hour. Cells were washed three times for 5 minutes with PBS. The developing 
solution was prepared: 513 µl of 3-amino-9-ethylcarbazole (AEC) substrate buffer 
(0.1 M sodium acetate, pH 4.8), 27 µl of 3-amino-9-ethylcarbazole (AEC) stock (4 
mg/ml
-1
) and 9 µl Hydrogen Peroxide (H2O2), per well. The developing solution was 
added to the well and the plates were incubated at 38.5
o
C until the red colour 




2.3.13. Immunohistochemistry of CEF Plaques with α-myc/HIS  
antibody 
 
Using BAC mutagenesis to replace MDV genes with an influenza gene tagged with 
the Myc/His tag meant that plaques could be visualised using either an α-myc 
antibody (Clone 4A6, Millipore, UK) or an α-His antibody (Penta-His, Qiagen, UK). 
Media from cells displaying CPE in the form of plaques were removed and the cells 
were gently rinsed twice with PBS. Transfected cells were fixed for 20 minutes using 
4% (w/v) paraformaldehyde in PBS and subsequently were washed twice for 5 
minutes using PBS. Cells were incubated for 20 minutes with 0.3% Triton X-100 (t-
Octylphenoxypolyethoxyethanol, Sigma, UK) in PBS to permeablise the cell 
membranes before being washed three times with PBS for 5 minutes.  
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Cells were subsequently incubated for 30 minutes in CAS Block. This was removed 
by pipetting and the cells were incubated for 2 hours with either α-myc or α-His 
antibody, diluted 1/50 (v/v) in CAS block. Cells were washed three times for 5 
minutes with PBS. The secondary antibody, goat anti-mouse Alexa Fluor 488 
conjugate (Invitrogen, UK), was diluted 1/500 in CAS block and applied to the cells 
for 1 hour. Cells were washed twice for 10 minutes with PBS. PBS was left on the 
cells, the plates were sealed and wrapped in foil at 4
o
C until viewed and 
photographed.  
 
Cells transfected with GFP constructs did not require antibody staining but were 
prepared, fixed and permeablised as described above. 
 
 
2.4. Western Blots 
 
2.4.1.            Protein Extraction  
Media from cells displaying CPE in the form of plaques was removed and the cells 
were gently rinsed twice with ice cold PBS. 250 µl ice cold lysis buffer (Section 
2.5.3) containing 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
(Pefabloc) (Fluka, UK) were added to the cells and incubated on a rocking platform 
at 4
o
C for 1 hour. Lysed cells were transferred to a non-stick, 1.5 ml microcentrifuge 
tube (Ambion, UK) and centrifuged at 18,000 x g at 4
o
C for 5 minutes to remove cell 
debris. The remaining supernatant, containing protein only, was divided into two 
aliquots and frozen at -80
o
C. Immediately prior to protein quantification, a 1/100 
dilution (v/v) of each protein sample in lysis buffer was prepared. 
 
2.4.2.           BCA protein quantification 
Total protein was quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific, UK) which was used to determine protein concentration with reference to 
standards of the common protein, bovine serum albumin (BSA). A series of dilutions 
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of known concentrations are prepared from the protein and assayed alongside the 
unknown samples so that the concentration of each may be determined using a 
standard curve. Using the enhanced test tube protocol, the albumin standard (BSA) 
(2 mg/ml) was used to prepare a set of diluted standards (Table 2.1). 
The BCA working reagent (WR) was prepared (2 ml per sample) by mixing 50 parts 
of BCA reagent A with 1 part BCA reagent B (50:1, Reagent A:B). 0.1 ml of each 
standard and unknown sample was mixed with 2 ml working reagent and incubated 
at 60
o
C for 30 minutes. A spectrophotometer was set to 562 nm and, using a cuvette 
filled with H2O, the instrument was zeroed. Once the samples had cooled to room 
temperature, the absorbance measurements of all tubes were made within 10 minutes 
of each other.  
 









The average 562 nm absorbance measurement of the blank standard was subtracted 
from the 562 nm absorbance measurement of all other individual standards and 
extracted protein samples. A standard curve was prepared by plotting the average 
blank-corrected 562 nm measurement for each BSA standard versus its concentration 
Vial Volume of 
diluent 




A 700 µl 100 µl of stock 250 µg/ml 
B 400 µl 400 µl of vial A Dilution 125 µg/ml 
C 450 µl 300 µl of vial B Dilution 50 µg/ml 
D 400 µl 400 µl of vial C Dilution 25 µg/ml 
E 400 µl 100 µl of vial D Dilution 5 µg/ml 
F 400 µl 0 0 
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in µg/ml. This standard curve was used to determine the protein concentration of 
each unknown, extracted protein sample. 
 
2.4.3.            Calculation of protein weight  
The theoretical molecular weight of the proteins of interest was calculated using the 
Expert Protein Analysis System (ExPASy) proteomics server of the Swiss Institute of 
Bioinformatics (SIB).       
    
2.4.4.           Sodium Dodecyl Sulfate - Polyacrylamide Gel  
                     Electrophoresis (SDS-PAGE). 
 
The gel plates were assembled with spacers and poured, first with a 10% acrylamide 
resolving gel (Section 2.5.3), followed by a stacking gel (Section 2.5.3). All gels 
were poured immediately after the addition of ammonium persulphate (AP) and 
N,N,N’,N’-tetramethylethylenediamine (TEMED). Resolving gels were poured, 
overlayed with butan-2-ol and allowed to set for 30 minutes. The butan-2-ol was 
removed and the top surface of the gel was rinsed with stacking gel solution. The 
stacking gel was poured, the 10 well comb was added and the gel was allowed to set 
for 30 minutes. Once polymerisation of the gel was complete, the gels were 
assembled in a vertical gel tank with two gels per tank. The reservoir was filled with 
SDS running buffer (Section 2.5.3). The combs were removed and the wells were 
rinsed out with SDS running buffer to remove any unpolymerised acrylamide. 
 
20 µg of each protein sample were mixed with 16 µl of SDS-PAGE boiling buffer 
(Section 2.5.3) by vortexing and heated at 95
o
C for 5 minutes. Samples were loaded 
into the wells of the gel and run at 175 V/cm
2
 until the bromophenol blue dye front 
had reached the bottom of the gel. For comparative size estimation of proteins, the 
ColorPlus Prestained Protein Marker (NEB, UK) was used. 
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2.4.5.           Tank blotting transfer of proteins to nitrocellulose  
          membranes  
Nitrocellulose membrane (Amersham Hybond-ECL, UK) was cut to the same size as 
the polyacrylamide gel (approximately 4.5 cm x 7.5 cm) and nine pieces of 
chromatography paper (Whatman, UK) were cut to a slightly larger size. Both the 
chromatography paper and membrane were soaked in tank blotting transfer buffer 
(Section 2.5.3) for 10 minutes prior to use. The tank blotting buffer contains a higher 
proportion of methanol and, as the buffer capacity is greater, it can be performed 
over extended periods (2-8 hours). This ensures more efficient transfer of proteins. 
Three sheets of the chromatography paper were laid on an absorbent filter pad in a 
blotting cassette. The nitrocellulose membrane was laid on top of this, followed by 
the resolving gel. The remaining six sheets of chromatography paper were placed on 
the gel and a pipette was used to roll out any trapped air bubbles. Finally, a second 
absorbant filter pad was laid on top and the blocking cassette was transferred to the 
tank containing tank blotting transfer buffer. The voltage used was 6 mV/cm
2
 of 
filter paper. Following blotting, the nitrocellulose membrane was carefully removed 
and washed twice in dH2O and stained with Ponceau S solution (Section 2.5.3) for 1 
minute. After a further two washes with dH2O, staining revealed defined bands 
confirming even transfer of protein. Subsequently, the blot was incubated for 1 hour 
in freshly prepared 5% reconstituted dried milk in TBS (Section 2.5.3) to block non-
specific binding sites.  
 
2.4.6.            Immunological Detection of Protein Blots 
 
Primary antibodies used were specific for the myc (Millipore, UK), HIS (Qiagen, 
UK) and MDV gB (Millipore, UK). 
 
The primary α-myc and α-HIS and α-gB antibodies were diluted 1:500 in TBS with 
5% reconstituted dried milk. Membranes were incubated for 1.5 hours and 
subsequently washed twice with 0.05% Tween-20/TBS for 15 minutes. Membranes 
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were then incubated for 1 hour with the secondary biotinylated anti-mouse IgG 
(rabbit) antibody (Dako, UK), which was diluted 1:2,000 in TBS with 5% 
reconstituted dried milk. Membranes were washed twice with 0.05 % Tween-20/TBS 
for 15 minutes and rinsed with 5 changes of dH2O. The tertiary stage used a 
Streptavidin Alkaline Phosphatase (AP) conjugate, diluted 1:500 in TBS with 5% 
reconstituted dried milk, which formed a biotin-avidin peroxidise complex with the 
secondary biotinylated antibody (Roche, UK). Following this, membranes were 
washed twice with 0.05% Tween-20/TBS for 15 minutes, twice with TBS for 15 
minutes and rinsed with dH2O.  
Bound antibody was detected by incubating the membrane with 5-bromo-4-chloro-3-
indolyl phosphate/nitro blue tetrazolium solution (1 SIGMAFAST BCIP/NBT tablet 
dissolved in 10 ml dH2O) until clear bands were visible. All antibody incubations 




2.5.1.            Commonly used Solutions 
 
PBS 
10 mM Sodium Phosphate 
140 mM Sodium Chloride 
pH 7.4 
 
2.5.2.            Nucleic Acid Electrophoresis 
Tris-Acetate EDTA (TAE) 
40 mM TRIS 
20 mM Acetic Acid 
1 mM EDTA 
pH 8.0 




15% (w/v) Ficoll 
0.25% (w/v) Orange G 
 
  
2.5.3.           Protein Electrophoresis 
TBS 
10 mM Tris-HCL 





50 mM Tris 
250 mM Sodium Chloride 
50 mM Sodium Fluoride 
5 mM EDTA 
1.25 mM 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (Pefabloc) 
0.1% (v/v) Nonyl phenoxypolyethoxylethanol (Np40) 
pH 7.4 
 
SDS-PAGE boiling buffer 
 
125 mM Tris (pH 6.7) 
5% (w/v) Sodium Dodecyl Sulphate 
25% (v/v) Glycerol 
12.5% (v/v) β-mercaptoethanol 
0.25% (w/v) Bromophenol Blue 
 
 




4% (w/v) Acrylamide/bis-Acrylamide (37.5:1) 
125 mM Tris 
0.1% (w/v) Ammonium Persulphate 
0.1% (w/v) Sodium Dodecyl Sulphate 




10% (w/v) Acrylamide/bis-Acrylamide (37.5:1) 
375 mM Tris 
0.1% (w/v) Ammonium Persulphate 
0.1% (w/v) Sodium Dodecyl Sulphate 
0.1% (v/v) N, N, N’, N’- Tetramethylethylenediamine (TEMED) 
pH 8.8 
 
SDS running buffer 
100 mM Tris 
38 mM Glycine 
0.1% (w/v) Sodium Dodecyl Sulphate 
pH 8.8 
 
Tank blotting transfer buffer 
25 mM Tris 
150 mM Glycine 
20% (v/v) Methanol 
pH 8.3 
 





0.5% (w/v) Ponceau S 
1% (v/v) Acetic Acid 
 
 
2.5.4.            Bacterial Media 
 
Luria-Bertani (LB) broth 
 
1% (w/v) Tryptone 
0.5% (w/v) Yeast extract 
1% (w/v) Sodium Chloride 
pH 7.0 
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3.1. MDV-HA BAC Construct 
 
3.1.1. Aims and Approach 
The ongoing threat of an influenza virus pandemic has highlighted the need to 
continually develop novel and improved vaccines as a successful control strategy. 
Vaccination of commercial poultry flocks against influenza could decrease the global 
levels of virus in circulation, thus managing the pandemic potential and help to 
preserve the poultry industry (Capua and Marangon, 2003). The aim of this research 
was to identify a viral vector that could deliver influenza antigens to poultry, eliciting 
both humoral and cellular immune responses. The viral vector chosen was the widely 
used vaccine for Marek’s Disease (MD), a common but important herpesvirus-
induced, lymphoproliferative disease of poultry (Gimeno, 2008). If influenza genes 
could be incorporated into the live attenuated Marek’s Disease Virus (MDV) CVI988 
vaccine genome, then dual vaccination would be possible, allowing simultaneous 
vaccination against both pathogens.  
Vaccine-induced protection against avian influenza (AI) is the result of the humoral 
immune response targeted against the haemagglutinin (HA) protein and, to a lesser 
extent, the neuraminidase (NA) protein, both found on the surface of the influenza 
virus (Swayne and Kapczynski, 2008). The primary objective of this study, therefore, 
was to incorporate a HA gene into the MDV viral genome. The approach taken was 
to first establish the location of a non-essential gene in the MDV genome, using 
previously published research, which could be deleted with no effect, or at most 
slight attenuation, on the ability of the parental virus to replicate. The manipulation 
of the MDV CVI988 viral genome is possible due to the creation of an MDV 
CVI988 Bacterial Artificial Chromosome (BAC), which allows genes of interest to 
be inserted or deleted using mutagenesis (Petherbridge et al, 2003). This method has 
the additional advantage of avoiding unmapped and intragenic promoters, the 
disruption of which may have impacted on essential genes in the region. Once 
identified, the non-essential gene can be replaced by the influenza HA gene, creating 
MDV-HA BAC constructs. Subsequently, using in vitro analysis, Chicken Embryo 
Fibroblast (CEF) cells, transfected with the MDV-HA constructs, should express 
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detectable levels of both MDV and HA proteins, determined by 
immunohistochemistry and western blot techniques. HA genes may be inserted into 
the MDV genome in the ‘forward’ orientation (F), where genes are transcribed from 
left to right, or the ‘reverse’ orientation (R), where genes are transcribed from right 
to left. Left is closest to the UL1 gene in the MDV genome or the origin of 
replication in a plasmid. 
To replace the non-essential gene with the influenza HA gene, a recombination 
plasmid based on the shuttle plasmid, pST76k, will be constructed, where the gene to 
be introduced (HA) is flanked by sequences (2-3 kb) homologous to the sequences 
flanking the gene to be replaced. This alignment of similar sequences will allow a 
crossover between the DNA strands resulting in an exchange of material (Figure 
3.1). pST76k is kanamycin resistant and contains the RecA gene and the SacB gene, 
which allows for selection in the presence of 5% sucrose. The shuttle plasmid, 
pST76k, has a low copy number and should be propagated at 30
o
C. Therefore, the 
insert (Flanking Sequence – Gene – Flanking Sequence) will first be constructed in 
the high copy vector, Zero Blunt II TOPO (Invitrogen, UK). This insert will be 
transferred to the shuttle plasmid (pST76k) in the final cloning step. The following 
sections describe the construction of this shuttle plasmid and the creation of the 
MDV-HA BAC construct. 
 
3.1.2. Identification of the non-essential genes in MDV 
Several genes were identified as non-essential in the MDV genome, based on 
previously published research. The UL41 open reading frame was the first to be 
targeted as a potential site for the insertion of the HA gene (Read and Frenkel, 1983; 
Chattoo et al, 2006; Gimeno and Silva, 2008). Gimeno and Silva (2008) determined 
that the MDV UL41 gene functioned as a viral host shut-off (VHS) protein. A UL41 
deletion mutant replicated as well as the parental strain in vitro. In vivo, the pattern 
and degree of neurovirulence and tumour lesions produced by the deletion mutant 
was the same as the pattern of lesions induced by the parental virus. The only 
observable difference between the parental MDV and the UL41 deletion mutant was  









                         
     
















Sequences A & B
Mutation
Figure 3.1 A diagrammatic representation of the shuttle plasmid and the 
MDV CVI988 BAC. The alignment of similar flanking sequences allows a 
crossover between the aligned DNA strands resulting in an exchange of 
material. 
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that the early in vivo cytolytic infection was of a longer duration. Subsequently, as it 
was concluded that the UL41 was non-essential, this open reading frame was 
targeted as the site for the insertion of the influenza HA gene. 
 
3.1.3. MDV UL41 Flanking sequences 
The MDV CVI988 BAC was isolated as described in Section 2.2.7. Primers were 
designed to amplify approximately 3 kb of the DNA sequence on either side of the 
UL41 gene (Appendix A.1.3.1). The unique restriction enzyme sites, KpnI, PacI and 
AgeI, were incorporated into the primers to facilitate downstream cloning. The 
flanking sequences (FSA and FSB) were successfully amplified as described in 
Section 2.1.1 and Appendix A.1.4.1. These flanking sequences were gel purified 
according to the protocol in Section 2.1.9 and cloned into Zero Blunt II TOPO, as 
described in Section 2.1.2. TOP10 chemically competent E. coli cells were 
transformed (Section 2.2.2) with the ligated plasmids UL41pTOPFSA and 
UL41pTOPFSB (Figure 3.2), and plated onto Luria Bertani (LB) agar containing 
kanamycin (50 µg/ml). Plasmid DNA was isolated from small cultures (Section 
2.2.5) and shown by restriction enzyme digest analysis (Section 2.1.6) to contain an 
insert of the correct size, in the correct orientation.  
 
3.1.4. UL41pTOPFSAB 
The plasmids, UL41pTOPFSA and UL41pTOPFSB, were digested with KpnI and 
AgeI, in preparation for cloning. The digested fragments were gel purified according 
to the protocol in Section 2.1.9. The purified FSB fragment was ligated into 
UL41pTOPFSA, as described in Section 2.1.10. Competent E. coli cells were 
transformed with the ligation mix (Section 2.2.2) and plasmid DNA was isolated 
(Section 2.2.5). The successfully ligated plasmid, UL41pTOPFSAB (Figure 3.2), 
was confirmed using restriction enzyme digestion with KpnI and AgeI, PacI and 
AgeI, and KpnI and PacI (Section 2.1.6). 
 

























Figure 3.2 A) A diagrammatic representation of the created plasmid 
UL41pTOPFSA. B) A diagrammatic representation of the created plasmid 
UL41pTOPFSB. C) The 3.1 kb UL41FSB DNA fragment was ligated into 
UL41pTOPFSA to create UL41pTOPFSAB. 
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3.1.5. Digestion and phosphatase treatment of UL41pTOPFSAB 
In preparation for cloning, the plasmid UL41pTOPFSAB was digested with AgeI 
(Promega, UK) (Section 2.1.6). The digested plasmid was gel purified (Section 2.1.9) 
and concentrated using ethanol precipitation (Section 2.1.5). The digested plasmid 
DNA was treated with Antarctic Phosphatase (AP) to remove 5’ phosphate groups 
and prevent self ligation upon ligation with the insert (Section 2.1.8). 
 
3.1.6. H10 gene 
In order to help facilitate future in vivo studies, it was decided that the HA gene from 
a low pathogenic (LP) strain of influenza virus should initially be incorporated into 
the MDV CVI988 genome. Any avian influenza virus with an intravenous 
pathogenicity index (IVPI) greater than 1.2 is classified as highly pathogenic (HP) 
(Lee and Saif, 2009). By locating an influenza strain with an IVPI with a value of 
1.0, it was reasoned that any ill-health could be used as readout, and the location of 
facilities with suitable containment levels for viral challenge studies would be easier.  
Dr Ilaria Capua, Director of the Virology Department and of the International 
Reference Laboratories at the Istituto Zooprofilattico Sperimentale delle Venezie in 
Italy, kindly supplied the genomic RNA of the strain: A/teal/Romania/4385/06 
(H10N1). Dr Capua advised that the H10 influenza viruses had the closest available 
match to an IVPI of 1.0. 
Using the gene-specific primer H10N1RT (Appendix A.1.3.1), 9 µl of the genomic 
RNA (0.7 ng/µl) were converted to cDNA by reverse transcription (Section 2.1.15). 
Primers (H10N1For and H10Rev) that incorporated the unique restriction sites, XhoI 
and XbaI, were designed to amplify the H10 cDNA (Appendix A.1.3.1). The H10 
DNA was successfully amplified as described in Section 2.1.1 and Appendix A.1.4.1. 
The amplified H10 DNA was purified using a QIAquick PCR purification kit 
(Section 2.1.3). In preparation for cloning, the purified H10 DNA was digested with 
XhoI and XbaI (Section 2.1.6) and gel purified according to the protocol in Section 
2.1.9. 




To ensure a high level of expression, the H10 DNA was cloned downstream of the 
cytomegalovirus (CMV) immediate early (IE) promoter. This promoter was acquired 
from the plasmid, pEGFP-Nl, which contains the CMV promoter upstream of a 
Green Fluorescent Protein (GFP) gene (Figure 3.3). The GFP gene, flanked by the 
restriction sites, XhoI and XbaI, was removed by restriction enzyme digestion 
(Section 2.1.6). However, to digest this plasmid with the methylation sensitive XbaI 
enzyme, Dam
–
 competent cells were first transformed with pEGFP-Nl (Section 
2.2.2). The unmethylated pEGFP-N1 plasmid DNA was isolated (Section 2.2.5) and, 
following digestion with XhoI and XbaI, the vector backbone was gel purified in 
preparation for cloning (Section 2.1.9). 
The digested and purified H10 DNA fragment was ligated downstream of the CMV 
promoter in the vector backbone (Section 2.1.10). Following transformation of 
competent E. coli cells with the ligation mix (Section 2.2.2), and plasmid DNA 
isolation (Section 2.2.5), the successfully created plasmid, pCMVH10 (Figure 3.3), 
was confirmed using XhoI and AhdI. 
 
3.1.8. pTOPCMVH10 
Primers (pCMVHA_For and pCMVHA_Rev; Appendix A.1.3.1) which both 
incorporated the unique restriction site, AgeI, were designed to amplify the CMV-
H10 DNA fragment so that this insert could be ligated between the flanking 
sequences in UL41pTOPFSAB (Figure 3.2). Using pCMVH10 as a template (20 ng), 
the CMV-H10 DNA was amplified (Section 2.1.1 and Appendix A.1.4.1), isolated by 
gel purification (Section 2.1.9) and cloned into Blunt II TOPO (Section 2.1.2) to 
create pTOPCMVH10 (Figure 3.3). Following the transformation of competent E. 
coli cells with the ligation mix (Section 2.2.2), and plasmid DNA isolation (Section 
2.2.5), the isolated plasmid, pTOPCMVH10, containing the CMVH10 insert in the 
forward orientation, was identified by digestion with XhoI. Following confirmation, 
pTOPCMVH10 plasmid DNA was prepared according to the protocol in Section 
2.2.6.  
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Figure 3.3 A) A diagrammatic representation the plasmid pEGFP-Nl. B) The 
H10 gene was cloned downstream of the CMV promoter to create 
pCMVH10. C) Using PCR, the CMVH10 DNA fragment was re-amplified 
with primers that both incorporated the AgeI restriction enzyme site and 
cloned into Blunt II TOPO (Invitrogen, UK) to create pTOPCMVH10. 
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Primers were designed to sequence the CMV promoter and H10 gene (Appendix 
A.1.3.1). Sequence reactions were carried out using Big Dye (Section 2.1.12) and 
sequencing was performed by GenePool (University of Edinburgh). Sequence results 
indicated no errors in the CMV promoter or the downstream H10 gene with complete 
identity with the published sequences. 
 
3.1.9. UL41pTOPFSABH10 (F) 
The plasmid, pTOPCMVH10, was digested with AgeI in preparation for cloning. The 
digested CMVH10 DNA fragment was gel purified according to the protocol in 
Section 2.1.9. As described in Section 2.1.10, the purified CMVH10 insert was 
ligated into the AgeI digested and phosphatased UL41pTOPFSAB (Section 3.1.5) to 
create UL41pTOPFSABH10(F) (Figure 3.4). XL-Gold ultracompetent E. coli cells 
were transformed with the ligation reaction (Section 2.2.3) and plated onto LB agar 
plates containing 50 µg/ml kanamycin. For the purpose of colony PCR and the 
subsequent propagation of colonies identified that contained the correct plasmid, 20 
colonies were inoculated onto a grid numbered (1-20) LB agar plate (50 µg/ml 
kanamycin) using a sterile pipette tip each time. The plate was incubated at 37
o
C 
overnight. To identify bacteria that contained the plasmid, UL41pTOPFSABH10(F), 
colony PCR was carried out with the H10-specific primers, pCMVHAID_For and 
pCMVHAID_Rev, which detected the H10 insert in the forward orientation (Section 
2.1.1 and Appendices A.1.3.1 and A.1.4.1). Three bacterial colonies tested positive 
for the plasmid, UL41pTOPFSABH10(F). 
These three colonies were cultured overnight in LB agar containing kanamycin (50 
µg/ml). Plasmid DNA was isolated from small cultures, as described in Section 
2.2.5. The plasmids were digested with the restriction enzymes, NdeI, AgeI and ApaI 
(Section 2.1.6), but only one sample contained a plasmid of the correct size and with 
the expected digest pattern. Following confirmation, UL41pTOPFSABH10(F) 
plasmid DNA was prepared according to the protocol in Section 2.2.6.  
 





                                           
        
                                                 














B. C.  UL41pST76kH10 (F)
L         1    2    3   4    5    6   7    8         L
8.4kb
6.3kb
Figure 3.4 A) A diagrammatic representation of the created plasmid 
UL41pTOPFSABH10 (F). The CMV-H10 DNA fragment was cloned into 
the plasmid UL41pTOPFSAB, between the flanking sequences FSA and 
FSB. B) In the final cloning step, the FSABCMVH10 DNA fragment was 
transferred to the shuttle plasmid, pST76k, to create the plasmid 
UL41pST76kH10(F). C) A restriction enzyme digestion of eight isolated 
UL41pST76kH10(F) plasmids (No. 1-8), using the enzymes KpnI and PacI.  




The shuttle plasmid, pST76k, was kindly provided by Mr Ian Bennet as a glycerol 
stock which was streaked onto a LB agar plate containing 50 µg/ml kanamycin. The 
plate was incubated at 30
o
C for 48 hours to allow the growth of single colonies. To 
ensure that the shuttle plasmid was sucrose sensitive, one kanamycin (50 µg/ml) LB 
agar plate and one kanamycin (50 µg/ml) with 5% sucrose LB agar plate was grid 
labelled with 6 squares. For each colony, a sterile pipette tip was used to inoculate a 
grid square with a single colony in both the kanamycin and kanamycin/sucrose agar 
plate. A colony that grew well on the kanamycin plate but that displayed complete 
sucrose sensitivity was isolated as described in Section 2.2.6. 
In preparation for cloning, the plasmid pST76k was digested with the restriction 
enzymes, KpnI and PacI, and gel purified (Section 2.1.9). Following purification, the 
DNA concentration was determined, as described in Section 2.1.11. 
 
3.1.11. UL41pST76kH10 (F) 
 
The plasmid, UL41pTOPFSABH10(F), was digested with KpnI and PacI, in 
preparation for cloning. The digested FSABH10 fragment was gel purified (Section 
2.1.9) and ligated into the digested and purified pST76k plasmid (Section 2.1.10) to 
create UL41pST76kH10(F) (Figure 3.4). Following transformation at 30
o
C (Section 
2.2.2), plasmid DNA was isolated from small cultures (Section 2.2.5). To confirm 
that the 6.3 kb plasmid, pST76k, contained the 8.4 kb FSABH10 DNA insert, eight 
plasmid DNA preparations were digested with KpnI and PacI. All colonies displayed 
the correct digest pattern (Figure 3.4).  
 
 
3.1.12. BAC Mutagenesis using UL41pST76kH10(F) 
BAC mutagenesis was performed, as described in Section 2.2.9. DH5-α bacteria, 
containing the MDV CVI988 BAC, were made competent according to the protocol 
in Section 2.2.8 and transformed with 10 ng of the shuttle plasmid, 
Chapter 3  Results 
101 
 
UL41pST76kH10(F), by electroporation. Kanamycin-sensitive colonies containing 
UL41(Rep) BACs, where the UL41 gene had been replaced with H10, were 
identified using colony PCR (Section 2.1.1 and Appendix A.1.4.1). The primers, 
pCMVHAID_For and pCMVHAID_Rev (Appendix A.1.3.1), were used to identify 
the 2.3 kb CMVH10 DNA fragment. UL41pTOPFSABH10(F) plasmid DNA was 
included as a positive control; CVI988 BAC DNA acted as a negative control. Both 
the positive and negative control produced expected results. 6 colonies out of the 20 
colonies tested were positive for the 2.3 kb H10 DNA sequence, indicating that the 
H10 gene had replaced the UL41 gene. A UL41(Rep) H10(F) BAC was selected and 
isolated, as described in Section 2.2.7.  
The CVI988 and UL41(Rep) H10(F) BAC were analysed by restriction enzyme 
digestion, using AgeI (Section 2.1.6 and Section 2.1.4). The introduction of the AgeI-
flanked CMVH10 DNA fragment into the MDV CVI988 BAC genome altered the 
predicted restriction enzyme digestion pattern. The results clearly indicated the 
successful insertion of the 2.3 kb CMV-H10 DNA fragment into the MDV CVI988 
genome (Figure 3.5). 
 
3.1.13. In vitro Characterisation of UL41(Rep) H10(F) BAC 
CEF cells, transfected with MDV CVI988 BAC DNA, develop focal cytopathic areas 
(CPE) as the highly cell-associated MDV virus spreads through the cell sheet by cell 
to cell contact (Churchill and Biggs, 1967) (Figure 3.6). These foci, also referred to 
as plaques, consist of rounded, highly refractile cells and appear after 7-10 days. 
They can be difficult to see by eye so to aid visualisation, plaques were stained red 
(Figure 3.6) using antibody specific for the MDV gB glycoprotein (HB3), combined 
with the specific developing solution, 3-amino-9-ethylcarbazole (AEC) (Section 
2.3.12).  
To determine if the UL41(Rep) H10(F) BAC DNA also induced the formation of 
plaques, CEF cells were transfected separately with CVI988 BAC DNA and 
UL41(Rep) H10(F) BAC DNA (Section 2.3.7). After 7 days, plaques were visible in 
CEF cells that had been transfected with CVI988 BAC DNA, with approximately 15  
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Figure 3.5 A) Predicted AgeI sites in the area affected by mutagenesis (for 
clarity, other AgeI sites are not shown). The changes caused by the 
introduction of the AgeI flanked CMVH10 DNA fragment are highlighted. 
B) Table displaying the predicted digest fragments of the CVI988 and UL41 
(Rep) H10 BAC following AgeI enzyme digestion. C) A restriction enzyme 
digestion of the CVI988 and the UL41 (Rep) H10 BAC using the enzyme, 
AgeI, clearly demonstrating the successful introduction of the 2.3 kb 
CMVH10 insert into the MDV CVI988 genome. 




                    
           
  
 





Figure 3.6 A) A photograph displaying a single plaque caused by the 
transfection of the MDV CVI988 BAC into Chicken Embryo Fibroblast 
(CEF) cells. B) Visualisation of a plaque using immunohistochemistry. The 
plaque was immunostained with 1
o
 HB3 antibody, specific for the MDV gB 
glycoprotein, 2
o
 Horseradish peroxidise-conjugated goat anti-mouse IgG and 
3-amino-9-ethylcarbazole (AEC) developing solution.  
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15 plaques in each of the three wells. No plaques were visible in CEF cells that had 
been transfected with UL41(Rep) H10(F) BAC DNA. The BAC transfections were 
repeated, with similar results. Three wells of CEF cells were transfected with each 
BAC (Section 2.3.7). After 7 days, CVI988 BAC DNA transfection resulted in the 
formation of plaques (an average of 15 plaques per well) but UL41(Rep) H10(F) 
BAC DNA did not.  
To ascertain if the BAC transfected CEF cells were expressing MDV-encoded 
mRNA or H10 mRNA, total RNA was extracted from unstained, transfected cells 
and isolated using an RNeasy Mini Kit (Section 2.1.14). 3 µg of the extracted, 
DNase-treated RNA was converted to complementary DNA (cDNA) by reverse 
transcription using random primers (Section 2.1.15).  
 
3.1.14. CVI988/UL41(Rep) H10 BAC cDNA PCR 
The cDNA created in Section 3.1.13 was tested by PCR using primers for H10, as 
well as two sets of MDV gene-specific primers (MDV UL18, vIL-8), kindly 
provided by Dr B. M. Dutia (Section 2.1.1 and Appendix A.1.3.1). Following PCR, 
the subsequent reactions were analysed using agarose gel electrophoresis on a 1% gel 
(Section 2.1.4). Results indicated that, as expected, the CVI988 BAC-transfected 
cells expressed MDV mRNA but not H10 mRNA. cDNA made from CEF cells 
transfected with the UL41(Rep) H10(F) BAC tested positive for H10 but only very 
weakly positive for the MDV genes (Figure 3.7). This indicated that the CEF cells 
were being successfully transfected with the UL41(Rep) H10(F) BAC and that the 
CMV promoter was driving H10 mRNA expression. However, when compared to 
the parental strain, MDV CVI988, the apparently weaker expression of the MDV 
genes (although the PCR was not quantitative), indicated that either the introduction 
of the H10 gene, or the deletion of UL41 gene, was having a disruptive effect on the 
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cDNA from CEFs transfected with 
CVI988 BAC DNA : - PCR primers
1) MDV UL18 (Capsid Protein gene)
2) MDV vIL-8 (Chemokine)
3) H10 gene
cDNA from CEFs transfected with 
UL41 (Rep) H10 BAC DNA : -
PCR primers
4) MDV UL18 (Capsid Protein gene)
5) MDV vIL-8 (Chemokine)
6) H10 gene
7) 1Kb Ladder
Figure 3.7 cDNA extracted from CEF cells transfected with CVI988 BAC 
DNA and UL41(Rep) H10 BAC DNA was tested using PCR with primers 
specific for the UL18, vIL-8 and the H10 gene.  
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3.1.15. UL41 Flanking sequences 
 
Although the CMVH10 DNA insert had been fully sequenced (Section 3.1.8), the 
flanking sequences were not. It was speculated that if errors were present in the 
flanking sequences, they could be incorporated into the UL41(Rep) H10(F) BAC and 
subsequently disrupt an essential gene in the region. The MDV genes adjacent to the 
UL41 gene that were homologous to the flanking sequences were UL39 
(Ribonucleotide reductase, large subunit), UL40 (Ribonucleotide reductase, small 
subunit), UL42 (DNA polymerase processivity factor), UL43 (Probable membrane 
protein) and UL44 (Virion Glycoprotein C) (Spatz et al, 2007). Sequencing primers 
were designed accordingly (Appendix A.1.3.1). Sequencing reactions were carried 
out (Section 2.1.12), using UL41pTOPFSABH10 DNA (Section 3.1.9) as a template. 
Sequencing results highlighted two issues. The first was that there was a point 
mutation in the FSB sequence, changing an amino acid of the UL40 gene from a 
histidine to a tyrosine, although the potential effect of this change is unknown. 
However, the UL40 open reading frame codes for the ribonucleotide reductase (small 
subunit) protein. Ribonucleotide reductase is a key enzyme in DNA synthesis 
reducing all four ribonucleotides to the corresponding deoxyribonucleotides 
(Reichard, 1988). Disruption of this gene, caused by the point mutation, may explain 
why the UL41(Rep) H10(F) BAC did not form CPE when transfected into CEF cells. 
The second issue was that there was an error in the design of the MareksFSB_Rev 
primer (Appendix A.1.3.1). Its position lay 17 base pairs upstream of the UL40 stop 
codon and therefore this would have been deleted in the subsequent UL41(Rep) H10 
BAC. Without the stop codon, the signal to terminate transcription was lost and this 
may have affected downstream open reading frames. To resolve both of these issues, 
the FSB sequence was re-amplified and replaced in the plasmid, UL41pTOPFSAB. 
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3.2. UL41(Rep) H10 BAC (Corrected) 
     
3.2.1. Re-amplification of MDV Flanking Sequence B 
 
Using MDV CVI988 BAC DNA (20 ng) as a template, the flanking sequence B 
(FSB) was successfully re-amplified as described in Section 2.1.1 and Appendix 
A.1.3.1. The amplified sequence was gel purified (Section 2.1.9) and cloned into 
Zero Blunt II TOPO (Section 2.1.2). Competent E. coli cells were transformed with 
the ligation mixture (Section 2.2.2) and plasmid DNA was isolated from small 
cultures (Section 2.2.5). The plasmid, UL41pTOPFSB (Figure 3.2), was shown by 
restriction enzyme digest analysis (KpnI and AgeI) to contain a product of correct 
size. 
 
3.2.2. UL41pTOPFSAB (#2) 
The plasmid, UL41pTOPFSB, was digested with KpnI and AgeI, and the FSB DNA 
fragment was gel purified in preparation for cloning (Section 2.1.9). The vector 
backbone, UL41pTOPFSA, was digested and purified previously (Section 3.1.4). 
The purified FSB fragment was ligated into UL41pTOPFSA (Section 2.1.10) and 
following transformation (Section 2.2.2), the plasmid DNA was isolated (Section 
2.2.5). The successfully ligated plasmid, UL41pTOPFSAB (#2), was confirmed 
using restriction enzyme digestion with ApaI. UL41pTOPFSAB (#2) plasmid DNA 
was prepared according to the protocol in Section 2.2.6.  
This plasmid, UL41pTOPFSAB (#2), was sequenced using pTOPFSABHA forward 
sequencing primers only (Appendix A.1.3.1). Sequencing results indicated that no 
mutations were present and that the UL40 gene was completely intact. 
The plasmid, UL41pTOPFSAB (#2) was digested with AgeI (Promega, UK) in 
preparation for cloning. The digested plasmid was gel purified (Section 2.1.9) and 
concentrated using ethanol precipitation (Section 2.1.5). The digested plasmid DNA 
was treated with AP (Section 2.1.8). 
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3.2.3. UL41pTOPFSABH10 (#2) 
The plasmid pTOPCMVH10 was previously digested with AgeI and purified in 
preparation for cloning (Section 3.1.9). This purified CMVH10 fragment was ligated 
into the AgeI digested and AP treated UL41pTOPFSAB (#2) (Section 3.2.2). 
Competent E. coli cells were transformed with the ligation mixture according to the 
protocol in Section 2.2.3 and plated onto LB agar plates (50 µg/ml kanamycin). All 
plates and subsequent cultures were incubated at 30
o
C to prevent recombination 
events occurring. 
Following transformation, 21 colonies were inoculated onto a grid numbered (1-21) 
LB agar plate (50 µg/ml kanamycin) using a sterile pipette tip. To identify bacteria 
that contained the plasmid, UL41pTOPFSABH10 (#2), colony PCR was carried out 
(Section 2.1.1 and Appendix A.1.4.1). The primers, H10N1For and H10Rev 
(Appendix A.1.3.1) were used to identify the H10 DNA fragment, regardless of 
orientation. Uncorrected UL41pTOPFSABH10 plasmid DNA (20 ng) acted as a 
positive control (Section 3.1.9). Five bacterial colonies tested positive for the 
plasmid, UL41pTOPFSABH10 (#2). 
As the insert was flanked by the same restriction site, AgeI, it could be ligated into 
UL41pTOPFSAB in either the forward or reverse orientation. To determine the 
orientation of the CMVH10 insert, these five positive colonies were tested using 
orientation-specific primers (Section 2.1.1 and Appendix A.1.4.1). The primers 
pCMVHAID_For and pCMVHAID_Rev were used to detect the CMVH10 insert in 
the forwards orientation; the primers pCMVHAID_For and CMVHA[REV]ID_Rev 
were used to detect the CMVH10 insert in the reverse orientation (Appendices 
A.1.3.1 and A.1.4.1). All five colonies were tested using both sets of primers to 
ensure no colony was positive for both orientations. Uncorrected 
UL41pTOPFSABH10 plasmid DNA (20 ng) acted as a positive control (Section 
3.1.9). In this plasmid, the H10 insert lies in the forward orientation, therefore, it was 
only positive for the forward orientation primers. Of the five H10 positive colonies, 
one plasmid was identified where the CMVH10 DNA fragment had been inserted in 
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the forward orientation, and four plasmids where it was found to be in the reverse 
orientation (Figure 3.8). 
Two bacterial colonies containing the plasmids, UL41pTOPFSABH10(F) and 
UL41pTOPFSABH10(R) (Figure 3.8) were cultured overnight in LB agar containing 
kanamycin (50 µg/ml). Plasmid DNA was isolated according to the protocol in 
Section 2.2.5. The plasmids were analysed using restriction enzyme digestion with 
KpnI and PacI, ApaI, XhoI, EcoRI and AgeI (Section 2.1.6). In both cases, the 
plasmids digested as expected, displaying bands of the appropriate sizes according to 
the orientation of the CMVH10 insert. The exception was the AgeI enzyme digest 
which failed to digest the DNA in either plasmid, indicating that the AgeI sites that 
flanked the CMVH10 insert may have been destroyed upon ligation. 
To confirm the successful ligation of CMVH10 with the plasmid UL41pTOPFSAB, 
the two plasmids were sequenced over the ligation sites only. Both of the plasmids, 
UL41pTOPFSABH10 (F and R), were sequenced using the primers pTOPFSABHA 
_For5 and pTOPFSABHA_Rev9 (Appendices A.1.3.1 and A.1.4.1). Sequencing 
results indicated that in both plasmids, the CMVH10 DNA fragment had been 
correctly inserted between the flanking sequences. Sequencing also confirmed that, 
in both cases, the AgeI sites had been destroyed but neither the MDV genes, nor the 
CMVH10 DNA, were affected by this.  
 
3.2.4. pST76kH10 (Forward and Reverse) 
 
The plasmids, UL41pTOPFSABH10(F) and UL41pTOPFSABH10(R), were 
digested with KpnI and PacI in preparation for cloning with the shuttle plasmid, 
pST76k. The digested FSABH10 fragments were gel purified (Section 2.1.9) and 
ligated into the digested and purified pST76k plasmid (Section 3.1.10) to create the 
plasmids UL41pST76kH10(F) and UL41pST76kH10(R) (Figure 3.8). Competent E. 
coli cells were transformed with each ligation reaction (Section 2.2.2) and plasmid 
DNA was isolated (Section 2.2.5). The plasmids were digested with the restriction 
enzymes, KpnI and PacI, to confirm that the ligation was successful. All plasmids 
gave the correct digest pattern.  
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Figure 3.8 A) Agarose gel electrophoresis showing positive results from an 
orientation specific PCR designed to detect the CMVH10 DNA insert in the 
plasmid pTOPFSABH10 (Forward and Reverse). B) A diagrammatic 
representation of the plasmids UL41pTOPFSABH10 (Forward and 
Reverse). The CMV-H10 DNA fragment was cloned into the plasmid 
UL41pTOPFSAB, between the flanking sequences FSA and FSB. C) In the 
final cloning step, the FSABCMVH10 DNA fragments were transferred to 
the shuttle plasmid, pST76k, to create the plasmids UL41pST76kH10 
(Forward and Reverse).  
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3.2.5. BAC Mutagenesis using the plasmids UL41pST76kH10(F) and  
           UL41pST76kH10(R) 
BAC mutagenesis was performed successfully for both plasmids (Section 2.2.9). 
DH5-α bacteria containing the MDV CVI988 BAC were made competent (Section 
2.2.8) and, using electroporation, were transformed with 10 ng of the shuttle 
plasmids, UL41pST76kH10(F) and UL41pST76kH10(R). Kanamycin-sensitive 
colonies containing UL41(Rep) H10 BACs, where the UL41 gene had been replaced 
with the CMVH10 DNA fragment, were identified using colony PCR (Section 2.1.1 
and Appendix A.1.4.1). The primers, H10N1For and H10Rev (Appendix A.1.3.1) 
were used to identify the 1.5 kb H10 gene, regardless of orientation. 
UL41pTOPFSABH10 plasmid DNA (20 ng) was included as a positive control; 
CVI988 BAC DNA (20 ng) acted as a negative control. Both the positive and 
negative control produced expected results. BAC mutagenesis that had utilised the 
UL41pST76kH10(F) shuttle plasmid yielded eight colonies that were positive for the 
H10 DNA insert. BAC mutagenesis carried out using the UL41pST76kH10(R) 
shuttle plasmid, also produced eight colonies positive for the H10 DNA insert 
(Figure 3.9). A UL41(Rep) H10(F) BAC and a UL41(Rep) H10(R) BAC colony was 
selected and isolated (Section 2.2.7).  
 
The CVI988 BAC, and one of each of the UL41(Rep) H10 BACs (Forward and 
Reverse), were analysed by restriction enzyme digestion using XhoI (Section 2.1.6 
and Section 2.1.4). AgeI was used previously (Section 3.1.12) but the AgeI sites 
flanking the CMV-H10 were destroyed so the results of that digest would have been 
ambiguous. The results indicated that the H10 gene had been successfully inserted 
into the MDV CVI988 genome, in the forward and reverse orientation, producing the 
UL41(Rep) H10(F) BAC and UL41(Rep) H10(R) BAC (Figure 3.9). 
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Figure 3.9 A) Agarose gel electrophoresis showing positive results from a 
colony PCR experiment designed to detect the H10 gene in the UL41(Rep) 
H10 BACs (Forward and Reverse). B) Table displaying the predicted digest 
fragments of the CVI988 BAC and UL41(Rep) H10 BACs following XhoI 
enzyme digestion. (DNA fragments of the same size and smaller than 2301 
bp were not shown) C) A restriction enzyme digestion of the CVI988 BAC 
and the UL41(Rep) H10 BACs using XhoI. 
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3.2.6. In vitro Characterisation of UL41(Rep) H10 BAC (Forward and  
Reverse) 
 
CEF cells were transfected with the CVI988 BAC and the UL41(Rep) H10 BACs 
(Forward and Reverse), as described in Section 2.3.7. Three wells of a six-well dish 
were transfected for each BAC. After 7 days, 10-15 plaques were visible in each of 
the three wells that had been transfected with MDV CVI988 BAC DNA. No plaques 
were visible in CEF cells transfected with either the UL41(Rep) H10(F) BAC or 




In vitro analysis demonstrated that the CVI988 BAC DNA induced focal CPE in the 
form of plaques when transfected into CEF cells. The UL41(Rep) H10 (F and R) 
BACs, where the H10 gene had replaced the UL41 gene, did not form plaques in 
CEF cells. It was shown that UL41(Rep) H10(F) BAC transfected cells were 
expressing H10 mRNA and weakly expressing MDV mRNA, but the absence of 
plaques indicated that viable infectious virus particles were not being produced. By 
sequencing the UL41 flanking sequences and re-amplifying the flanking sequence B, 
the possibility of errors being introduced into the UL41(Rep) H10(F) BAC by 
mutagenesis was eliminated. Finally, the orientation of the introduced H10 gene was 
not a factor, as neither UL41(Rep) H10(F) BAC nor UL41(Rep) H10(R) BAC 
produced CPE. 
 
To resolve this problem, several new viral BAC constructs were designed: -  
 
a) UL41 Deleted (Del) BAC 
Previous research demonstrating that the UL41 gene was not essential (Section 3.1.1) 
could be confirmed by creating a UL41 (Del) BAC where the UL41 gene was 
deleted and not replaced with any gene. Deleting the UL41 gene could be achieved 
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by performing BAC mutagenesis with a shuttle plasmid that contained only the 
UL41 flanking sequences, FSA and FSB. 
 
b) UL41(Rep) H10 Truncated BAC 
The inserted influenza gene may be the reason why plaques did not form when the 
UL41(Rep) H10 BACs were transfected into CEF cells. Once expressed, the 
insertion of the N-terminal polypeptide of the HA protein into adjacent CEF cellular 
membranes may lead to destabilisation of those membranes. As MDV is highly cell 
associated, this membrane disruption and subsequent cell lysis would prevent the 
formation of CPE. This could be prevented by removing the transmembrane domain 
from the end of the H10 gene, thereby truncating it and preventing the H10 protein 
from interacting with the CEF cell membrane. 
 
c) UL41(Rep) GFP BAC 
Replacing the UL41 gene with GFP would serve to help identify if it was the H10 
gene insertion that was preventing the formation of plaques. In addition, transfected 
cells and plaques would be easier to observe if the GFP protein was produced. 
 




The plasmid UL41pTOPFSAB (#2) (Section 3.2.2) was digested with KpnI and PacI 
in preparation for cloning. The digested FSAB DNA fragment was gel purified 
(Section 2.1.9) and ligated into the digested and purified pST76k plasmid (Section 
3.1.10) to create the plasmid, pST76kFSAB (Figure 3.10). Competent E. coli cells 
were transformed with the ligation reaction as described in Section 2.2.2 and plasmid 
DNA was isolated (Section 2.2.5). Previously, shuttle plasmids were digested with 
the restriction enzymes, KpnI and PacI, to confirm that the ligation was successful.  
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Figure 3.10 A) A diagrammatic representation of the created plasmid 
UL41pTOPFSAB (#2). B) A diagrammatic representation of the plasmid 
UL41pST76kFSAB, created by cloning the FSAB DNA fragment into the 
shuttle plasmid, pST76k. The plasmid was used to delete the UL41 by BAC 
mutagenesis. C) Agarose gel electrophoresis showing positive results from a 
colony PCR experiment designed to detect UL41(Del) BACs where the 
UL41 gene had been deleted.  
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However, in this case, the pST76k vector and the FSAB insert were both 6.3 kb in 
size so the isolated plasmids were instead digested with XhoI. All plasmids displayed 
the expected digest pattern indicating that the plasmid, UL41pST76kFSAB, had been 
successfully created. 
 
3.3.2. BAC Mutagenesis using UL41pST76kFSAB 
BAC mutagenesis was performed, as described in Section 2.2.9. DH5-α bacteria 
containing the MDV CVI988 BAC were made competent (Section 2.2.8) and 
transformed with 10 ng of the shuttle plasmid UL41pST76kFSAB, using 
electroporation. Kanamycin-sensitive colonies containing UL41(Del) BACs, where 
the UL41 gene had been deleted, were identified using colony PCR (Section 2.1.1 
and Appendix A.1.4.1). Primers were designed to lie either side of the UL41 gene 
(Appendix A.1.3.1). By amplifying that region using PCR, the detection of a small 
product (507 bp) meant that the UL41 gene had been successfully deleted, whereas a 
larger product (1731 bp) meant that the UL41 gene was still present (Appendix 
A.1.3.1). 8 colonies out of the 20 colonies tested produced an approximately 500 bp 
product, indicating that the UL41 gene had been deleted by BAC mutagenesis 
(Figure 3.10). Two UL41(Del) BAC colonies were selected and isolated, as 
described in Section 2.2.7.  
 
3.3.3. In vitro Characterisation of UL41(Del) BAC 
CEF cells, seeded in six-well dishes, were transfected with MDV CVI988 BAC 
DNA and both UL41(Del) BAC clones, as described in Section 2.3.7. Three wells of 
a six-well dish were transfected for each BAC. After 7 days, 10-15 plaques were 
visible in the wells transfected with the CVI988 BACs. CEF cells transfected with 
the UL41(Del) BACs displayed approximately 5-10 plaques per well. The in vitro 
analysis confirmed that the UL41 gene is not essential as the UL41(Del) BAC 
mutants were capable of producing CPE. 
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Therefore, the problem was not with the UL41 gene deletion, but with the insertion 
of the foreign H10 DNA. To resolve if the haemagglutinin gene was having a toxic 
effect, the UL41 gene was replaced with a truncated H10 gene and a GFP gene. 
 
3.4. UL41(Rep) H10 (Truncated) BAC 
 
The predicted site of the transmembrane domain in the H10 gene was located using 
the website www.psipred.com (UCL Bioinformatics group). The DNA sequence of 
the H10 was translated to reveal the predicted amino acid sequence of the gene. The 
transmembrane domain was situated at the COOH-terminal end, and is characterised 
by a predominance of hydrophobic non-polar amino acids (See Figure 3.11). 
Truncating the H10 gene was achieved by amplifying the CMVH10 DNA sequence 
from pTOPCMVH10 (Section 3.1.8) using PCR, placing the reverse primer upstream 
of the transmembrane domain (pTOPCMVH10(T)_Rev).  
 










       430       440       450       460       470       480 
----------------------------------------------OOOOOOXXXXXXXX 
IYHACDDSCMESIRNNTYDHSQYREEALLNRLNINPVKLSSGYKDIILWFSFGASCFVLL 
        
         GGTCACTTTGAGAGAAGATGGCCA 
        [pTOPCMVH10(T)_Rev] 
 
       490       500 
XXXXXIIIIII+++++++++++ 
AVVMGLVFFCLKNGNMRCTICI 
Key: - + : Inside loop 
- : Outside loop 
O : Outside helix cap 
X : Central transmembrane helix segment 
I : Inside helix cap 
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Primers (pTOPCMVHA10T_For and pTOPCMVH10T_Rev) that incorporated the 
unique restriction site, AgeI, were designed to amplify the CMV-H10 (Truncated) 
DNA fragment (Appendix A.1.3.1). Using pTOPCMVH10 as a template (20 ng), the 
CMVH10(t) DNA fragment was successfully amplified as described in Section 2.1.1 
and Appendix A.1.4.1. The amplified CMV-H10(t) DNA was cloned first into Blunt 
II TOPO (Section 2.1.2) to create pTOPCMVH10(t) and subsequently into 
UL41pTOPFSAB, in both orientations. As described previously, the FSABH10(t) 
DNA insert was then ligated into pST76k to create the shuttle plasmids, 
pST76kH10(t) (F) and pST76kH10(t) (R) (Figure 3.12). 
BAC mutagenesis was performed using these shuttle plasmids and the UL41(Rep) 
BACs, UL41(Rep) H10(t) (F) BAC and UL41(Rep) H10(t) (R) BAC, were created 
and isolated (Section 2.2.7).  
In vitro analysis was performed. CEF cells were transfected with MDV CVI988 
BAC DNA and the UL41(Rep) H10(t) BACs, as described in Section 2.3.7. After 7 
days, 10-15 plaques were visible in each of the three wells that had been transfected 
with the CVI988 BAC. No plaques were visible for either the UL41(Rep) H10(t) (F) 
BAC or the UL41(Rep) H10(t) (R) BAC.  
These results suggested that the intact H10 protein was not the cause of the lack of 
CPE as without a transmembrane domain, it reduced the possibility of cell membrane 
lysis occurring. 
 
3.5. UL41(Rep) GFP BAC 
Due to the presence of an AgeI restriction enzyme site between the CMV promoter 
and the GFP gene in the plasmid pEGFP-N1, the GFP DNA fragment was amplified 
with the primers (pGFP_For and pGFP_Rev) incorporating the unique enzyme 
restriction sites NheI and AccI (Appendix A.1.3.1). Using site directed mutagenesis, 
the forward primer destroyed the AgeI restriction enzyme site.  
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Figure 3.12 A) A diagrammatic representation of the plasmid 
pTOPCMVH10(t), created by cloning the PCR amplified CMV-H10(t) DNA 
fragment into the TOPO vector. B) The plasmids UL41pTOPFSABH10(t) 
(Forward and Reverse) were created by cloning the CMV-H10 DNA 
fragment between the flanking sequences FSA and FSB, in the plasmid 
UL41pTOPFSAB (#2). C) In the final cloning step, the FSABCMVH10(t) 
DNA fragments were transferred to the shuttle plasmid, pST76k, to create 
the plasmids UL41pST76kH10(t) (Forward and Reverse). 
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The GFP gene was successfully amplified (Section 2.1.1. and Appendix A.1.4.1) and 
cloned into Blunt II TOPO (Section 2.1.2) to create pTOPGFP. Subsequently, the 
GFP was isolated using restriction enzyme digestion (NheI and AccI) and purified 
before being cloned downstream of the CMV promoter to create pTOPCMVGFP. 
The CMV-GFP DNA fragment was isolated using restriction enzyme digestion 
(AgeI) and purified before being cloned between the flanking sequences of 
UL41pTOPFSAB (Section 3.2.2). As described previously, the FSABGFP DNA 
insert was then ligated into pST76k to create pST76kGFP(F) (Figure 3.13). BAC 
mutagenesis was carried out and the UL41(Rep) GFP(F) BAC was created and 
isolated according to the protocol in Section 2.2.7.  
CEF cells were transfected with the CVI988 BAC and the UL41(Rep) GFP(F) BAC, 
as described in Section 2.3.7. After 7 days, 10-15 plaques were visible in each of the 
three wells that had been transfected with CVI988. Unfortunately, no plaques were 
visible in CEF cells transfected with the UL41(Rep) GFP(F) BAC. 
 
3.6. The UL41 open reading frame 
To summarise, bibliographic research and subsequent in vitro analysis has 
demonstrated that the UL41 gene may be deleted from the MDV CVI988 BAC 
genome, without affecting the ability of the BAC to produce CPE once it has been 
transfected into CEF cells. The introduction of any foreign DNA into the UL41 open 
reading frame, however, seems to disrupt the production of infectious virus particles, 
preventing plaque formation. Truncating the H10 gene by removing the 
transmembrane region or replacing the H10 gene with GFP did not produce positive 
results. The hypothesis that it was simply not possible to insert foreign DNA into this 
area of the MDV genome was feasible and this could be tested by attempting the 
process with a new, non-essential MDV gene other than UL41. 
However, in a final attempt to resolve why the insertion of non-MDV DNA into the 
UL41 gene site was producing such a detrimental effect to the parental MDV 
CVI988 BAC, the BAC transfections of CEF cells were repeated. 
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Figure 3.13 A) A diagrammatic representation of the plasmid 
pTOPCMVGFP, created by cloning the GFP DNA fragment downstream of 
the CMV promoter. B) The plasmid UL41pTOPFSABGFP(F) was created 
by cloning the CMV-GFP DNA fragment into the plasmid UL41pTOPFSAB 
(#2), between the flanking sequences FSA and FSB. C) In the final cloning 
step, the FSABCMVGFP DNA fragment was transferred to the shuttle 
plasmid, pST76k, to create the plasmid UL41pST76kGFP(F). 
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It was hypothesised that, if transfecting 1 µg of CVI988 BAC DNA into one well of 
a six-well dish of CEF cells resulted in the formation of only 15 plaques, then the 
detrimental effect caused by the introduction of foreign DNA may reduce this to 
zero. Increasing the transfection efficiency so that the MDV CVI988 BAC produced 
more plaques would potentially offset this detrimental effect, revealing a small 
number of plaques in CEF cells transfected with the UL41(Rep) BAC DNA. 
Previous research by Morgan et al (1990) found that the transfection of CEFs with 
MDV DNA is greatly improved if DNA is introduced at the seeding stage, rather 
than once the CEF monolayer is formed. This method was referred to as a ‘Reverse’ 
transfection. 
Furthermore, two more set of primers were designed to analyse cDNA extracted 
from the BAC transfected CEF cells (Appendix A.1.3.1). These primers were 
specific for UL42 and UL44 and were selected due to their proximity to the deleted 
UL41 gene and the fact that they are deemed essential. 
 
3.6.1. BAC transfections 
CEF cells were simultaneously transfected with CVI988 BAC DNA, UL41(Del) 
BAC DNA and UL41(Rep) GFP(F) BAC DNA, as described in Section 2.3.8. After 
7 days, cytopathic effect (CPE) in the form of plaques was visible. In CEF cells that 
had been transfected with the CVI988 BAC, there was an average of 77 plaques in 
each of the three wells. In CEF cells that had been transfected with the UL41(Del) 
BAC, there was an average of 38 plaques in each of the three wells. No plaques were 
visible in the CEF cells transfected with UL41(Rep) GFP(F) BAC DNA, although 
there were individual cells expressing GFP. This suggested that the transfection was 
successful, and that GFP mRNA was being expressed, but no virus replication was 
taking place. 
RNA was extracted from the BAC transfected cells as described in Section 2.1.14. 
The RNA was isolated and, using random primers, approximately 3 µg of the 
extracted DNase-treated RNA was converted to complementary DNA (cDNA) by 
reverse transcription (Section 2.1.15).  
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3.6.2. CVI988/UL41(Rep) BAC cDNA PCR 
PCR was carried out as described in Section 2.1.1 and Appendix A.1.4.1. The cDNA 
created from the CVI988 BAC and the UL41(Del) BAC transfected cells was tested, 
as well as cDNA created from untransfected CEF cells. In addition, cDNA 
previously created from the UL41(Rep) H10 BACs (Forward and Reverse) was 
tested. Four sets of primers specific to MDV (MDV UL18, vIL-8, UL42 and UL44) 
were used along with primers for H10 and GFP (Appendix A.1.3.1). 
 
Following PCR, products were analysed using agarose gel electrophoresis on a 1% 
gel (Section 2.1.4) (Figure 3.14). PCR analysis of cDNA created from untransfected 
CEF cells revealed, as expected, no expression of MDV or H10 mRNA. The analysis 
of cDNA created from the CVI988 BAC and UL41(Del) BAC transfected cells 
demonstrated that all four sets of MDV genes, but not H10 or GFP, were expressed. 
cDNA that had been made from cells transfected with UL41(Rep) H10 (F and R) 
BAC DNA were shown to express H10 mRNA but not GFP mRNA. UL41(Rep) 
H10(F) BAC cDNA tested positive for all four sets of MDV primers, however, the 
UL41(Rep) H10(R) BAC cDNA was negative for UL42 and UL44. In this 
orientation, these essential genes are adjacent to the CMV promoter of the CMVH10 
DNA insert.  
 
3.6.3.           CMV promoter  
PCR analysis of the cDNA extracted from UL41(Rep) H10(R) BAC transfected cells 
has revealed that the mRNA of two essential genes, adjacent to the CMV promoter, 
was not being expressed. It was observed that the introduction of foreign DNA into 
the UL41 open reading frame affected the ability of the MDV BAC to form plaques 
upon transfection into CEF cells. However, it may be that it was not the genes that 
were causing this detrimental effect, but the CMV promoter itself. To test this 
hypothesis, it was decided that a different promoter would be used. 
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Figure 3.14 A) PCR products from cDNA created from untransfected CEF 
cells and MDV CVI988 transfected cells B) PCR products from cDNA 
created from the UL41(Del) BAC transfected cells. C) PCR products from 
cDNA made from cells transfected with the UL41(Rep) H10 BACs 
(Forward and Reverse). 
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The murine PGK-1 promoter can efficiently drive high levels of expression but it 
was found to work less efficiently in CEF cells than the CMV promoter (Prof. H. 
Sang, personal communication). It was speculated that, if the powerful CMV 
promoter was inhibiting other promoters or essential genes in the region, then a less 
powerful promoter like PGK-1 might not have the same antagonistic effect. The 




3.7. UL41(Rep) GFP BAC – PGK-1 Promoter 
 
3.7.1. pTOPPGKGFP 
The plasmid, pEGFP-1 PGK, that contained the murine PGK-1 promoter upstream of 
the GFP gene, was kindly provided by Professor H. Sang (The Roslin Institute, 
Edinburgh). In this plasmid, the PGK-1 promoter is situated upstream of the GFP 
gene (Figure 3.15). Using HindIII and NotI, the PGKGFP DNA fragment was 
removed by restriction enzyme digestion (Section 2.1.6) and gel purified in 
preparation for cloning (Section 2.1.9). The plasmid vector, pTOPCMVH10 (Section 
3.1.8), was digested with HindIII and NotI to remove the CMVH10 DNA fragment 
and the plasmid backbone was gel purified (Section 2.1.9). The digested and purified 
PGKGFP fragment was ligated into the plasmid backbone, as described in Section 
2.1.10. Competent E. coli cells were transformed with the ligation mixture (Section 
2.2.2) and plasmid DNA was isolated from small cultures (Section 2.2.5). The 
successfully ligated plasmid, pTOPPGKGFP (Figure 3.15), was confirmed using 
restriction enzyme digestion with HindIII and NotI. 
Zero Blunt II TOPO primers, M13 forward and reverse, were used to sequence the 
PGK promoter and the GFP gene (Appendix A.1.3.1). Sequence results indicated 
complete homology with the published sequences for both the PGK promoter and the 
downstream GFP gene. Subsequently, pTOPPGKGFP plasmid DNA was prepared 
according to the protocol in Section 2.2.6.  




















Figure 3.15 A) The PGK-1 promoter is situated upstream of the GFP gene in 
the plasmid, pEGFP-1 PGK. B) Using the restriction enzymes, HindIII and 
NotI, the PGKGFP fragment was digested, purified and ligated into the 
TOPO vector to create pTOPPGKGFP. 
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3.7.2. UL41pTOPFSAB (#2) 
In previous work (Section 3.1.5 and Section 3.2.2), the AgeI restriction enzyme was 
used to digest the plasmid UL41pTOPFSAB in preparation for cloning with the 
appropriate gene insert. Unfortunately, there was an AgeI site located in the PGK-1 
promoter sequence so this was no longer possible. With no other unique restriction 
enzymes sites available between the two flanking sequences, it was decided that the 
PGKGFP gene insert should be blunt cloned into the plasmid UL41pTOPFSAB (#2).  
In preparation for blunt cloning, the plasmid UL41pTOPFSAB (#2) (Section 3.2.2) 
was digested with AgeI-High Fidelity (HF) enzyme. Following digestion, the 5’ 
overhangs of UL41pTOPFSAB (#2) plasmid DNA (5 µg) were converted to 5’ 
phosphorylated, blunt-ended DNA, as described in Section 2.1.7, and 
dephosphorylated according the protocol in Section 2.1.8. 
 
3.7.3. UL41pTOPFSABPGKGFP 
In preparation for cloning, pTOPPGKGFP was digested with EcoRV and SnaBI to 
produce ‘blunt’ ends. The digested PGKGFP fragment was gel purified (Section 
2.1.9) and ligated into the AgeI digested, blunted and AP treated UL41pTOPFSAB 
(#2) (Section 3.7.2). XL-Gold Ultracompetent E. coli cells were transformed with the 
ligation reaction as described in Section 2.2.3 and plasmid DNA was isolated from  
small cultures (Section 2.2.5). The plasmids were digested with PstI and XhoI, to 
confirm that the PGKGFP insert had ligated with the vector successfully and to 
ascertain the orientation of the insert. Two plasmids were found to contain the 
PGKGFP insert in the forward orientation, and five in the reverse orientation (Figure 
3.16). 
To confirm the successful ligation of PGKGFP, both plasmids, 
UL41pTOPFSABPGKGFP (F and R), were sequenced using the primers pCMVHA 
ID_For and pTOPFSABHA_Rev6 (Appendix A.1.3.1). Sequencing results indicated 
that for both plasmids, the PGKGFP insert had been correctly inserted between the 
flanking sequences.  
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Figure 3.16 A) Agarose gel electrophoresis showing restriction enzyme 
digests of the plasmids pTOPFSABPGKGFP (F and R), using the enzymes 
PstI and XhoI. B) A diagrammatic representation of the plasmids 
UL41pTOPFSABPGKGFP (F and R). The PGK-GFP DNA fragment was 
cloned into the plasmid UL41pTOPFSAB (#2), between the flanking 
sequences FSA and FSB. C) In the final cloning step, the FSABPGKGFP 
DNA fragments were transferred to the shuttle plasmid, pST76k, to create 
the plasmids UL41pST76kPGKGFP (F and R).  
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3.7.4. UL41pST76kPGKGFP (F and R) 
 
The plasmids, UL41pTOPFSABPGKGFP (F and R), were digested with KpnI and 
PacI in preparation for cloning with the shuttle plasmid, pST76k. The digested 
FSABPGKGFP DNA fragments were gel purified (Section 2.1.9) and ligated into the 
digested and purified pST76k plasmid (Section 3.1.10) to create the plasmids 
UL41pST76kPGKGFP (F and R) (Figure 3.16). Competent E. coli cells were 
transformed with the ligation mixture (Section 2.2.2) and plasmid DNA was isolated 
(Section 2.2.5). The plasmids were digested with the restriction enzymes, KpnI and 
PacI, to confirm that the ligation was successful. For both constructs, 




3.7.5. BAC Mutagenesis using the plasmids UL41pST76kPGKGFP(F)     
           and UL41pST76kPGKGFP(R) 
BAC mutagenesis was successfully carried out using the constructs, 
UL41pST76kPGKGFP(F) and UL41pST76kPGKGFP(R) (Section 2.2.9). DH5-α 
bacteria containing the MDV CVI988 BAC were made competent (Section 2.2.8) 
and transformed, by electroporation, with 10 ng of the shuttle plasmids. Kanamycin-
sensitive colonies containing UL41(Rep) BACs, where the UL41 gene had been 
replaced with the PGKGFP DNA insert, were identified using colony PCR (Section 
2.1.1 and Appendix A.1.4.1). The primers, peGFP_For and peGFP_Rev3 (Appendix 
A.1.3.1) were kindly provided by Dr B. M. Dutia and used to identify the PGKGFP 
insert. pEGFP-N1 plasmid DNA (25 ng) (Section 3.1.7) was included as a positive 
control, which produced expected results. BAC mutagenesis that had utilised the 
UL41pST76kPGKGFP(F) construct produced five colonies which were positive for 
the PGKGFP insert. BAC mutagenesis carried out using the UL41pST76k 
PGKGFP(R) shuttle plasmid, produced five colonies positive for the PGKGFP insert 
(Figure 3.17). A bacterial colony containing the UL41(Rep) PGKGFP(F) BAC and a  
 

















L          PC         1 2     3 4     5 6     7     8    9   10   11  12  13   14   15   16   17  18   19    20        L   
0.2kb
UL41(Rep) PGKGFP BAC (R)
UL41(Rep) PGKGFP BAC (F)




Figure 3.17 A) An agarose gel electrophoresis photograph showing positive 
results from a colony PCR experiment designed to detect a 0.2 kb DNA 
fragment of the GFP gene in the UL41(Rep) GFP BAC (Forward). B) 
Agarose gel electrophoresis showing positive results from a colony PCR 
experiment designed to detect a 0.2 kb DNA fragment of the GFP gene in 
the UL41(Rep) GFP BAC (Reverse).   
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UL41(Rep) PGKGFP(R) BAC was selected and the BAC DNA was isolated 
according to the protocol in Section 2.2.7.  
To confirm the successful insertion of PGKGFP into the CVI988 BAC, the 
constructs were sequenced using the primers pCMVHAID_For and pTOPFSABHA_ 
Rev6 (Appendix A.1.3.1). Sequencing results indicated that for both UL41(Rep) 




3.8. UL41(Rep) H10 BAC – PGK-1 Promoter 
 
As with GFP, the H10 gene was cloned downstream of the PGK-1 promoter. In 
anticipation of in vitro analysis, the H10 gene was linked to a Myc-HIS tag, so that in 
lieu of a specific H10 antibody, the H10 protein could be detected if expressed in 
CEF cells. The following sections describe the construction this shuttle plasmid and 
the creation of the UL41(Rep) H10myc BAC. 
 
3.8.1. pcDNA3.1H10myc 
The plasmid, pcDNA3.1/myc-HIS(-)A, contains the myc-HIS tag downstream of a 
multiple cloning site (Figure 3.18). Using the restriction enzymes XhoI and HindIII, 
the H10 gene could be cloned upstream of this tag, in the same frame. Primers 
(pH10Rpt_For and pH10Rpt_Rev) that incorporated these unique restriction enzyme 
sites were designed to amplify the H10 gene (Appendix A.1.3.1). The H10 PCR 
product was inserted the same distance from the end of the promoter as the original 
GFP (13 bp). Using pTOPCMVH10 (Section 3.1.8) as a template (20 ng), the H10 
gene was successfully amplified (Section 2.1.1 and Appendix A.1.4.1) and gel 
purified (Section 2.1.6). It was subsequently ligated into Blunt II TOPO (Section 
2.1.2) to create the plasmid pTOPH10 (Figure 3.18). Following transformation 
(Section 2.2.2), the plasmid DNA was isolated (Section 2.2.5) and the successfully 
ligated plasmid was confirmed using restriction enzyme digestion with XhoI and 
HindIII. 
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Figure 3.18 A) The H10 gene was PCR amplified with primers incorporating 
the restriction enzyme sites, XhoI and HindIII, and cloned into Blunt II 
TOPO to create pTOPH10. B) The plasmid, pcDNA3.1/myc-HIS(-) A, 
contained the myc-HIS tag downstream of a multiple cloning site. C) Using 
the restriction enzymes XhoI and HindIII, the H10 DNA fragment was 
cloned upstream of the myc-HIS tag to create the plasmid 
pcDNA3.1H10myc. D) The H10myc-HIS DNA fragment was amplified 
with primers that incorporated the restriction enzyme sites, BamHI and XhoI, 
and ligated downstream of the PGK-1 promoter to create the plasmid 
pTOPPGKH10myc.  
pcDNA3.1/myc-HIS (-) A 
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Using XhoI and HindIII, the H10 DNA fragment was removed by enzyme digestion 
and gel purified in preparation for cloning (Section 2.1.9). The plasmid vector, 
pcDNA3.1/myc-HIS was also digested with XhoI and HindIII and gel purified 
(Section 2.1.9). The digested and purified vector and insert were ligated, as described 
in Section 2.1.10, to create the plasmid pcDNA3.1H10myc (Figure 3.18). Competent 
E. coli cells were transformed with the ligation mix according to the protocol in 
Section 2.2.2, and plasmid DNA was isolated from small cultures (Section 2.2.5). 
The plasmid, pcDNA3.1H10myc, was identified by digestion with AhdI. 
 
3.8.2. pTOPPGKH10myc 
Primers (pH10myc_For and pH10myc_Rev) which incorporated the unique 
restriction sites, BamHI and XhoI, were designed to amplify the H10myc-HIS DNA 
fragment (Appendix A.1.3.1). Using pcDNA3.1H10myc (Section 3.8.1) as a 
template (20 ng), the H10myc gene was amplified (Section 2.1.1 and Appendix 
A.1.4.1), gel purified (Section 2.1.9) and subsequently ligated into Blunt II TOPO 
(Section 2.1.2) to create pTOPH10myc. Competent E. coli cells were transformed 
with the ligation reaction (Section 2.2.2) and, following plasmid DNA isolation 
(Section 2.2.5), the successfully ligated plasmid was confirmed using restriction 
enzyme digestion with BamHI and XhoI. 
Using BamHI and XhoI, the H10myc DNA fragment was removed by enzyme 
digestion and gel purified (Section 2.1.9). The plasmid vector, pTOPPGKGFP, was 
digested with BamHI and XhoI to remove the GFP gene and the vector backbone was 
gel purified (Section 2.1.9). The digested and purified vector and H10myc insert 
were ligated, as described in Section 2.1.10, to create the plasmid pTOPPGKH10myc 
(Figure 3.18). Following transformation (Section 2.2.2), plasmid DNA was isolated 
from small cultures (Section 2.2.5). The plasmid, pTOPPGKH10myc, was 
successfully identified using restriction enzyme digestion with BamHI and XhoI, and 
HindIII. 
The primers, M13 forward and reverse and pTOPCMVHA_For 3, were used to 
sequence the PGK promoter and H10myc DNA (Appendix A.1.3.1). Sequence 
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results indicated complete homology to the published sequences for both the PGK 
promoter and the downstream H10 gene and myc-HIS tag. 
 
3.8.3. UL41pTOPFSABPGKH10myc 
In preparation for cloning, pTOPPGKH10myc was digested with EcoRV and SnaBI. 
The digested PGKH10myc fragment was gel purified (Section 2.1.9) and ligated into 
the AgeI digested, blunted and phosphatased UL41pTOPFSAB (Section 3.7.2). XL-
Gold Ultracompetent E. coli cells were transformed with the ligation reaction 
(Section 2.2.3) and plasmid DNA was isolated, as described in Section 2.2.5. To 
confirm the successful ligation of the PGKH10myc insert into the UL41pTOPFSAB 
plasmid vector, the isolated plasmid DNA was digested with PstI and XhoI. This 
digest also demonstrated the orientation of the PGKH10myc insert. Four plasmids 
were identified that contained the PGKH10myc insert in the forward orientation, and 
two in the reverse orientation (Figure 3.19). 
To confirm the successful ligation of PGKH10myc, both of the plasmids, 
UL41pTOPFSABPGKH10myc (F) and UL41pTOPFSABPGKH10myc (R), were 
sequenced using the primers pCMVHAID_For and pTOPFSABHA_Rev6 (Appendix 
A.1.3.1). For both orientations, sequencing results indicated that the PGKH10myc 
insert had been correctly inserted between the flanking sequences.  
 
3.8.4. UL41pST76kPGKH10myc (F and R) 
 
In preparation for cloning, the plasmids, UL41pTOPFSABPGKH10myc (F and R), 
were digested with KpnI and PacI. The digested FSABPGKH10myc fragments were 
gel purified (Section 2.1.9) and ligated into the digested and purified pST76k 
plasmid (Section 3.1.10), creating the plasmids UL41pST76kPGKH10myc (F and R) 
(Figure 3.19). Following transformation of competent E. coli cells (Section 2.2.2), 
plasmid DNA was isolated (Section 2.2.5) and digested with KpnI and PacI to 
confirm that the ligation was successful.  
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Figure 3.19 A) Agarose gel electrophoresis showing restriction enzyme 
digests of the plasmids pTOPFSABPGKH10myc (F and R), using the 
enzymes PstI and XhoI. B) A diagrammatic representation of the plasmids 
UL41pTOPFSABPGKH10myc (F and R). The PGK-H10myc DNA 
fragment was cloned into the plasmid UL41pTOPFSAB (#2), between the 
flanking sequences FSA and FSB. C) In the final cloning step, the 
FSABPGKH10myc DNA fragments were transferred to the shuttle plasmid, 
pST76k, to create the plasmids UL41pST76kPGKH10myc (F and R).  
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For both constructs, UL41pST76kPGKH10myc (F and R), the enzyme digests 
produced the expected digest pattern.  
 
3.8.5. BAC Mutagenesis using the plasmids UL41pST76kPGKH10myc    
           (F) and UL41pST76kPGKH10myc (R) 
BAC mutagenesis, using the constructs UL41pST76kPGKH10myc(F) and 
UL41pST76kPGKH10myc(R) was performed (Section 2.2.9). DH5-α bacteria 
containing the MDV CVI988 BAC were made competent (Section 2.2.8) and 
transformed with 10 ng of the shuttle plasmids using electroporation. Kanamycin-
sensitive colonies containing UL41(Rep) BACs, where the UL41 gene had been 
replaced with H10myc gene, were identified using colony PCR (Section 2.1.1 and 
Appendix A.1.4.1). The primers, pH10myc_For and pH10myc_Rev (Appendix 
A.1.3.1) were used to identify the 1.7 kb H10myc insert. The pTOPH10myc plasmid 
(Section 3.8.2) was included as a positive control, which produced the expected 
results. BAC mutagenesis performed with the UL41pST76kPGKH10myc(F) shuttle 
plasmid yielded four colonies which were positive for the PGKH10myc insert. BAC 
mutagenesis carried out using the UL41pST76kPGKH10myc(R) construct, produced 
five colonies which were positive for the PGKH10myc insert (Figure 3.20). 
Subsequently, the BAC DNA of a UL41(Rep) PGKH10myc(F) BAC and a 
UL41(Rep) PGKH10myc(R) BAC construct was isolated, as described in Section 
2.2.7.  
     
Using the primers pCMVHAID_For and pTOPFSABHA_Rev6 (Appendix A.1.3.1), 
sequencing was used to confirm the successful insertion of PGKH10myc into the 
MDV CVI988 BAC. Sequencing results indicated that for both UL41(Rep) BACs, 








     
 











UL41(Rep) PGKH10myc BAC (F)
L          PC          1 2     3 4    5    6     7     8    9   10   11   12   13  14 15   16  17  18   19 20          L   
1.7kb
A.
L          PC         1    2     3 4 5 6     7     8    9   10   11  12  13 14  15  16   17  18   19 20         L   
UL41(Rep) PGKH10myc BAC (R)B.
1.7kb
Figure 3.20 A) Agarose gel electrophoresis photograph showing positive 
results from a colony PCR experiment designed to detect an approximately 
1.7 kb H10myc DNA fragment in the UL41(Rep) H10myc BAC (F). B) 
Agarose gel electrophoresis showing positive results from a colony PCR 
experiment designed to detect an approximately 1.7 kb H10myc DNA 
fragment in the UL41(Rep) H10myc BAC (R).   
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3.9. In vitro Characterisation of the UL41(Rep) PGKGFP/H10myc  
           BACs 
 
 
3.9.1. BAC transfections 
 
BAC transfections were carried out using the ‘reverse’ transfection method (Section 
3.6). CEF cells were seeded at a density of 5.0 x 10
5 
cells per well in six-well dishes 
and simultaneously transfected with the following BACs, according to the protocol 
in Section 2.3.8: - 
 
 CVI988    - 6 wells 
 UL41(Rep) PGKGFP (F)  - 2 wells 
 UL41(Rep) PGKGFP (R)  - 2 wells  
 UL41(Rep) PGKH10myc (F)   - 8 wells 
 UL41(Rep) PGKH10myc (R)  - 8 wells 
 
After 7 days, CPE in the form of plaques was visible in all wells. The number of 
plaques in each well was counted and documented in Table 3.1. The presence of 
plaques in the CEF cells, following transfection with all the UL41(Rep)PGK 
GFP/H10myc BAC constructs, indicated that viable recombinant viruses were being 
produced and were spreading through the CEF cell sheet. The hypothesis that it was 
the CMV promoter preventing the UL41(Rep) BACs from forming CPE can now be 
regarded as valid. By disrupting essential genes in the UL41 region, or other MDV 
promoters in the UL41(Rep) CMV BACs, the presence of the CMV promoter 
inhibited the formation of infectious virus particles and subsequently prevented 
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Table 3.1 Plaque counts following transfection 
Construct Well Plaque Number Next step 
CVI988 Well 1 74 Virus  
propagation 
Well 2 53 
Well 3 102 Protein Quantification 
Well 4 61 
Well 5 79 Myc/HIS 




Well 1 122 Immunofluorescence  
and virus propagation Well 2 105 
UL41(Rep) 
PGKGFP(R) 
Well 1 99  
Immunofluorescence Well 2 109 
UL41(Rep) 
PGKH10myc(F) 




Well 2 16 
Well 3 12 
Well 4 14 
Well 5 10 
Well 6 10 
Well 7 13 Myc/HIS 
Immunohistochemistry Well 8 7 
UL41(Rep) 
PGKH10myc(R) 
Well 1 75  
Virus 
propagation 
Well 2 67 
Well 3 72 
Well 4 62  
Protein Quantification Well 5 60 
Well 6 44 
Well 7 52 Myc/HIS 
Immunohistochemistry Well 8 64 
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The CEF cells that had been transfected with the UL41(Rep) PGKGFP BACs 
developed CPE. As the PGK-1 promoter was successfully driving the expression of 
the GFP gene, these plaques exhibited bright green fluorescence. However, to fulfil 
the primary objective of this study, which was to incorporate a haemagglutinin gene 
into the MDV viral genome, it needed to be proved that the PGK-1 promoter was 
also driving the expression of the H10 gene. This was carried out using 
immunohistochemistry and western blot techniques, utilising antibodies specific to 




CEF cells that were transfected with UL41(Rep) PGKH10myc (F and R) BAC DNA 
demonstrated extensive plaque formation. To determine if the PGK-1 promoter was 
working effectively and H10myc protein was being manufactured, CEF cells were 
analysed using immunohistochemistry, utilising α-myc and α-HIS antibodies 
(Section 2.3.13).  
Mock-transfected CEF cells were analysed, as controls, and stained using α-myc, α-
HIS and HB3 (α-gB) antibodies. Non-infected cells that were stained with α-myc and 
α-HIS antibodies were photographed using UV light; cells stained with the HB3 
antibody and unstained cells were photographed using white light. As expected, the 
primary α-myc and HB3 antibodies did not bind to the non-infected CEF cells, due to 
the lack of myc and MDV gB protein, respectively, and no fluorescence was 
detected. However, α-HIS antibody did bind non-specifically to non-infected CEF 
cells, producing some background fluorescence (Figure 3.21). 
MDV CVI988 BAC-transfected CEF cells displaying CPE were analysed and 
plaques were stained using α-myc, α-HIS and HB3 (α-gB) antibodies. Plaques 
stained with the α-myc antibody did not fluoresce, as expected. Plaques stained with 
α-HIS antibody displayed some background florescence and this would have been 
regarded as a false positive. Finally, plaques stained with the HB3 antibody 
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displayed the distinctive bright red stain under white light. Stained plaques were 
photographed using white and UV light (Figure 3.22). 
CEF cells transfected with the UL41(Rep) PGKGFP(F and R) BAC constructs did 
not require antibody staining but were prepared as described in Section 2.3.13. 
Infected CEF cells within the plaque, expressing GFP, displayed bright green 
fluorescence when viewed using UV light. Plaques were also photographed using 
white light to observe the individual plaques and combined UV and white light to 
observe both simultaneously (Figure 3.23). 
Used separately, staining with either the α-myc or the α-HIS antibodies resulted in 
plaques on the CEF cell sheet that displayed bright green fluorescence. The plaques 
were photographed using white light to observe the individual plaques and UV light 
to observe the fluorescence (Figure 3.24). Non-infected CEF cells, that separated the 
plaques on the cell sheet, did not display fluorescence when using the α-myc 
antibody. Non-infected CEF cells that were stained with α-HIS antibody, however, 
did display some background fluorescence indicating that this antibody bound non-
specifically to CEF cells (Figure 3.21). 
The immunohistochemistry results confirmed that the myc-HIS tagged H10 protein 
was being produced by CEF cells infected with the MDV mutants. This provided 
conclusive proof that the haemagglutinin gene had successfully been incorporated 
into the MDV genome and that the PGK-1 promoter was efficiently driving the 
expression of the H10 gene. To complete the in vitro work, the final step was to 










              
              
                             

















Figure 3.21 Immunohistochemistry of untransfected CEF cells using α-Myc, 
HB3 (α-gB) and α-HIS antibodies. Cells were photographed using white and 
UV light.  
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Figure 3.22 A) Immunohistochemistry of a single plaque developing on CEF 
cells transfected with the MDV CVI988 BAC and immunostained using 
HB3 (α-gB) antibody. B) Immunohistochemistry of MDV CVI988 
transfected CEF cells using α-myc antibody. C) Immunohistochemistry of 
MDV CVI988 transfected CEF cells using α-HIS antibody.  
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White Light, x100 UV, x100 Combined, x100
White Light, x100 UV, x100 Combined, x100
UL41(Rep) PGKGFP BAC (Forward)
Plaque 1   
Plaque 2   
White Light, x100 UV, x100 Combined, x100
White Light, x100 UV, x100 Combined, x100
UL41(Rep) PGKGFP BAC (Reverse)
Plaque 1   
Plaque 2   
Figure 3.23 Chicken Embryo Fibroblast cells, transfected with the UL41 
(Rep) PGKGFP BACs, displaying cytopathic effect in the form of plaques. 
The plaques were photographed using white light, UV light and both 
combined to observe the MDV infected CEF cells and the subsequent 
expression of the GFP protein. 
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UL41(Rep) PGKH10myc BAC (Forward)
B.










Figure 3.24 A) Immunohistochemistry of a single plaque developing on CEF 
cells transfected with the UL41(Rep) PGKH10myc BAC (Forward) and 
immunostained using the α-myc antibody. B) Immunohistochemistry of the 
UL41(Rep) PGKH10myc BAC (Forward) transfected CEF cells using α-HIS 
antibody. C) Immunohistochemistry of the UL41(Rep) PGKH10myc BAC 
(Reverse) transfected CEF cells using α-myc antibody. D) 
Immunohistochemistry of the UL41(Rep) PGKH10myc BAC (Reverse) 
transfected CEF cells using α-HIS antibody.  
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3.9.3.             Western blot analysis 
Western blot analysis was performed on protein samples extracted from CEF cells 
transfected with the following BACs: - 
 CVI988 
 UL41(Rep) PGKH10(R) BAC 
Once extensive CPE was observable, total protein was extracted using lysis buffer 
containing Pefabloc, a protease inhibitor (Section 2.4.1). In addition, protein was 
extracted from untransfected CEF cells to be used as a negative control. Once 
extracted, the protein solution was diluted 1:100 (v:v) in lysis buffer and quantified 
using the Pierce BCA protein assay kit (Section 2.4.2). Table 3.2 displays the 
calculated protein concentration of each of the samples and the volume required to 
load 20 µg of protein into one well of an SDS-PAGE gel. 
 






SDS-PAGE was performed, according to the protocol in Section 2.4.4. The protein 
samples were loaded into the wells, as below: - 
 
 
The SDS-PAGE was repeated five times, producing five replicates. Following 
electrophoresis, proteins of each of the five gels were transferred to a nitrocellulose 
Sample Concentration  Volume for 20 µg 
CEF 8153 µg/ml 2.45 µl 
CVI988 8967 µg/ml 2.25 µl 
UL41 H10 8804 µg/ml 2.25 µl 
Blank Ladder CEF CVI988 UL41H10 Ladder Blank 
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membrane (Section 2.4.5). These five membranes were incubated with one of the 
following combinations (Section 2.4.6): - 
 1o α-Myc, 2o biotinylated antibody and 3o streptavidin AP 
 1o α-HIS, 2o biotinylated antibody and 3o streptavidin AP 
 1o HB3 (α-gB), 2o biotinylated antibody and 3o streptavidin AP 
 2o biotinylated antibody and 3o streptavidin AP  
 3o streptavidin AP 
 
Two membranes were stained without using the primary antibodies (1
o
 α-Myc, α-




antibodies bound non-specifically to proteins 
on the membrane. Incubating a membrane with the secondary biotinylated anti-
mouse IgG combined with the 3
o
 Streptavidin AP conjugate, or only the 3
o
 
Streptavidin AP conjugate, should have produced a negative result. Without the 





 streptavidin AP should not bind. 
 
Bound antibody was detected using the Sigmafast BCIP/NBT stain (Section 2.4.6). 
Protein sizes were predicted using the ExPASy proteomics server (Section 2.4.3). 
The H10myc-HIS protein was predicted to be approximately 80 kDa in size; the 
MDV gB glycoprotein was predicted to be 110 kDa in size. Proteins of this size were 





 streptavidin AP both bound non-specifically. The same non-specific binding 
occurred for all protein samples regardless of whether they were the UL41 H10 
sample or the CEF and CVI988 control protein samples that did not possess a myc-
HIS tag (Figure 3.25). 
Unfortunately, due to time limitations this could not be resolved, but the next step 
would have been to select a different 2
o 
biotinylated antibody and 3
o
 streptavidin AP 
that do not bind, non-specifically, to CEF cells. 
 
 


















































B) α - HIS
Figure 3.25 Western blot analysis was performed on protein samples 
extracted from untransfected CEF cells and CEF cells transfected with 
CVI988 and the UL41(Rep) H10 BAC. Following SDS-PAGE, proteins 
were transferred to nitrocellulose membranes and immunostained with: A) 
α-myc B) α-HIS C) HB3 D) 2
o 
biotinylated antibody and 3
o
 streptavidin AP 
only E) 3
o
 streptavidin AP only.  
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3.9.4.          Recombinant virus propagation  
The formation of plaques, following transfection with each of the UL41(Rep) PGK 
BACs, demonstrated that the viruses were replicating successfully. To prepare 
master stocks for each of the recombinant viruses, MDV-PGKH10 and MDV-
PGKGFP, as well as the parental MDV CVI988 strain, infected CEF cells that had 
been transfected with BAC DNA (Section 3.9.1) were subcultured for two passages, 
as described in Section 2.3.9, to allow the viruses to grow to sufficient titres. Virus 
stocks were created for the following:-  
 CVI988 
 UL41(Rep)PGKGFP (F) 
 UL41(Rep)PGKH10myc (F) 
 UL41(Rep)PGKH10myc (R) 
 
For each virus, two T175cm
2
 flasks of infected CEF cells (Pass #2) were 
resuspended in 2 ml freezing solution (90% v/v FCS, 10% v/v dimethyl sulphoxide) 
and aliquoted into 0.2 ml quantities (Section 2.3.9). All cryovials were frozen at -
80
o
C to act as master stocks. 
The infectivity titre, in PFU/ml, of these frozen stocks of the cell-associated MDV 
CVI988 strain and MDV mutants was determined using plaque assays, as described 
in Section 2.3.10. After 6 days, plaques had developed to a sufficient size and the 
CEF cells were fixed using ice cold 1:1 acetone-methanol. To aid visualisation of the 
CPE, the CEF cells were stained using an antibody specific for the MDV gB 
glycoprotein (Section 2.3.12). The number of plaques in each well was counted and 
used to determine the virus titre in Plaque Forming Unit (PFU)/ml (Table 3.3). In a 
commercially available MD vaccine, the standard required PFU of MD per 0.2 ml 
chicken dose is 1.0 x 10
3
 PFU (Landman and Verschuren, 2003). The infectivity 
titres of the frozen stocks of MDV CVI988 strain and recombinant virus mutants 
were greatly in excess of this figure. 
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Table 3.3 Plaque numbers following a plaque assay 
 
















































3.10.         Future Work 
The success of the project dismissed the hypothesis that the haemagglutinin gene was 
toxic. As the source of the disruption was the CMV promoter, and not the H10 gene, 
more genes may now be incorporated into the MDV CVI988 genome. For this 
purpose, the neuraminidase (NA) gene and the haemagglutinin (HA) gene from the 
highly pathogenic strain, A/chicken/Ivory Coast/1787-35 H5N1, were kindly 
supplied by Dr Haas who acquired them from the Institute Zooprofilattico 
Sperimentale delle Venezie (Padua, Italy). Unfortunately, time constraints prevented 
the successful creation of MDV mutants containing these genes; however, the initial 




The H5 gene was amplified using the primers, pDONRH5_For and pDONRH5_Rev, 
which incorporated the unique enzyme restriction sites XhoI and HindIII (Appendix 
A.1.3.1). These sites would allow the H5 gene to be cloned upstream of the myc tag 
in the plasmid pCDNA3.1Myc-HIS. In addition, using site directed mutagenesis, the 
H5 stop codon (TAG) was removed by the reverse primer. The H5 gene was 
successfully amplified (Section 2.1.1 and Appendix A.1.4.1) and cloned into Blunt II 
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TOPO (Section 2.1.2). Following transformation (Section 2.2.2), plasmid DNA was 
isolated from small cultures (Section 2.2.5). The successfully ligated plasmid, 
pTOPH5 (Figure 3.26), was confirmed using restriction enzyme digestion with 
HindIII and XhoI and HindIII. 
The primers, M13 forward and reverse, were used to sequence the PGK promoter 
and H5 gene (Appendix A.1.3.1). Sequencing results indicated that the H5 gene had 
been successfully incorporated into TOPO and the site directed mutagenesis to 
remove the stop codon was successful. 
In addition, primers were designed to amplify H5myc, once the H5 gene had been 
cloned upstream of the myc tag. These primers, pH5myc(rpt)_For and 
pH10myc_Rev, incorporated the restriction sites, BamHI and XhoI, that would allow 




Using the primers, pNA_For (Fixed) and pNA_Rev, that incorporated the unique 
enzyme restriction sites NheI and XhoI (Appendix A.1.3.1), the NA gene was 
successfully amplified (Section 2.1.1 and Appendix A.1.4.1). The gene was 
subsequently cloned into Blunt II TOPO (Section 2.1.2), competent E. coli cells were 
transformed with the ligation mix (Section 2.2.2) and plasmid DNA was isolated 
(Section 2.2.5). The successfully ligated plasmid, pTOPNA (Figure 3.26), was 
confirmed using restriction enzyme digestion with NheI and XhoI. 
 
 
3.11.             Conclusion 
The primary objective in this study was to incorporate a haemagglutinin gene into the 
MDV viral genome. This has now been achieved and confirmed using 
immunohistochemistry. Attempts to insert the H10 or GFP gene, under the control of 
the CMV promoter, were not successful, as the promoter appears to inhibit virus 
gene expression, resulting in the failure of UL41(Rep) BACs to induce plaque 





                    
                                  
 

















Figure 3.26 A) A diagrammatic representation of the created plasmid 
pTOPNA, starting with the plasmid pDONR207N1. The amplified NA gene 
was cloned into the TOPO vector to create pTOPNA. B) The H5 gene was 
amplified from the plasmid pDONR207H5, and cloned into the TOPO 
vector to create pTOPH5. 
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formation in CEF cells. Further investigation into the detrimental effect of the CMV 
promoter on the MDV genome could be carried out, but lies outside the scope of this 
current research. 
MDV recombinant mutants have been propagated by passage in CEF cells and virus 
stocks were frozen at -80
o
C. In collaboration with the Istituto Zooprofilattico 
Sperimentale delle Venezie in Italy, these will be tested in future in vivo studies to 
determine if they induce a protective level of antibody response in chickens to the 
H10 protein, while insuring adequate protection to MDV challenge. If so, the 
creation of a vaccine that allows simultaneous vaccination against both pathogens 
would be a major achievement.  
To follow on from the successful research to introduce the H10 and GFP genes into 
the UL41 site of the MDV CVI988 genome, the next step will focus on the 
identification of a second non-essential gene site. Additional sites would allow 
multiple HA genes to be introduced or combinations of HA and NA genes. The next 
site identified as the target for the insertion of HA genes was the US10 open reading 
frame. 
 












Chapter 4: The Construction and Characterisation of 
recombinant CVI988 Bacterial Artificial Chromosomes 
(BACs) expressing Haemagglutinin and GFP within the 
US10 Open Reading Frame 
 
 
4.1 US10 Deleted BAC Construct 
4.2 US10 (Rep) PGKGFP BAC Construct 
4.3 US10 (Rep) PGKH10myc BAC Construct  
4.4 In vitro Characterisation of US10(Rep) PGKGFP/H10myc  
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4.1. US10 Deleted BAC Construct 
 
4.1.1. Aims and approach 
Following on from the successful research to introduce the H10 and GFP genes into 
the UL41 site of the MDV CVI988 genome, additional sites were identified so that, 
in future, genes could be introduced into multiple locations. Again, as with the UL41 
open reading frame, the focus was on the identification and replacement of a non-
essential gene, so that unmapped and intragenic promoters could be avoided.  
Initial work involved the identification and deletion of a second non-essential gene, 
which would allow the insertion of a novel gene (H10 or GFP) into the CVI988 
genome. As in Section 3.3, the goal was to initially delete the proposed non-essential 
MDV gene by creating a shuttle plasmid that contained only the gene flanking 
sequences, thus confirming the previously published deletion studies. Once the gene 
was deleted, the subsequent in vitro analysis would reveal if the identified MDV 
gene was essential for virus growth in tissue culture, determined by the ability of the 
CVI988 (Del) BAC to form CPE in CEF cells. If the identified MDV gene was 
confirmed to be non-essential, then the H10 and GFP gene would be incorporated 
into the open reading frame. All genes inserted into the MDV viral genome would be 
under the control of the PGK-1 promoter.  
 
4.1.2. Identification of the non-essential gene US10 
In Section 3.1.2, several genes that had been deemed to be non-essential in the MDV 
genome were identified using previously published research. The US10 open reading 
frame was identified as a site that could potentially be targeted (Jones et al, 1991; 
Parcells et al, 1994; Sakaguchi et al, 1994). Sakaguchi et al (1994) demonstrated that 
the US10 gene, a minor virion protein of MDV-1, was an effective site for the 
insertion of foreign genes from which to construct a polyvalent live vaccine for 
poultry. They incorporated the E. coli lacZ gene into the US10 open reading frame of 
the MDV-1 genome by homologous recombination. When tested in vitro, the 
recombinant virus replicated as well as the parental strain, indicating that the US10 
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gene was non-essential for viral growth in tissue culture. In vivo, the deletion of this 
gene did not affect vaccine-induced immunity. Therefore, it was decided that the 
US10 open reading frame of MDV CVI988 would be the next target for the insertion 
of genes into the MDV viral genome. 
 
4.1.3. MDV US10 gene flanking sequences 
Primers were designed to amplify approximately 2 kb of the DNA sequence on either 
side of the US10 gene (Appendix A.1.3.2). The MDV CVI988 BAC was isolated, as 
described in Section 2.2.7, and used as the template. To facilitate downstream 
cloning, the unique restriction enzyme sites, KpnI, PacI and BamHI, were 
incorporated into the primers. The flanking sequences (US10FSA and US10FSB) 
were successfully amplified as described in Section 2.1.1 and Appendix A.1.4.2. 
Both DNA fragments were gel purified (Section 2.1.9) and separately cloned into 
Zero Blunt II TOPO (Section 2.1.2) to create the plasmids US10pTOPFSA and 
US10pTOPFSB (Figure 4.1). Competent E. coli cells were transformed with the 
ligation reactions (Section 2.2.2) and plasmid DNA was isolated from small cultures 
(Section 2.2.5). US10pTOPFSA was shown by restriction enzyme digest analysis 
(BamHI, BamHI and PacI, and AseI) to contain an insert of the correct size, in the 
correct orientation. Digestion with EcoR1 demonstrated that the plasmid, 
US10pTOPFSB, contained an insert of the correct size (Sections 2.1.6). 
 
4.1.4. US10pTOPFSAB 
The plasmids, US10pTOPFSA and US10pTOPFSB, were sequentially digested with 
KpnI and BamHI in preparation for cloning. Following the KpnI enzyme digest 
(Buffer 1), the DNA was ethanol precipitated (Section 2.1.5) and subsequently 
digested with BamHI, in buffer 3. The digested fragments were gel purified 
according to the protocol in Section 2.1.9. The purified FSB fragment was ligated 
into US10pTOPFSA (Section 2.1.10) to create the plasmid, US10pTOPFSAB 
(Figure 4.1). Competent E. coli cells were transformed with the ligation mix (Section 
2.2.2) and plasmid DNA was isolated according to the protocol in Section 2.2.5. The 
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successfully ligated plasmid was confirmed using restriction enzyme digestion with 
AseI and PstI (Section 2.1.6). Following confirmation, US10pTOPFSAB DNA was 
prepared according to the protocol in Section 2.2.6. 
Primers were designed to sequence the US10pTOPFSAB plasmid (Appendix 
A.1.3.2). Sequencing results indicated that, when compared to the published 
sequence, no errors were present in the plasmid, US10pTOPFSAB.  
 
4.1.5. US10pST76kFSAB 
In preparation for cloning, the US10pTOPFSAB plasmid was digested with KpnI and 
PacI to isolate the FSAB insert. Digestion of US10pTOPFSAB with these enzymes, 
however, produced two DNA fragments very similar in size (3.6 kb and 3.5 kb) 
preventing gel purification. By digesting the DNA with a third enzyme, AatII, this 
problem was resolved as it digested the smaller, vector DNA fragment into 2 kb and 
1.5 kb fragments. The remaining 3.6 kb fragment (FSAB) was gel purified (Section 
2.1.9) and ligated into the digested and purified pST76k plasmid (Section 3.1.10) to 
create the plasmid, US10pST76kFSAB (Figure 4.1). Following transformation 
(Section 2.2.2) the plasmid DNA was isolated (Section 2.2.5). To confirm that the 
ligation had been successful the isolated plasmids were digested with KpnI and PacI. 
Both colonies displayed the correct digest pattern (6.3 and 3.6 kb bands) indicating 
that the plasmid US10pST76kFSAB had been successfully created (Figure 4.1). 
 
4.1.6. BAC Mutagenesis using US10pST76kFSAB 
BAC mutagenesis was performed, as described in Section 2.2.9. DH5-α bacteria, that 
contained the MDV CVI988 BAC, were made competent (Section 2.2.8) and 
transformed with 10 ng of the shuttle plasmid US10pST76kFSAB, by 
electroporation. Kanamycin-sensitive colonies containing US10(Del) BACs, where 
the US10 gene had been deleted, were identified using colony PCR (Section 2.1.1 
and Appendix A.1.4.2). Two sequencing primers, US10pTOPFSAB_F5 and  




         
 
 
   



















Figure 4.1 A) A diagrammatic representation of the created plasmid 
US10pTOPFSA. B) A diagrammatic representation of the created plasmid 
US10pTOPFSB C) The 2.1 kb US10FSB DNA fragment was ligated into 
US10pTOPFSA to create US10pTOPFSAB. D) A diagrammatic 
representation of the plasmid US10pST76kFSAB, created by cloning the 
FSAB DNA fragment into the shuttle plasmid, pST76k. E) A restriction 
enzyme digestion of the UL41pST76kFSAB plasmid using the enzymes, 
KpnI and PacI.  
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US10pTOPFSAB_R5, which lay either side of the US10 gene, were selected 
(Appendix A.1.3.2). By amplifying that region using PCR, the detection of a small 
product (854 bp) meant that the US10 gene had been successfully deleted, whereas a 
larger product (1301 bp) meant that the US10 gene was still intact. CVI988 BAC 
DNA (20 ng) was tested as a positive control and, as expected, produced an 
approximately 1.3 kb band. Nine colonies tested produced an approximately 0.9 kb 
product, indicating that the US10 gene had been deleted (Figure 4.2). A colony was 
selected, and the US10(Del) BAC DNA was isolated, as described in Section 2.2.7.  
To confirm the successful deletion of the US10 gene, the US10(Del) BAC was 
sequenced with the primers US10pTOPFSAB_F5 and US10pTOPFSAB_R4.  
(Appendix A.1.3.2). Sequencing results indicated that the US10 gene had been 
effectively deleted, creating the US10(Del) BAC. 
 
4.1.7. In vitro Characterisation of US10 (Del) BAC 
CEF cells, seeded in six-well dishes, were transfected with MDV CVI988 BAC and 
the US10(Del) BAC DNA, as described in Section 2.3.8. CEF seeding and the BAC 
transfections were carried out simultaneously, using the ‘reverse’ transfection 
method (Section 2.3.8). For each BAC construct, three wells of a six-well dish were 
transfected. After 7 days, approximately 70 plaques were visible in all the wells 
transfected with the CVI988 and US10(Del) BAC (Figure 4.2). The presence of CPE 
demonstrated that viable recombinant viruses were being produced, following 
transfection with the US10(Del) BAC. This in vitro analysis confirmed the previous 
research, by Sakaguchi et al (1994), that the US10 gene was not essential for virus 
growth in cell culture. 
Therefore, the next step was to introduce the GFP and the H10 gene into the US10 
open reading frame. Previously, it had been found that the PGK promoter effectively 
drove the expression of the H10 and GFP genes, without disrupting the MDV 
CVI988 BAC. To ensure that the US10 gene site was suitable for the introduction of 
foreign genes, this work was repeated, inserting the GFP and H10 gene under the 
control of this promoter.  


















Figure 4.2 A) Agarose gel electrophoresis showing positive results from a 
colony PCR experiment designed to detect US10 (Del) BACs. A small 
product (0.9 kb) meant that the US10 gene had been successfully deleted; a 
large product (1.3 kb) meant that the US10 gene was still intact. B) A 
photograph displaying a single plaque caused by the transfection of the 
US10 (Del) BAC into CEF cells.  
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4.2. US10 (Rep) PGKGFP BAC 
 
4.2.1. pTOPPGKGFP 
This plasmid, containing the murine PGK-1 promoter upstream of the GFP gene, was 
created previously (Section 3.7.1 and Figure 3.14). In preparation for cloning, the 
PGKGFP DNA fragment had been isolated using the restriction enzymes, EcoRV 




In preparation for blunt cloning, the plasmid US10pTOPFSAB (Section 4.1.3) was 
digested with BamHI. Following digestion, the 5’ overhangs of the US10pTOPFSAB 
plasmid DNA (5 µg) were converted to 5’ phosphorylated, blunt ended DNA 
(Section 2.1.7). Subsequently, the digested and blunted plasmid DNA was gel 





The digested and purified PGKGFP fragment (Section 4.2.1) was ligated into the 
BamHI digested, blunted and AP-treated US10pTOPFSAB plasmid (Section 4.2.2). 
Competent E. coli cells were transformed with the ligation reaction (Section 2.2.2) 
and plasmid DNA was isolated from small cultures (Section 2.2.5). The plasmids 
were digested with PstI and ApaI to confirm that the PGKGFP insert had ligated into 
US10pTOPFSAB successfully and to determine the orientation of the insert. Agarose 
gel electrophoresis revealed that five plasmids were found to contain the PGKGFP 
insert in the forward orientation, and two in the reverse orientation (Figure 4.3). To 
confirm the successful ligation of PGKGFP, both of the plasmids, 
US10pTOPFSABPGKGFP (F and R), were sequenced using the primers US10 
pTOPFSAB_F5 and US10pTOPFSAB_R4 (Appendix A.1.3.2). Sequencing results  
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Figure 4.3 A) Agarose gel electrophoresis showing restriction enzyme 
digests of the plasmids pTOPFSABPGKGFP (F and R) using the enzymes 
PstI and ApaI. B) A diagrammatic representation of the plasmids 
US10pTOPFSABPGKGFP (F and R). The PGK-GFP DNA fragment  was 
blunt cloned into the plasmid US10pTOPFSAB, between the flanking 
sequences A and B. C) In the final cloning step, the FSABPGKGFP DNA 
fragments were transferred to the shuttle plasmid, pST76k, to create the 
plasmids US10pST76kPGKGFP (F and R).  
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indicated that for both plasmids, the PGKGFP insert had been correctly inserted 
between the flanking sequences.  
 
 
4.2.4. US10pST76kPGKGFP (F and R) 
 
The plasmids, US10pTOPFSABPGKGFP (F and R) were digested with KpnI and 
PacI and gel purified, in preparation for cloning with the shuttle plasmid, pST76k 
(Section 3.1.10). The digested FSABPGKGFP fragments were ligated into the 
digested and purified pST76k plasmid to create the plasmids 
US10pST76kPGKGFP(F and R) (Figure 4.3). Following transformation (Section 
2.2.2), the plasmid DNA was isolated (Section 2.2.5). The plasmids were digested 
with BamHI to confirm that the ligation was successful. With this enzyme, digestion 
of the plasmid US10pST76kPGKGFP (F) was expected to produce an 8.7 kb and a 
2.7 kb DNA fragment; the plasmid US10pST76kPGKGFP (R) was expected to 
produce an 8.3 kb and a 3.1 kb DNA fragment. The correct digest pattern was 
displayed for both constructs. 
 
 
4.2.5. BAC Mutagenesis using the plasmids US10pST76kPGKGFP (F)  
           and US10pST76kPGKGFP (R) 
BAC mutagenesis was successfully carried out for both plasmids (Section 2.2.9). 
DH5-α bacteria containing the MDV CVI988 BAC were made competent (Section 
2.2.8) and transformed with 10 ng of the shuttle plasmids, US10pST76kPGKGFP (F 
and R), using electroporation. Kanamycin-sensitive colonies were tested using 
colony PCR (Section 2.1.1 and Appendix A.1.4.2) to identify those that had the 
US10 gene replaced with the GFP gene. The primers, p2AGFP_For and 
p2AGFP_Rev (Appendix A.1.3.2), were used to identify the GFP gene. pTOPGFP 
plasmid DNA (Section 6.2.2) was used as a positive control and produced expected 
results. BAC mutagenesis performed with the US10pST76kPGKGFP (F) shuttle 
plasmid produced 10 colonies that were positive for the GFP insert. BAC 
mutagenesis carried out with the US10pST76kPGKGFP (R) shuttle plasmid yielded 
13 colonies which were positive for the GFP insert (Figure 4.4). Subsequently, the  



















L          PC         1    2     3    4     5     6 7     8    9   10   11  12  13    14 15    16  17  18   19    20        L   
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US10(Rep) PGKGFP BAC (Forward)
L          PC          1     2 3    4     5     6    7 8 9    10 11  12   13  14   15  16  17 18   19 20          L    
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Figure 4.4 A) An agarose gel electrophoresis photograph showing positive 
results from a colony PCR experiment designed to detect the GFP gene in 
the US10(Rep) PGKGFP BAC (F).  B) Agarose gel electrophoresis showing 
positive results from a colony PCR experiment designed to detect the GFP 
gene in the US10(Rep) PGKGFP BAC (R).   
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BAC DNA of one US10(Rep) PGKGFP(F) BAC and one US10(Rep) PGKGFP(R) 
BAC was selected and isolated as described in Section 2.2.7.  
 
To confirm the successful insertion of PGKGFP into the MDV CVI988 genome, 
both US10(Rep) BACs were sequenced using the primers US10pTOPFSAB_F5 and 
US10pTOPFSAB_R4 (Appendix A.1.3.2). Sequencing results indicated that for both 
US10(Rep) PGKGFP (F and R) the PGKGFP insert had successfully replaced the 
US10 gene.  
 
4.3. US10(Rep) PGKH10myc BAC 
 
4.3.1. pTOPPGKH10myc 
This plasmid was constructed previously (Section 3.8.2 and Figure 3.17). The H10 
gene was initially cloned upstream of a Myc-HIS tag (Section 3.8.1). Subsequently, 
the H10myc DNA fragment was cloned downstream of the PGK-1 promoter to 
create the plasmid pTOPPGKH10myc. In preparation for cloning, the PGKH10myc 
DNA fragment was digested with the restriction enzymes, EcoRV and SnaBI, and 




The purified PGKH10myc fragment (Section 4.3.1) was ligated into the BamHI 
digested, blunted and AP-treated US10pTOPFSAB plasmid (Section 4.2.2). 
Competent E. coli cells were transformed with the ligation mix (Section 2.2.2) and 
plasmid DNA was isolated from small cultures (Section 2.2.5). The plasmids were 
digested with PstI and ApaI to confirm the ligation was successful and to ascertain 
the orientation of the insert. Three plasmids were found to contain the PGKH10myc 
insert in the forward orientation, and five plasmids with the insert ligated in the 
reverse orientation (Figure 4.5). The plasmids, US10pTOPFSABPGKH10myc (F 
and R), were sequenced to confirm the successful ligation of the PGKH10myc insert.  
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Figure 4.5 A) Agarose gel electrophoresis showing restriction enzyme 
digests of the plasmids pTOPFSABPGKH10myc (F and R), using the 
enzymes PstI and ApaI. B) A diagrammatic representation of the plasmids 
US10pTOPFSABPGKH10myc (F and R). The PGK-H10myc DNA 
fragment was blunt cloned into the plasmid US10pTOPFSAB. C) In the 
final cloning step, the FSABPGKH10myc DNA fragments were transferred 
to the shuttle plasmid, pST76k, to create the plasmids 
US10pST76kPGKH10myc (F and R). 
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Sequencing was carried out using the primers US10pTOPFSAB_F5 and 
US10pTOPFSAB_R4 (Appendix A.1.3.2). Sequencing results indicated that for both 
plasmids, the PGKH10myc insert had been correctly inserted between the flanking 
sequences.  
 
4.3.3. US10pST76kPGKH10myc (F and R) 
The plasmids, US10pTOPFSABPGKH10myc (F and R), were digested with KpnI 
and PacI in preparation for cloning with the shuttle plasmid, pST76k. The digested 
FSABPGKH10myc fragments were gel purified (Section 2.1.9) and ligated into the 
digested and purified pST76k plasmid (Section 3.1.10), to create the plasmids 
US10pST76kH10myc (F and R) (Figure 4.5). Competent E. coli cells were 
transformed with the ligation mix, as described in Section 2.2.2 and plasmid DNA 
was isolated (Section 2.2.5). To confirm that the ligation was successful, the 
plasmids were digested with the restriction enzyme, BamHI. With this enzyme, 
digestion of the plasmid US10pST76kH10myc(F) would produce a 9.6 kb and a 2.7 
kb DNA fragment; the plasmid US10pST76kH10myc(R) was expected to produce an 
8.3 kb and a 4.1 kb DNA fragment. For both constructs, US10pST76kH10myc (F 
and R), the enzyme digests produced the expected digest pattern. 
              
4.3.4. BAC Mutagenesis using the plasmids US10pST76kPGKH10myc  
          (F) and US10pST76kPGKH10myc (R) 
BAC mutagenesis was carried out according to the protocol in Section 2.2.9. DH5-α 
bacteria containing the MDV CVI988 BAC were made competent (Section 2.2.8) 
and transformed with 10 ng of the shuttle plasmids, US10pST76kPGKH10myc (F 
and R). US10(Rep) BACs, where the US10 gene had been replaced with the H10myc 
gene, were identified using colony PCR (Section 2.1.1 and Appendix A.1.4.2). The 
primers, pH10myc_For and pH10myc_Rev (Appendix A.1.3.2) were used to identify 
the 1.7 kb H10myc insert. The plasmid, pTOPPGKH10myc (Section 3.8.2), was used 
as a positive control and produced expected results. BAC mutagenesis, performed 
with the US10pST76kPGKH10myc (F) shuttle plasmid, yielded one colony that was 
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positive for the H10myc insert. BAC mutagenesis carried out with the US10pST76k 
PGKH10myc(R) shuttle plasmid produced three colonies that were positive for the 
H10myc insert (Figure 4.6). Subsequently, the BAC DNA of a US10(Rep) 
PGKH10myc(F) BAC and a US10(Rep) PGKH10myc(R) BAC was selected and 
isolated as described in Section 2.2.7.  
 
Using the primers US10pTOPFSAB_F5 and US10pTOPFSAB_R4 (Appendix 
A.1.3.2 and A.1.4.2), sequencing was used to confirm the successful insertion of 
PGKH10myc into the CVI988 BAC genome. Sequencing results indicated that for 
US10(Rep) PGKH10myc (F and R) the PGKH10myc insert had successfully 
replaced the US10 gene.  
 
4.4. In vitro Characterisation of the US10(Rep) BACs 
The in vitro analysis of the US10(Rep) BAC constructs was carried out in parallel 
with the studies of the UL41(Rep) PGK constructs. For clarity, the data arising from 
transfections using the MDV CVI988 BAC have also been included here. These data 
can also be found in Section 3.9. 
BAC transfections were carried out using the ‘reverse’ transfection method described 
in Section 2.3.8. CEF cells were seeded at a density of 5.0 x10 
5
cell per well in six-
well dishes and simultaneously transfected with the following BACs, according to 
the protocol in Section 2.3.8:- 
   
 US10(Rep) PGKGFP (F)   - 2 wells 
 US10(Rep) PGKGFP (R)  - 2 wells 
 US10(Rep) PGKH10myc (F)   - 7 wells 
 US10(Rep) PGKH10myc (R)  - 5 wells 
 
After 7 days, cytopathic effect (CPE) in the form of plaques was visible in all wells. 
The number of plaques in each well was counted and documented in Table 4.1. 
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Figure 4.6 A) Agarose gel electrophoresis photograph showing positive 
results from a colony PCR experiment designed to detect an approximately 
1.7 kb H10myc DNA fragment in the US10(Rep) PGKH10myc BAC (F). B) 
Agarose gel electrophoresis showing positive results from a colony PCR 
experiment designed to detect an approximately 1.7 kb H10myc DNA 
fragment in the US10(Rep) PGKH10myc BAC (R).   




Table 4.1 Plaque counts following transfection 
 
 





Well 1 79 Virus  
Propagation Well 2 53 
Well 3 102 Protein Quantification 
Well 4 61 
Well 5 79 Myc/HIS 
Immunohistochemistry Well 6 88 
US10(Rep) 
 PGKGFP (F) 
 
Well 1 129 Immunofluorescence 
and virus propagation Well 2 141 
US10(Rep) 
 PGKGFP (R) 
Well 1 121  
Immunofluorescence Well 2 101 
US10(Rep) 
PGKH10myc (F) 
Well 1 139  
Virus  
Propagation 
Well 2 128 
Well 3 101 
Well 4 109 Protein Quantification 
Well 5 146 
Well 6 137 Myc/HIS 
Immunohistochemistry Well 7 144 
US10(Rep) 
PGKH10myc (R) 
Well 1 138  
Virus 
Propagation 
Well 2 151 
Well 3 133 
Well 4 78 Myc/HIS 
Immunohistochemistry Well 5 59 
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The presence of CPE indicated that viable recombinant viruses were being produced 
following transfection with the US10(Rep) BACs. This indicated that it was possible 
to insert foreign genes, under the control of the PGK-1 promoter, into the US10 open 
reading frame of the MDV CVI988 genome.  
The CEF cells that had been transfected with the US10(Rep) PGKGFP BAC DNA 
exhibited bright green fluorescence. This established that the PGK-1 promoter was 
successfully driving the expression of the GFP gene. In order to determine if the 
PGK-1 promoter was also prompting the expression of the H10myc gene in CEF 
cells transfected with the US10(Rep)PGKH10myc BAC constructs, western blot 




CEF cells, demonstrating extensive CPE following transfection with the US10(Rep) 
PGKH10myc (F and R) BAC DNA were analysed using immunohistochemistry. The 
antibody, α-myc, was used to detect the presence of the H10myc protein and to 
determine if it was being produced by MDV infected cells. Previously, in Section 
3.9.2, the α-HIS antibody had been found to bind non-specifically to CEF cells so 
this was not used again. 
As controls, mock-transfected CEF cells were incubated with α-myc, α-HIS and HB3 
(α-gB) antibodies. CEF cells that had been transfected with MDV CVI988 BAC 
DNA and which had subsequently developed CPE were also stained with α-myc, α-
HIS and HB3 antibodies. These data can be seen in Section 3.9.2 and in Figures 3.21 
and 3.22. 
CEF cells transfected with the US10(Rep) PGKGFP constructs developed plaques 
that expressed GFP so did not require antibody staining. CEF cells transfected with 
US10(Rep) PGKGFP BAC DNA were prepared as described in Section 2.3.13.   
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Plaques were photographed using white light to observe the individual plaques and 
combined UV and white light to observe the cells and the GFP fluorescence 
simultaneously (Figure 4.7). 
CEF cells, transfected with the US10(Rep) PGKH10myc BAC constructs, were 
incubated with the α-myc antibody (Section 2.3.13). This resulted in plaques on the 
CEF cell sheet that displayed bright green fluorescence when viewed using a 
fluorescent microscope. This was confirmation that the CEF cells, infected by the 
recombinant US10(Rep) MDV viruses, were also expressing the myc-tagged H10 
protein. The plaques were photographed using white light to observe the individual 
plaques and UV light to observe the fluorescence (Figure 4.8). 
The immunohistochemistry results confirm that the plaques of infected CEF cells, 
formed as a result of the transfection with US10(Rep) PGKH10myc BAC DNA, 
produced the myc-tagged H10 protein. This demonstrates that the PGK-1 promoter is 
successfully driving the expression of the H10 protein and confirms that it had been 
fully incorporated into the MDV viral genome. This also proves that foreign genes 
can be incorporated into two gene sites of the MDV genome, UL41 and US10. To 
complete the in vitro work, western blot analysis was used to try and determine the 
presence of the H10myc protein.  
 
4.4.2. Western Blot analysis 
Western blot analysis was performed on protein samples extracted from CEF cells 
transfected with the following BACs: - 
 CVI988 
 US10(Rep) PGKH10 BAC (F) 
 
Total protein was extracted using lysis buffer containing Pefabloc (Section 2.4.1), 
once extensive CPE was observable. Protein samples from untransfected CEF cells 
and the CVI988 transfected CEF cells were prepared previously in Section 3.9.3. 
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US10(Rep) PGKGFP BAC (Forward)
Plaque 1   
Plaque 2   
US10(Rep) PGKGFP BAC (Reverse)
Plaque 1   
Plaque 2   
White Light, x100 UV, x100 Combined, x100
White Light, x100 UV, x100 Combined, x100
White Light, x100 UV, x100 Combined, x100
White Light, x100 UV, x100 Combined, x100
Figure 4.7 CEF cells, transfected with the US10(Rep) PGKGFP BACs, 
displaying cytopathic effect in the form of plaques. The plaques were 
photographed using white light, UV light and both combined to observe the 
MDV infected CEF cells and the subsequent expression of the GFP 
fluorescent protein. 
























Figure 4.8 A) Immunohistochemistry of a single plaque developing on CEF 
cells transfected with the US10(Rep) PGKH10myc (F) BAC using the α-
myc antibody. B) Immunohistochemistry of the US10(Rep) PGKH10myc 
(R) BAC transfected CEF cells using the α-myc antibody.  
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Once extracted, protein samples were diluted 1:100 (v:v) in lysis buffer and 
quantified using the Pierce BCA protein assay kit (Section 2.4.2). Table 4.2 displays 
the calculated concentrations of each of the samples and the volume required to load 
20 µg of protein into one well of an SDS-PAGE gel. For clarity, the protein 
concentrations of the previously calculated CEF only and CVI988 samples are 
included (Section 3.9.3, Table 3.2): - 
 
Table 4.2 Protein sample concentration (µg/ml) 
Sample Concentration  Volume for 20 µg 
CEF 8153 µg/ml 2.45 µl 
CVI988 8967 µg/ml 2.25 µl 
US10 H10 9292 µg/ml 2.15 µl 
 
 
SDS-PAGE was performed, according to the protocol in Section 2.4.4. The protein 
samples (20 µg) were loaded into the wells, as below: - 
 
 
The SDS-PAGE was repeated five times, producing five replicate gels. Following 
electrophoresis, proteins of each of the five gels were transferred to a nitrocellulose 
membrane (Section 2.4.5). These five membranes were incubated with one of the 
following combinations (Section 2.4.6): - 
 1o α-Myc, 2o biotinylated antibody and 3o streptavidin AP 
 1o α-HIS, 2o biotinylated antibody and 3o streptavidin AP 
 1o HB3 (α-gB), 2o biotinylated antibody and 3o streptavidin AP 
 2o biotinylated antibody and 3o streptavidin AP  
 3o streptavidin AP 
Blank Ladder CEF CVI988 US10H10 Ladder Blank 
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As in Section 3.9.3, two membranes were stained with the secondary biotinylated 
anti-mouse IgG combined with the 3
o
 Streptavidin AP conjugate, or only the 3
o
 
Streptavidin AP conjugate only. By not incubating the membranes with the primary 





 streptavidin AP bound non-specifically to the nitrocellulose membranes. 
As determined previously in Section 3.9.3, the H10myc-HIS protein was expected to 
be approximately 80 kDa in size; the MDV gB glycoprotein was predicted to be 110 
kDa in size. Bound antibody was detected using the Sigmafast BCIP/NBT stain 
(Section 2.4.6). As was the case with the protein samples extracted from CEF cells, 
transfected with the UL41(Rep) PGKH10myc BAC DNA, western blots failed to 
detect proteins of appropriate size using the HB3, α-myc or α-HIS antibodies. In 
addition, the 2
o 
biotinylated antibody and 3
o
 streptavidin AP both bound non-
specifically (Figure 4.9). Due to time limitations, this could not be resolved but 
future work would involve the selection of a different 2
o 
biotinylated antibody and 3
o
 
streptavidin AP that did not bind non-specifically.  
 
4.4.3. Recombinant virus propagation  
To prepare master stocks of each of the recombinant viruses, US10MDV-PGKH10 
and US10MDV-PGKGFP, infected CEF cells that had been transfected with the 
US10 (Rep) BAC constructs were subcultured for two passages (Section 2.3.9) using 
fresh CEF cells, to allow the viruses to grow to sufficient titres. Once widespread 
CPE was visible in the T175cm
2
 flasks, virus stocks were created for the following: - 
 
 US10(Rep) PGKGFP (F) 
 US10(Rep) PGKH10myc (F) 
 US10(Rep) PGKH10myc (R) 
 
In each case, two T175cm
2
 flasks of infected CEF cells (Pass #2) were resuspended 
in 2 ml freezing solution (90% v/v FCS, 10% v/v DMSO) and aliquoted in 200 µl 
quantities (Section 2.3.9). All cryovials were frozen at -80
o
C to act as master stocks. 
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To determine the infectivity titre of the frozen stocks of cell-associated MDV 
US10(Rep) viruses, plaque assays were performed according to the protocol in 
Section 2.3.10. Six days after the CEF cell-associated MDV US10(Rep) viruses were 
introduced to the fresh CEF monolayer, plaques had developed to a sufficient size. 
Using ice cold 1:1 acetone-methanol, the CEF cells were fixed and stained using the 
HB3 antibody (Section 2.3.12). The number of plaques in each well was counted, to 
determine the virus titre in PFU/ml (Table 4.3). The infectivity titres of the frozen 
stocks of recombinant US10(Rep) viruses were all in excess of the commercial 
standard of 1.0x10
3
 PFU per 0.2 ml chicken vaccine dose. 
 
Table 4.3 Plaque numbers following a plaque assay 
 






























































































B) α - HIS
Figure 4.9 Western blot analysis was performed on protein samples 
extracted from untransfected CEF cells and CEF cells transfected with 
CVI988 and the mutant US10 H10 BAC. Following SDS-PAGE, proteins 
were transferred to nitrocellulose membranes and immunostained with: A) 
α-myc B) α-HIS C) HB3 D) 2
o 
biotinylated antibody and 3
o
 streptavidin AP 
only E) 3
o
 streptavidin AP only. 





The H10 gene has now been successfully incorporated into two sites of the MDV 
genome, under control of the PGK-1 promoter, although work must continue to 
prove by western blot that the haemagglutinin protein is being produced by CEF cells 
transfected and infected by the recombinant viruses. The US10(Rep) recombinant 
viruses have been propagated to sufficient titre by passage in CEF cells and frozen at 
-80
o
C. As with the UL41 recombinant viruses, they will be tested in future in vivo 
studies to determine if they induce a protective level of antibody response to MDV 
and influenza. 
 
Finally, the presence of two non-essential gene sites in the MDV genome means that 
a permanent selective marker such as GFP may be introduced for further in vitro 
analysis. In addition, it opens up the possibility of incorporating multiple 
haemagglutinin strains or a haemagglutinin and a neuraminidase gene (Section 3.10). 
To conclude this work to identify non-essential gene sites in the MDV genome, and 
to introduce foreign genes, the final gene site to be targeted was the UL50 open 
reading frame.  














Chapter 5: Analysis of the MDV CVI988  
UL50 Open Reading Frame 
 
 
5.1 UL50 Deleted BAC Construct and in vitro characterisation 















Chapter 5  Results 
181 
 
5.1. UL50 Deleted (Del) BAC Construct 
 
5.1.1. Identification of the non-essential gene UL50 
The third, and final, MDV gene site target identified was the UL50 gene. The UL50 
gene product is the ubiquitous enzyme, dUTPase (deoxyuridine triphosphatase), 
which is required during dTTP synthesis and for the prevention of uracil-
incorporation into DNA (Fuchs et al, 2000). It has been studied in several other 
alphaherpesviruses including HSV-1, VZV and ILTV. It is dispensable for normal 
viral replication in HSV (Fisher and Preston, 1986). In VZV, deletion of viral 
dUTPase had no effect on growth and syncytia formation in vitro (Ross et al, 1997). 
Fuchs et al (2000) determined that, in ILTV, a UL50 deletion virus propagated like 
wild-type ILTV in cell culture proving that the gene was non-essential for virus 
replication. To date, the impact of deleting the UL50 gene in MDV has not been 
studied. The first objective was to assess if this gene can be deleted from the MDV 
genome to establish if it is essential for virus propagation. If the growth of the UL50 
MDV deletion mutant was comparable to that of the parental MDV CVI988 BAC, 
then the effect of inserting foreign genes into this open reading frame could be 
assessed. 
 
5.1.2. MDV UL50 gene flanking sequences 
Using the MDV CVI988 BAC as the template, approximately 3 kb of the DNA 
sequence on either side of the UL50 gene was amplified, as described in Section 
2.1.1 and Appendix A.1.4.3. To facilitate downstream cloning, the unique restriction 
enzyme sites KpnI, PacI and AgeI, were incorporated into the primers (Appendix 
A.1.3.3). Due to the presence of a naturally occurring AgeI restriction enzyme site at 
the end of the UL50 gene, however, there was no need to incorporate this site into 
the primer, pUL50FSA_For (Appendix A.1.3.3). Once amplified, the flanking 
sequences were gel purified (Section 2.1.9), and cloned separately into Zero Blunt II 
TOPO (Section 2.1.2) to create the plasmids UL50pTOPFSA and UL50pTOPFSB 
(Figure 5.1).  




    
 
 
         
 
 
   
 













Figure 5.1 A) A diagrammatic representation of the created plasmid 
UL50pTOPFSA. B). A diagrammatic representation of the created plasmid 
UL50pTOPFSB. C) A diagrammatic representation of the plasmid 
UL50pTOPFSAB, created by cloning the FSB DNA fragment into the 
plasmid, UL50pTOPFSA. 
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Competent E. coli cells were transformed with the ligated plasmids (Section 2.2.2) 
and plasmid DNA was isolated from small cultures according to the protocol in 
Section 2.2.5. UL50pTOPFSA was correctly identified using BamHI; 
UL50pTOPFSB was identified using XhoI (Section 2.1.6). 
 
5.1.3. UL50pTOPFSAB 
In preparation for cloning, the UL50pTOPFSA and UL50pTOPFSB plasmids were 
digested with KpnI and AgeI, and the resulting DNA fragments were gel purified 
(Section 2.1.9). To create the plasmid UL50pTOPFSAB, the purified FSB fragment 
was ligated into UL50pTOPFSA (Section 2.1.10) (Figure 5.1). Following 
transformation (Section 2.2.2), the plasmid DNA was isolated (Section 2.2.5). The 
successfully ligated plasmid was confirmed using restriction enzyme digestion with 
ApaI (Section 2.1.6). Following confirmation, UL50pTOPFSAB plasmid DNA was 
prepared according to the protocol in Section 2.2.6. 
Primers were designed to sequence the UL50pTOPFSAB plasmid (Appendix 
A.1.3.3). Sequencing results indicated that, when compared to the published 
sequence, no errors were present. 
 
5.1.4. UL50pST76kFSAB 
Using KpnI and PacI, the UL50pTOPFSAB plasmid was digested to isolate the 
FSAB insert in preparation for cloning with the shuttle plasmid, pST76k. The 6.0 kb 
FSAB DNA insert was gel purified (Section 2.1.9) and ligated into the digested and 
purified pST76k plasmid (Section 3.1.10), to create the UL50pST76kFSAB plasmid 
(Figure 5.2). Competent E. coli cells were transformed with the ligation reaction 
(Section 2.2.2) and four plasmid DNA samples were isolated from small cultures 
(Section 2.2.5). As the pST76k vector was 6.3 kb in size and the FSAB insert was 6.0 
kb, the isolated plasmids were digested with XhoI to confirm that the ligation was 
successful. All plasmids displayed the correct digest pattern indicating that the 
UL50pST76kFSAB plasmid had been successfully created (Figure 5.2). 





             



























Figure 5.2 A) In the final cloning step, the FSAB DNA fragment was 
transferred to the shuttle plasmid, pST76k, to create the plasmid 
UL50pST76kFSAB. B) A restriction enzyme digestion of the 
UL50pST76kFSAB plasmid using the enzyme, XhoI. C) Agarose gel 
electrophoresis showing positive results from a colony PCR experiment 
designed to detect UL50(Del) BACs where the UL50 gene had been deleted.  
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5.1.5. BAC Mutagenesis using UL50pST76kFSAB 
BAC mutagenesis was performed, as described in Section 2.2.9. DH5-α bacteria 
containing the MDV CVI988 BAC were made competent (Section 2.2.8) and 
transformed with 10 ng of the shuttle plasmid, UL50pST76kFSAB, using 
electroporation. Kanamycin-sensitive colonies containing UL50(Del) BACs, where 
the UL50 gene had been deleted, were identified using colony PCR (Section 2.1.1 
and Appendix A.1.4.3). The primers, UL50MutBAC_For and UL50MutBAC_Rev, 
were designed to lie either side of the UL50 gene (Appendix A.1.3.3). By amplifying 
that region using PCR, the detection of a small product (594 bp) would mean that the 
UL50 gene had been successfully deleted. A larger product (1821 bp) would mean 
that the UL50 gene was still intact (Appendix A.1.3.3). Ten colonies tested produced 
an approximately 0.6 kb product, indicating that the UL50 gene had been 
successfully deleted (Figure 5.2). A colony was selected, and the UL50(Del) BAC 
DNA was isolated, as described in Section 2.2.7. 
 
5.1.6. In vitro Characterisation of UL50(Del) BAC 
CEF cells, seeded in six-well dishes, were transfected with the CVI988 and the 
UL50(Del) BAC (Section 2.3.7). Three wells of a six-well dish were transfected for 
each BAC. After 7 days, approximately 15 plaques were visible in the CEF cells that 
were transfected with the CVI988 BAC. No plaques were visible in the CEF cells 
that had been transfected with the UL50(Del) BAC. Two more UL50(Del) BAC 
clones were isolated and the in vitro analysis was repeated (Section 2.2.7). Again, in 
vitro analysis failed to demonstrate the ability of these BAC constructs to form CPE 
in the form of plaques.  
These results seemed to indicate that the UL50 gene is essential for normal viral 
replication of MDV in CEF cells. To determine if this was the case, revertant viruses 
were created where the UL50 gene was re-inserted into the UL50(Del) BAC. If the 
UL50 gene was essential to the formation of CPE, then the re-insertion of this gene 
would restore the plaque forming ability of the virus.  
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5.2. UL50 re-insertion 
The re-insertion of the UL50 gene was achieved by finding compatible, unique and 
naturally occurring enzyme restriction sites on either side of the UL50 gene. This 
would allow the insertion of the UL50 gene between the flanking sequences of the 
plasmid, UL50pTOPFSAB (Section 5.1.3).  In addition, as the enzyme sites already 
exist in the MDV CVI988 BAC, no new DNA would be introduced. The following 
sections describe the construction the shuttle plasmid, containing the UL50 gene, and 




Using the CVI988 BAC DNA as a template, the UL50 gene was amplified, as 
described in Section 2.1.1 and Appendix A.1.4.3. The primers, pUL50_For and 
pUL50_Rev, were designed to amplify the region of DNA that included the UL50 
gene, as well as the flanking enzyme restriction sites, SacII and ClaI (Appendix 
A.1.3.3). The amplified sequence was gel purified (Section 2.1.9) and cloned into 
Zero Blunt II TOPO (Section 2.1.2), to create the pTOPUL50 plasmid (Figure 5.3). 
Following transformation (Section 2.2.2), plasmid DNA was isolated (Section 2.2.5). 
The successfully ligated plasmid, pTOPUL50, was confirmed using restriction 




The restriction enzyme, ClaI, is methylation sensitive so will not cut methylated 
DNA effectively. Dam
–
 competent cells were transformed (Section 2.2.2) with the 
plasmids, UL50pTOPFSAB (Section 5.1.3) and pTOPUL50 (Section 5.2.1), and 
isolated according to the protocol in Section 2.2.5. In preparation for cloning, the 
unmethylated UL50pTOPFSAB plasmid and the UL50 DNA fragment were digested 
with SacII and ClaI and gel purified (Section 2.1.9). The digested and purified  
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Figure 5.3 A) A diagrammatic representation of the created plasmid 
pTOPUL50 B). Using the restriction enzyme sites, SacII and ClaI, the UL50 
gene was cloned between the flanking sequences of UL50pTOPFSAB to 
create the plasmid, UL50pTOPFSABUL50. C) The FSABUL50 DNA 
fragment was cloned into the shuttle plasmid, pST76k, to create the plasmid 
UL50pST76kUL50. D) A restriction enzyme digestion of the 
UL50pST76kUL50 plasmid using the enzyme, SacII. 
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vector and insert were ligated (Section 2.1.10) to create the plasmid 
UL50pTOPFSABUL50 (Figure 5.3). Competent E. coli cells were transformed 
(Section 2.2.2) and plasmid DNA was isolated (Section 2.2.5). The plasmid, 
UL50pTOPFSABUL50, was confirmed using restriction enzyme digestion with 
BamHI. 
This plasmid was sequenced using the UL50pTOPFSAB sequencing primers 
pUL50TOPFSAB_For 3-6, as well as two extra sequencing primers, pTOPFSAB 
UL50_For1 and 2 (Appendix A.1.3.3). Sequencing results indicated that, compared 
to the published sequence, there was a single point mutation present where a 
thymidine had been replaced with a cytosine. However, this did not result in an 
amino acid change (leucine) so was disregarded. 
 
5.2.3. UL50pST76kUL50 
The plasmid, UL50pTOPFSABUL50, was digested with KpnI and PacI in 
preparation for cloning with the shuttle plasmid. The digested FSABUL50 fragment 
was gel purified (Section 2.1.9) and ligated into the digested and purified pST76k 
plasmid (Section 3.1.10), creating the plasmid UL50pST76kUL50 (Figure 5.3). 
Competent E. coli cells were transformed with the ligation reaction as described in 
Section 2.2.2 and plasmid DNA was isolated (Section 2.2.5). 
As the pST76k vector was 6.3 kb in size and the FSABUL50 insert was 7.2 kb, the 
isolated plasmids were digested with the restriction enzyme, SacII, to confirm that 
the ligation was successful. All plasmids displayed the correct digest pattern 
indicating that the plasmid UL50pST76kFSABUL50 had been successfully 
constructed (Figure 5.3). 
 
5.2.4. BAC Mutagenesis using the plasmid UL50pST76kUL50 
A glycerol stock of DH5-α bacteria, containing the UL50(Del) BAC, was plated onto 
to a LB agar plate that contained chloramphenicol (20 µg/ml). Previously this clone 
had failed to form CPE when transfected into CEF cells (Section 5.1.6). The bacteria 
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cells were made competent (Section 2.2.8) and transformed with 10 ng of the shuttle 
plasmid, UL50pST76kUL50, by electroporation. BAC mutagenesis was successfully 
performed (Section 2.2.9) and kanamycin sensitive colonies containing UL50(Rep) 
BACs, where UL50 gene had been re-introduced, were identified using colony PCR 
(Section 2.1.1 and Appendix A.1.4.3).  
 
The primers, UL50MutBAC_For and UL50MutBAC_Rev, were designed previously 
to identify colonies that contained the UL50(Del) BAC (Appendix A.1.3.3). With 
these same primers, the detection of a large product (1821 bp) would indicate that the 
UL50 gene had successfully been re-inserted into the MDV BAC genome. A smaller 
product (594 bp) meant that the UL50 gene had not been restored. CVI988 BAC 
DNA was tested as a positive control and produced expected results. Three colonies 
produced an approximately 1.8 kb product, indicating that the UL50 gene had been 
successfully re-inserted (Figure 5.4). A colony was selected and the UL50(Rep) BAC 
was isolated using as described in Section 2.2.7.  
 
To confirm the successful insertion of the UL50 gene into the UL50(Del) BAC, 
sequencing was carried out using the primers pUL50TOPFSAB_For6 and 
pTOPFSABHA_Rev6 (Appendix A.1.3.3). Sequencing results indicated that UL50 
gene had been successfully re-inserted.  
 
5.2.5. In vitro Characterisation of the UL50(Rep) BAC 
 
BAC transfections were carried out using the ‘reverse’ transfection method (Section 
2.3.8). CEF cells were seeded at a density of 5.0 x 10
5 
cells per well in six-well 
dishes and simultaneously transfected with the following BACs, according to the 
protocol in Section 2.3.8 – 
 
 CVI988    - 3 wells 
 UL50(Del) BAC   - 2 wells 
 UL50(Rep) BAC   - 3 wells 











     
UL50 (Rep) BAC (Replacement)A.
L       PC      1   2   3   4   5  6   7    8   9 10 11 12 13 14 15 1617 18 19 20        L
1.8kb
0.6kb
Figure 5.4 A) Agarose gel electrophoresis showing positive results from a 
colony PCR experiment designed to detect mutant BACs where the UL50 
gene had been re-inserted into the UL50 (Del) BAC. A large product (1.8 
kb) meant that the UL50 gene had been successfully re-inserted; a small 
product (0.6 kb) meant that the UL50 gene was not present. 
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After 7 days, cytopathic effect (CPE) in the form of plaques was visible. The CEF 
cells were fixed using ice cold 1:1 acetone-methanol and to aid plaque visualisation, 
the CEF cells were stained using the HB3 antibody (Section 2.3.12). The number of 
plaques in each well was counted (Table 5.1) and the stained plaques were 
photographed (Figure 5.5).  
 
Table 5.1 Plaque counts following transfection 
Construct Well Plaque Number 
CVI988 Well 1 102 
Well 2 97 




Well 1 14 
Well 2 4 
UL50 
(Rep) BAC  
Well 1 91 
Well 2 72 
Well 3 76 
 
The most surprising result was that transfection with the UL50(Del) BAC resulted in 
the formation of a small number of plaques. This can be explained by the fact that, 
using the reverse transfection method, the transfection efficiency was sufficiently 
increased to allow the formation of CPE. Previous in vitro analysis (Section 5.1.5) 
had been carried out according to the protocol in Section 2.3.7, where transfections 
had been performed using previously seeded CEF cells that had already formed a 
monolayer. The formation of CPE indicated that the UL50 gene is not essential, 
however, its deletion severely reduced the number of plaques formed per well. 
Replacement of the UL50 gene fully restored the ability of the BAC to form CPE, 
and plaque numbers were comparable to that of the parental strain, the MDV CVI988 
BAC.  




         
                                                                   
 















Figure 5.5 A) Visualisation of two plaques, using immunohistochemistry, 
resulting from the transfection of the UL50(Del) BAC. The plaque was 
stained with 1
o
 HB3 antibody, specific for the MDV gB glycoprotein, 2
o
 
Horseradish peroxidise-conjugated goat anti-mouse IgG and 3-amino-9-
ethylcarbazole (AEC) developing solution. B) Immunohistochemistry of 
two plaques, developing on CEF cells, which were transfected with the 
UL50(Rep) BAC and stained using the HB3 antibody. 




The work to establish if the UL50 gene was dispensable for normal viral replication 
in MDV CVI988 has confirmed that this is not the case.  Without the presence of the 
enzyme, dUTPase, the recombinant virus failed to replicate well in vitro and did not 
produce CPE that was comparable to the parental strain. Re-inserting the gene 
completely restored this ability of the BAC to cause plaque formation when 
transfected into CEF cells, confirming that the UL50 gene is important for successful 
virus replication. The results confirmed that the UL50 open reading frame would not 
be an appropriate site for the introduction of the influenza haemagglutinin gene. 
 
 













Chapter 6: The 2A Polypeptide 
 
 
6.1 The 2A Polypeptide 
6.2 pTOPPGKGFP2AH10myc 
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6.1. The 2A polypeptide 
In collaboration with the University of St Andrews, work was undertaken to develop 
a co-expression system, based upon the short oligopeptide sequence, 2A. The 2A 
polypeptide, derived from the foot and mouth virus, mediates a co-translational 
cleavage at its own COOH-terminus by manipulating the ribosome into skipping the 
synthesis of a specific peptide bond, producing a discontinuity in the peptide 
backbone (Felipe and Ryan, 2004). The translation of downstream genes is not 
disrupted. By joining together genes using 2A, a single open reading frame would be 
created which would prevent unequal expression or gene silencing. This means that 
multiple discrete genes could be expressed from the same promoter.  
This research was undertaken because it would be advantageous to be able to join 
together multiple haemagglutinin genes with 2A. Using this system, multiple HA 
genes, or combinations of haemagglutinin and neuraminidase genes, could be 
introduced into the same non-essential gene site of the MDV genome. The genes 
would be expressed using the same PGK-1 promoter. To assess the potential of 2A to 




The JC3 plasmid, previously created in St Andrews, contains a GFP and a DsRED 
gene, linked by the 2A polypeptide (Figure 6.1). Both genes were expressed by the 
CMV IE promoter. When the JC3 plasmid DNA (400 ng/µl) was transfected into 
Vero cells (Section 2.3.6), cells subsequently expressed both red and green 
fluorescence simultaneously (Figure 6.1). This indicated that the GFP and DsRed 
proteins were being co-expressed as discrete proteins from the same promoter, 
confirmation that the 2A protein was working as expected. As controls, Vero cells 
were also transfected with plasmids containing the GFP (pEGFP-N1) and DsRED 
(pDsRed) genes individually (Figure 6.1). 
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S R G S G E G R G S L L T C G D V E E N P G
NsiI ApaI
Figure 6.1 A diagrammatic representation of the plasmid JC3, acquired from 
the University of St Andrews. The plasmid contains the GFP gene and the 
DsRed gene, linked by the polypeptide, 2A (protein sequence shown). B) 
Photographs displaying Vero cells transfected with the control plasmids, 
pEGFP-N1 and pDsRed. C) Three photographs of the same Vero cell, 
transfected with JC3, simultaneously expressing GFP and DsRed proteins.  




The creation of the plasmid, pTOPPGKGFP2AH10myc, would determine if the GFP 
and the myc-HIS tagged H10 gene could be linked by the 2A polypeptide. Upon 
transfection, the production of the individual H10 and GFP proteins, detectable using 
immunofluorescence and western blots, would establish if this is was the case. If 
successful, work could progress towards introducing these genes, linked by 2A, into 
a single open reading frame of the MDV CVI988 BAC (UL41 or US10).  
 
6.2.1. pTOPPGKGFP2A 
The first step in creating the plasmid, pTOPPGKGFP2AH10myc, was to clone the 
GFP2A DNA fragment downstream of the PGK promoter. The plasmids, JC3 and 
pTOPPGKGFP (Section 3.9.1), were sequentially digested with BamHI and ApaI in 
preparation for cloning. Following digestion with ApaI at 25
o
C, the reaction 
temperature was raised to 37
o
C and the DNA was subsequently digested with BamHI 
(Section 2.1.6). The digested fragments were gel purified according to the protocol in 
Section 2.1.9. The purified 830 bp GFP2A fragment was ligated into pTOPPGK- 
vector backbone, as described in Section 2.1.10. Competent E. coli cells were 
transformed with the ligation reaction (Section 2.2.2) and plasmid DNA was isolated 
from small cultures (Section 2.2.5). The successfully ligated plasmid, 
pTOPPGKGFP2A (Figure 6.2), was confirmed using restriction enzyme digestion 
with EcoRI and SmaI. 
The primers, peGFP_For and peGFP_Rev3, were used to sequence the GFP gene 
(Appendix A.1.3.4). Sequence results indicated that that there were several mutations 
present in the GFP gene that differed from the published GFP sequence. The decision 
was made to re-amplify the GFP gene, cloned and sequenced previously (Section 
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Figure 6.2 A) The GFP2A fragment was excised from JC3 and cloned 
downstream of the PGK promoter to form the plasmid, pTOPPGKGFP2A. 
B) Due to mutations present in the GFP gene, the gene was re-amplified and 
cloned into Blunt II TOPO. C) The GFP gene was cloned upstream of the 
2A sequence to form the plasmid, pTOPGFP2A. D) The GFP2A was 
excised and cloned downstream of the PGK promoter to create the plasmid 
pTOPPGKGFP2A #2 (Repeat). 





Primers (p2AGFP_For and p2AGFP-Rev) that incorporated the unique restriction 
enzyme sites, AseI and NsiI, were designed to amplify the GFP gene (Appendix 
A.1.3.4). The reverse primer lay upstream of the stop codon removing it from the end 
of the GFP gene. Using pTOPPGKGFP as a template (Section 3.7.1), the GFP gene 
was successfully amplified as described in Section 2.1.1 and Appendix A.1.4.4. The 
amplified GFP gene was gel purified (Section 2.1.6) and subsequently cloned into 
Blunt II TOPO (Section 2.1.2) to create pTOPGFP (Figure 6.2). Following 
transformation (Section 2.2.2), the plasmid DNA was isolated (Section 2.2.5). The 
successfully ligated plasmid was confirmed using restriction enzyme digestion with 
AseI and NsiI. 
 
6.2.3. pTOPGFP2A 
Using the restriction enzymes AseI and NsiI, the GFP DNA fragment was removed 
by enzyme digestion and gel purified in preparation for cloning (Section 2.1.9). The 
plasmid vector, pTOPPGKGFP2A was also digested with AseI and NsiI, removing 
the PGKGFP fragment, and gel purified. The digested and purified vector and insert 
were ligated, as described in Section 2.1.10, to create the plasmid pTOPGFP2A 
(Figure 6.2). Competent E. coli cells were transformed according to the protocol in 
Section 2.2.2, and plasmid DNA was isolated (Section 2.2.5). The plasmid, 
pTOPGFP2A, was confirmed using restriction enzyme digestion with AseI and NsiI, 
and BamHI and ApaI. 
 
6.2.4. pTOPPGKGFP2A #2 (Repeat) 
Previously in Section 6.2.1, the GFP2A DNA fragment was cloned downstream of 
the PGK promoter, and this was repeated with the replacement GFP2A DNA 
fragment. The plasmid, pTOPGFP2A (Section 6.2.3), was sequentially digested with 
BamHI and ApaI in preparation for cloning (Section 2.1.6). The digested GFP2A 
fragment was subsequently gel purified (Section 2.1.9). The plasmid vector, 
Chapter 6  Results 
200 
 
pTOPPGK-, was digested and purified previously. The purified GFP2A fragment 
was ligated into pTOPPGK-, as described in Section 2.1.10. Following 
transformation (Section 2.2.2), plasmid DNA was isolated (Section 2.2.5). The 
successfully ligated plasmid, pTOPPGKGFP2A #2 (Repeat) (Figure 6.2), was 
confirmed using restriction enzyme digestion with NsiI and SmaI. 
 
6.2.5. pTOP(PGKGFP2A) 
The PGKGFP2A DNA fragment was amplified using PCR in preparation for the 
ligation upstream of the H10myc gene. Using the primers, pPGKGFP2A_For and 
pPGKGFP2A_Rev, the PGKGFP2A DNA fragment was successfully amplified 
(Section 2.1.1 and Appendix A.1.4.4). Due to the presence of a naturally occurring 
AseI restriction enzyme site at the start of the DNA fragment, there was no need to 
incorporate this site into the primer, pPGKGFP2A_For. The unique enzyme 
restriction site, KpnI, was incorporated into the reverse primer, pPGKGFP2A_Rev 
(Appendix A.1.3.4). Following amplification, the gene was cloned into Blunt II 
TOPO (Section 2.1.2), competent E. coli cells were transformed with the ligation 
mix (Section 2.2.2) and plasmid DNA was isolated (Section 2.2.5). The successfully 
ligated plasmid, pTOP(PGKGFP2A) (Figure 6.3), was confirmed using restriction 
enzyme digestion with AseI and KpnI.  
 
6.2.6. pTOPH10myc 
This plasmid was created previously (Section 3.8.2). The H10myc DNA fragment 
however, had been blunt cloned into TOPO as an intermediate step, and the gene 
orientation had not been a consideration. To ensure that the orientation was correct, 
the previously digested (BamHI and XhoI) and purified H10myc DNA fragment 
(Section 3.8.2) was re-cloned into a TOPO vector. The plasmid vector, pTOPGFP 
(Section 6.2.2), was digested with BamHI and XhoI, removing the GFP fragment. 
The vector was gel purified and ligated, according to the protocol in Section 2.1.10, 
with the H10myc insert to create the plasmid pTOPH10myc (Figure 6.3). Competent  
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Figure 6.3 A) The PGKGFP2A fragment was PCR amplified with primers 
incorporating the enzyme restriction sites, AseI and KpnI, and cloned into 
Blunt II TOPO to create the plasmid, pTOP(PGKGFP2A). B) The H10myc 
DNA fragment was re-cloned into the TOPO vector to ensure that it was in 
the correct orientation. C) The PGKGFP2A DNA fragment was excised 
using the enzymes, AseI and KpnI, and cloned into pTOPH10myc, to form 
the plasmid, pTOPPGKGFP2AH10myc. 
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E. coli cells were transformed with the ligation reaction (Section 2.2.2) and plasmid 
DNA was isolated (Section 2.2.5). The plasmid, pTOPH10myc, was confirmed using 
restriction enzyme digestion with BamHI and XhoI, and HindIII. 
 
6.2.7. pTOPPGKGFP2AH10myc 
In preparation for cloning, the PGKGFP2A DNA fragment was removed from the 
plasmid, pTOP(PGKGFP2A), using AseI and KpnI. The plasmid vector, 
pTOPH10myc (Section 6.2.6), was digested with the same enzymes. Subsequently, 
the insert and the vector were gel purified, and ligated (Section 2.1.10), to create the 
plasmid pTOPPGKGFP2AH10myc (Figure 6.3). Following transformation (Section 
2.2.2), plasmid DNA was isolated as described in Section 2.2.5. The successfully 
created plasmid, pTOPPGKGFP2AH10myc, was confirmed using restriction enzyme 
digestion with AseI and KpnI, and HindIII. 
 
6.3. Conclusion and Future work 
Unfortunately, due to time limitations, it was not possible to perform expression 
studies using pTOPPGKGFP2AH10myc, or to incorporate the GFP and H10 genes, 
linked by the 2A polypeptide, into the MDV CVI988 genome. To hypothesise, the 
ideal result would have been the development of CPE that simultaneously expressed 
GFP and H10myc, the latter protein detectable using an Alexa Fluor 594 (red) 
antibody. In addition, with further work to correct and improve the western blot 
techniques, it would be possible to detect the presence of the discrete GFP and 
H10myc proteins. Finally, and looking ahead, work to link different haemagglutinin 
genes would complete the study to create an effective recombinant vaccine for 
Marek’s Disease Virus and influenza that would protect against multiple influenza 
subtypes.  















Appendix: PCR Programs 
 
A.1.1 Recipes 
A.1.2 Reaction Conditions 
A.1.3 Primers 
















1. Phusion High Fidelity DNA Polymerase (Finnzyme, Finland) 
 
5x Buffer              10 µl 
dNTP (10 mM)       1 µl 
Primer 1 (10 pmol/µl)      5 µl 
Primer 2 (10 pmol/µl)       5 µl 
Template DNA/cDNA   1 µl 
Pfu Polymerase            0.5 µl 
dH2O            27.5 µl 
 
 
- Template DNA diluted to between 1-50 ng/µl 
- cDNA not diluted 
 
 
2. Taq DNA polymerase (Invitrogen) 
 
10x Buffer        5 µl    
MgCl2 (50 mM)       3 µl 
dNTP (10 mM)       1 µl 
Primer 1 (10 pmol/µl)       1 µl 
Primer 2 (10 pmol/µl)       1 µl 
Taq DNA Polymerase    2.5 µl  
dH2O    36.5 µl 
 
 
- Taq DNA Polymerase diluted 1/5 in dH2O 
- Reaction mixture aliquoted into 10 µl quantities 



















A.1.2 Reaction Conditions 
 
A. Mareks FSA and FSB 
Pre heat  - 98
o
C   
Initial Denaturing  - 98
o
C  1 min 
Denaturing  - 98
o
C  30 sec 
Annealing  -  * 
o
C  40 sec        x 35 cycles 
Extension  - 72
o
C  *  min 
Final Extension - 72
o
C  7 min 
   0 4
o
C  Hold 
 
 
B. H10 Amplification 
Pre heat  - 98
o
C   
Initial Denaturing  - 98
o
C  1 min 
Denaturing  - 98
o
C  20 sec 
Annealing  -  * 
o
C  30 sec        x 35 cycles 
Extension  - 72
o
C  *  min 
Final Extension - 72
o
C  7 min 
   0 4
o
C  Hold 
 
C. Taq DNA polymerase (Invitrogen) 
 
Pre heat  - 95
o
C   
Initial Denaturing  - 95
o
C  3 min 
Denaturing  - 94
o
C  45 sec 
Annealing  -  * 
o
C  45 sec        x 35 cycles 
Extension  - 72
o
C  *  min 
Final Extension - 72
o
C  7 min 
   0 4
o




Note - Annealing temperatures and extension times (*) varied according to the 
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A.1.3 Primer Sequences 
 
 




UL41 Flanking Sequences  
MareksFSA_For and AgeI ATACCGGTTCATACATCCATATACTCCC 
MareksFSA_Rev and PacI CATTAATTAAAGATTTCACTACATAGGCAG 
MareksFSB_For and KpnI TTGGTACCCTGTGTCAATTCTTCGTTCG 
MareksFSB_Rev and AgeI TCACCGGTCGCTTCCAGAGTATGCAG 
  
H10 Gene Specific Primer  
H10N1RT AGCCAATGGAACCGTCG 
  
H10 Amplification  
H10N1For and XhoI CTCGAGTGAAGAAGTGACCAATGC 
H10Rev and XbaI GGTCTAGAGGCTAAATACAGATTGTGC 
  
CMVH10 Amplification  
pCMVHA_For and AgeI AAACCGGTATTCTTTCCTGCGTTATCCC 
pCMVHA_Rev and AgeI CAACCGGTCTACAAATGTGGTATGGCTG 
  











H10 Reverse Orientation 
primer 
 
pCMVHA[REV]ID_Rev  GATGGGAAGGAATGGTGG 
  













H10 cDNA PCR primers  
pCMVHAID_For2 ATTCAATAACCGACATCTGGAC 








pCMVHAID_For As above 
pTOPCMVHA_For2 As above 
pTOPCMVHA_For3 As above 





















UL41 Flanking Sequence B 
(Rpt) 
 
CVI988FSB_Rev and AgeI CCACCGGTCCGCTAGCACTATCGTATCCC 
  







pTOPCMVHA10T_For and AgeI AAACCGGTATTCTTTCCTGC 
pTOPCMVH10T_Rev and AgeI GAACCGGTAGAAGAGAGTTTCACTGG 
  
  





GFP Amplification  
pGFP_For and NheI TCGCTAGCATCCACAAGTCGCCACC 
pGFP_Rev and AccI AAGTCTACCTGATTATGATCTAGAGTCG 
  








H10 Amplification (Repeat)  
pH10 (Rpt)_For and XhoI ATCTCGAGTGAAGAAGTGACC 
pH10 (Rpt)_Rev and HindIII AGAAGCTTAATACAGATTGTGCATCGC 
  
-H10myc- Amplification  
pH10myc_For and BamHI AAGGATCCAAAGAGGTTGTGCATGAAGG 
pH10myc_Rev and XhoI AACTCGAGGGGCAAACAACAGATGGC 
  
NA (H5N1) Amplification  
pNA_For (fixed) and NheI CCGCTAGCATGAATCCAAATCAGAAG 
pNA_Rev and XhoI AACTCGAGAACTACTTGTCAATGGTG 
  
HA (H5N1) Amplification  
pDONRH5_For and XhoI TTCTCGAGTTTGACTGATAGTGACCTG 
pDONRH5_Rev and HindIII TAAAGCTTCGGGTCAATGCAAATTCTGC 
  
H5myc Amplification  
pH5myc(rpt)_For and BamHI TAGGATCCTAAAGCAGGCTCCGCCATG 
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US10 Flanking Sequences  
pUS10FSA_For and BamHI ATGGATCCTATCTGACAAATCTTCGGG 
pUS10FSA(4)_Rev and PacI ACTTAATTAAACAGACCTACTTGCTACC 
pUS10FSB_For and KpnI TTGGTACCTGCGTATTTTCCCCGTGC 























p2aGFP_For and AseI CCATTAATTCCTCTTCCTCATCTCC 
p2aGFP_Rev and NsiI CTATGCATCTTGTACAGCTCGTCC 
  
H10myc Colony PCR  
pH10myc_For See Appendix A.1.3.1 
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UL50 Flanking Sequences  
pUL50FSA_For CAGTAGGTAAATGTCGTCGCC 
pUL50FSA_Rev and PacI TATTAATTAAGTAACACGGGTATGAGCC 
pUL50FSB_For and KpnI TAGGTACCAGCGTATCGTATGTATCGTC 
































UL50 Amplification  
pUL50_For (Rpt) TAACAGACGGAGCAACCAG 












pUL50TOPFSAB_For3 As above 
pUL50TOPFSAB_For4 As above 
pUL50TOPFSAB_For5 As above 













GFP Sequencing primers  
peGFP_For Section A1.3.1 
peGFP_Rev3 Section A1.3.1 
  
GFP Amplification Primers  
p2aGFP_For and AseI CCATTAATTCCTCTTCCTCATCTCC 



















Appendix  PCR Programs 
225 
 
A.1.4 Specific Reaction Conditions 
 
 
A.1.4.1 Chapter 3: UL41 Open Reading Frame  
MDV UL41 FSA  
Recipe A 
Product size – 3167 bp 
Primer 1 – Mareks FSA_For and AgeI 
Primer 2 – Mareks FSA_Rev and PacI 
Template DNA - CVI988 BAC DNA, Diluted 
Reaction Conditions A 
Annealing Temperature – 52
o
C 
Extension Time – 4 min 
 
 
MDV UL41 FSB 
Recipe A 
Product size – 2962 bp 
Primer 1 – Mareks FSB_For and KpnI 
Primer 2 – Mareks FSB_Rev and AgeI 
Template DNA - CVI988 BAC DNA, Diluted 
Reaction Conditions A 
Annealing Temperature – 52
o
C 





Product size – 1582 bp 
Primer 1 – H10N1For and XhoI 
Primer 2 – H10Rev and XbaI 
Template DNA – H10 cDNA 
Reaction Conditions B 
Annealing Temperature – 49
o
C 





Product size – 2219 bp 
Primer 1 – pCMVHA_For and AgeI 
Primer 2 – pCMVHA_Rev and AgeI 
Template DNA – Diluted pCMVH10 maxiprepped DNA 
Reaction Conditions B 
Annealing Temperature – 55
o
C 
Extension Time – 2 min 30 
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CMVH10 Colony PCR 
Recipe B 
Product size – 2320 bp 
Primer 1 – pCMVHAID_For 
Primer 2 – pCMVHAID_Rev 
Template DNA – Bacterial Colony 
Reaction Conditions C 
Annealing Temperature – 52
o
C 
Extension Time – 2 min 30 
 
CVI988 cDNA PCR – MDV30 
Recipe B 
Product size – 530 bp 
Primer 1 –VP23cloneFor 
Primer 2 –VP23cloneRev 
Template DNA – CVI988/H10 cDNA 
Reaction Conditions C 
Annealing Temperature – 54
o
C 
Extension Time – 2 min 30 
 
CVI988 cDNA PCR –vIL-8 
Recipe B 
Product size – 569 bp 
Primer 1 –vIL-8For 
Primer 2 –vIL-8Rev 
Template DNA – CVI988/H10 cDNA 
Reaction Conditions C 
Annealing Temperature – 54
o
C 
Extension Time – 2 min 30 
 
CVI988/H10 cDNA PCR – H10 
Recipe B 
Product size – 212 bp 
Primer 1 –pCMVHAID_For2 
Primer 2 –pCMVHAID_Rev 
Template DNA – CVI988/H10 cDNA 
Reaction Conditions C 
Annealing Temperature – 54
o
C 
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MDV UL41 FSB (Rpt) 
Recipe A 
Product size – 3144 bp 
Primer 1 – Mareks FSB_For and KpnI 
Primer 2 – CVI988 FSB_Rev and AgeI 
Template DNA - CVI988 BAC DNA, Diluted 
Reaction Conditions A 
Annealing Temperature – 52
o
C 
Extension Time – 4 min 
 
H10 Colony PCR 
Recipe B 
Product size – 1582 bp 
Primer 1 – H10N1For 
Primer 2 – H10Rev 
Template DNA – Bacterial Colony 
Reaction Conditions C 
Annealing Temperature – 52
o
C 
Extension Time – 2 min 30 
 
Forward Orientation H10 Colony PCR 
Recipe B 
Product size – 2503 bp 
Primer 1 – pCMVHAID_For 
Primer 2 – pCMVHAID_Rev 
Template DNA – Bacterial Colony 
Reaction Conditions C 
Annealing Temperature – 52
o
C 
Extension Time – 2 min 30 
 
Reverse Orientation H10 Colony PCR 
Recipe B 
Product size – 1125 bp 
Primer 1 – pCMVHAID_For 
Primer 2 – CMVHA[REV]ID_Rev 
Template DNA – Bacterial Colony 
Reaction Conditions C 
Annealing Temperature – 52
o
C 
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UL41 (Deletion) Colony PCR 
Recipe B 
Product size – Gene deletion: 507 bp; No gene deletion: 1731 bp 
Primer 1 – UL41MutBAC_For 
Primer 2 – UL41MutBAC_Rev 
Template DNA – Bacterial Colony 
Reaction Conditions C 
Annealing Temperature – 52
o
C 
Extension Time – 2 min 30 
 
 
CMVH10 (t)  
Recipe A 
Product size – 2129 bp 
Primer 1 – pTOPCMVHA10T_For and AgeI 
Primer 2 – pTOPCMVH10T_Rev and AgeI 
Template DNA – Diluted pTOPCMVH10 maxiprepped DNA 
Reaction Conditions B 
Annealing Temperature – 52
o
C 




Product size – 776 bp 
Primer 1 – pGFP_For and NheI 
Primer 2 – pGFP_Rev and AccI 
Template DNA – Diluted pEGFP-N1 DNA 
Reaction Conditions B 
Annealing Temperature – 52
o
C 
Extension Time – 2 min 30 
 
 
CVI988 cDNA PCR – UL42 
Recipe B 
Product size – 1102 bp 
Primer 1 –pUL42_For 
Primer 2 –pUL42_Rev 
Template DNA – CVI988/H10 cDNA 
Reaction Conditions C 
Annealing Temperature – 54
o
C 
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CVI988 cDNA PCR – UL44 
Recipe B 
Product size – 1212 bp 
Primer 1 –pUL44_For 
Primer 2 –pUL44_Rev 
Template DNA – CVI988/H10 cDNA 
Reaction Conditions C 
Annealing Temperature – 54
o
C 
Extension Time – 2 min 30 
 
PGKGFP Colony PCR 
Recipe B 
Product size – 193 bp 
Primer 1 – peGFP_For 
Primer 2 – peGFP_Rev3 
Template DNA – Bacterial Colony 
Reaction Conditions C 
Annealing Temperature – 59
o
C 




Product size – 1572 bp 
Primer 1 – pH10(Rpt)_For and XhoI 
Primer 2 – pH10(Rpt)_Rev and HindIII 
Template DNA – Diluted pTOPCMVH10 maxiprepped DNA  
Reaction Conditions B 
Annealing Temperature – 52
o
C 




Product size – 1679 bp 
Primer 1 – pH10myc_For and BamHI 
Primer 2 – pH10myc_Rev and XhoI 
Template DNA – Diluted pcDNA3.1H10myc DNA  
Reaction Conditions B 
Annealing Temperature – 52
o
C 









Product size – 1364 bp 
Primer 1 – pNA_For (fixed) and NheI 
Primer 2 – pNA_Rev and XhoI 
Template DNA – pDONR207NA, diluted 
Reaction Conditions B 
Annealing Temperature – 48
o
C 




Product size – 1814 bp 
Primer 1 –pDONRH5_For and XhoI 
Primer 2 –pDONRH5_Rev and HindIII 
Template DNA – pDONR207H5, diluted 
Reaction Conditions B 
Annealing Temperature – 52
o
C 




A.1.4.2 Chapter 4: US10 Open Reading Frame  
 
MDV US10 FSA  
Recipe A 
Product size – 1436 bp 
Primer 1 – pUS10FSA_For and BamHI 
Primer 2 – pUS10FSA(4)_Rev and PacI 
Template DNA - CVI988 BAC DNA, Diluted 
Reaction Conditions A 
Annealing Temperature – 52
o
C 
Extension Time – 3 min 
 
 
MDV US10 FSB 
Recipe A 
Product size – 2184 bp 
Primer 1 – pUS10FSB_For and KpnI 
Primer 2 – pUS10FSB_Rev and BamHI 
Template DNA - CVI988 BAC DNA, Diluted 
Reaction Conditions A 
Annealing Temperature – 50
o
C 
Extension Time – 3 min 
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PGKGFP Colony PCR 
Recipe B 
Product size – 793 bp 
Primer 1 – p2aGFP_For 
Primer 2 – p2aGFP_Rev 
Template DNA – Bacterial Colony 
Reaction Conditions C 
Annealing Temperature – 52
o
C 
Extension Time – 1 min 30 
 
 
PGKH10myc Colony PCR 
Recipe B 
Product size – 1680 bp 
Primer 1 – pH10myc_For 
Primer 2 – pH10myc_Rev 
Template DNA – Bacterial Colony 
Reaction Conditions C 
Annealing Temperature – 52
o
C 




A.1.4.3 Chapter 5: UL50 Open Reading Frame  
 
MDV UL50 FSA  
Recipe A 
Product size – 3086 bp 
Primer 1 – pUL50FSA_For 
Primer 2 – pUL50FSA_Rev and PacI 
Template DNA - CVI988 BAC DNA, Diluted 
Reaction Conditions A 
Annealing Temperature – 52
o
C 
Extension Time – 4 min 
 
 
MDV UL50 FSB 
Recipe A 
Product size – 3053 bp 
Primer 1 – pUL50FSB_For and KpnI 
Primer 2 – pUL50FSB_Rev and AgeI 
Template DNA - CVI988 BAC DNA, Diluted 
Reaction Conditions A 
Annealing Temperature – 52
o
C 
Extension Time – 4 min 
 
Appendix  PCR Programs 
232 
 
UL50 (Deletion) Colony PCR 
Recipe B 
Product size – Gene deletion: 594 bp; No gene deletion: 1821 bp 
Primer 1 – UL50MutBAC_For 
Primer 2 – UL50MutBAC_Rev 
Template DNA – Bacterial Colony 
Reaction Conditions C 
Annealing Temperature – 52
o
C 





Product size – 3123 bp 
Primer 1 – pUL50_For (rpt) 
Primer 2 – pUL50_Rev (rpt) 
Template DNA - CVI988 BAC DNA, Diluted 
Reaction Conditions A 
Annealing Temperature – 48
o
C 








Product size – 793 bp 
Primer 1 – p2aGFP_For and AseI 
Primer 2 – p2aGFP_Rev and NsiI 
Template DNA – Diluted pTOPPGKGFP maxiprep DNA 
Reaction Conditions B 
Annealing Temperature – 52
o
C 





Product size – 1625 bp 
Primer 1 –pPGKGFP2a_For 
Primer 2 –pPGKGFP2a_Rev and KpnI 
Template DNA – pTOPPGKGFP2a miniprep DNA 
Reaction Conditions B 
Annealing Temperature – 52
o
C 
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